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Abstract
Development of androgen independent prostate cancer (AlPC) carries a poor 
prognosis. The underlying molecular mechanisms are complex and not completely 
understood. Androgen receptor dependent and independent mechanisms have been 
postulated. AP-1 is a transcription factor whose components are nuclear proteins 
encoded by c-Jun and c-Fos proto-oncogenes. The possible role of c-Jun and c-Fos 
in contributing to the development of androgen independent prostate cancer in-vivo 
using paired human prostate cancer tissue samples has not been studied before. 
Study hypothesis- AP-1 transcription factor related proteins are dysregulated in the 
emergence of androgen independent prostate cancer.
Aims of the study-
1. To establish a paired clinical cohort of patients in which prostate cancer tissue is 
available at diagnosis of prostate cancer and also following the development of 
androgen independence in order to test the hypothesis by immunohistochemistry.
2. To evaluate the expression of AP-1 related proteins in androgen sensitive and 
androgen independent prostate cancer, by immunohistochemistry.
We demonstrated that both androgen sensitive and androgen independent prostate 
cancers express c-Jun, c-Fos, phosphorylated c-Jun, PKC, COX-2 and AR proteins.
VI
A significant proportion of tumours expressed high levels of AP-1 at relapse (c-Jun 
68.6%, 35/51; P-Jun, 47%, 24/51; c-Fos 40%, 20/51). An increase or no change in 
AP-1 (c-Jun, P-Jun & c-Fos) was observed in >80% of AlPCs. Also An increase or 
no change in PKC (55%), COX-2(70%) and AR (90%) protein expression in AlPC 
was observed.
Differences in the levels of protein expression were observed as androgen sensitive 
prostate tumours progressed to androgen independent state.
In androgen sensitive prostate tumours, we demonstrated a statistically significant 
correlation in expression of c-Jun, c-Fos and p-Jun proteins (table 14).
In androgen independent prostate tumours c-Jun expression correlated with 
phosphorylated c-Jun with statistical significance (p=<0.0001).
We also demonstrated that, high levels of phosphorylated c-Jun and an increase in 
Protein Kinase C expression at relapse were associated with a decrease in the 
duration of survival from relapse (p=0.003).
Protein Kinase C expression correlated with COX-2 expression in both androgen 
sensitive as well as in androgen independent prostate tumours (p=0.014 & 0.002 
respectively).
Also AR protein expression correlated with phosphorylated c-Jun expression in both 
ASPC and AlPC (p=0.003 & 0.07 respectively). This confirms that both the proteins
VII
are involved in the progression of ASPC to AlPC as demonstrated in cell line studies 
[110, 204].
The study has demonstrated that AP-1 related proteins are dysregulated with the 
emergence of androgen independent prostate cancer in a subset of patients thus 
proving the hypothesis.
VII!
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CHAPTER 1
INTRODUCTION
1.1 Incidence and Epidemiology
Prostate cancer is the most common cancer of the male genitourinary 
tract. In the UK, by incidence prostate cancer is the fourth commonest 
cancer in men, after skin, lung and bowel cancer. The incidence of 
prostate cancer increases with age such that the probability of prostate 
cancer developing in a man under the age of 40 years is approximately 
0.01%: increasing to 1% for men aged 40-59 and to >12% in men aged 
60-79 [1]. Even if the age standardised incidence rates were to remain at 
their present level, an ageing population means that the number of 
prostate cancers requiring treatment and care is bound to increase over 
the next 10-15 years. Every year around 19,000 men are diagnosed with 
prostate cancer in England and Wales. In England and Wales the 
incidence of prostate cancer tripled between 1971 and 1993 (the number 
of registered cases increasing from 6,174 to 17,210 [2] In the USA, 
information on cancer epidemiology is provided by the Surveillance, 
Epidemiology, and End results (SEER) program of the National Cancer 
Institute. At present the number of new cases of prostate cancer 
diagnosed in the USA is estimated at over 220,000 per annum and 
incidence is expected to increase to more than 380,000 cases per annum 
by 2025 [3] The contributing factors to the continuing increase in prostate 
cancer incidence include screening, greater awareness of the disease and 
improved diagnostic techniques (e.g. PSA, transrectal ultrasound etc).
These tests have led to the diagnosis of many cancers, some of which 
might not have presented within the life-times of the men concerned.
Figure 1 : incidence rates of prostate cancer in différent age groups 
in USA, 1996-2000, from the SEER data base.
Agr at diagntpxix
^  lO W t
i 5., sf. S '2^  S' ^  ^  ^  4
A l l  ia ^ o >
Wlutf
Hku.k
1.1.1 Geographical and Ethnic variation
There are well recognised geographic and racial differences in prostate 
cancer incidence (Figure 2). The incidence is highest in the American 
population and lowest in the Far East (Figure 3). Japan and China have 
the lowest prostate cancer incidence rates in the world (3.4 per 100,000 
and 2.5 per 100,000 respectively) [4,5]. African-American men have a 
particularly high incidence of prostate cancer, greater than that of US 
Whites (170 per 100,000 vs 110 per 100,000) [6]. Whilst in Asian-
American men the annual incidence was lowest (82 per 100,000). 
Hispanic-American men had an intermediate incidence in this period of 
104 per 100,000 [6].
Figure 2:lncldence rates of prostate cancer in différent races (55-64 
yrs) in USA, 1992-2001, from the SEER data base.
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Figure 3: International variation in prostate cancer incidence
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1.1.2 Mortality from prostate cancer
In the western world prostate cancer is the second leading cause of male 
cancer related death [7]. By 80 years of age about 50%  of all men have a 
focus of cancer in their prostate. But only 1 in 25 i.e. 4%  will actually die 
from this disease. Prostate cancer mortality rates have geographical and 
ethnic variations (Figure 4a-b). In the European Union more than 100,000  
men are diagnosed with prostate cancer and 35,000 die from it each year 
[8]. Scandinavian countries have a particularly high rate of prostate cancer 
diagnosis and death compared with southern European countries. For
example prostate cancer mortality is twice as high in Nonvay as in Spain 
(24 per 100,000 vs 13 per 100,000). Asian countries such as Japan and 
China have the lowest mortality rates in the world [4,5]. These differences 
could be secondary to low incidence of prostate cancer in general as well 
as differences in the early diagnosis and treatment of prostate cancer. In 
USA mortality from prostate cancer increased slowly during the 1970s and 
1980s, with an annual increase of 0.7%  & 1.6% in whites and African- 
Americans respectively. Between 1987 and 1991 an annual increase of 
3.1%  was observed, which then decreased at rate of 1.9% annually up to 
1995 [9,10]. It is possible that aggressive screening and treatment are 
responsible for the decrease in prostate cancer mortality.
Figure 4a: Prostate cancer mortality rates from the SEER data base
I
10
20012000
Year n f death
* WliiU*
HLiLk
♦ ♦ A jiitriic .u i liid iu jt/A lask .t N u liv r
A sia n  o i 1*ai.il is IslaiKlvi
< <3 H isp an is
Figure 4b: Prostate cancer mortality rates from the SEER data
1.2 Risk Factors Associated With The Development Of 
Prostate Cancer
The precise factors responsible for prostate cancer initiation and 
progression are not yet known. But considerable evidence suggests that a 
number of factors play a role in the evolution of this disease.
1.2.1 Hereditary prostate cancer
Members of the same family may be affected by prostate cancer 
suggesting that some prostate cancers may be inherited [11]. Men with 
one first-degree relative with prostate cancer have a 2-fold increased risk
o f developing pros tate cancer, while men with two or three affected first 
degree relatives have a 5 to 10-fold increased risk [12,13,14] The risk 
increases if the prostate cancer, in the affected relative, is diagnosed at an 
early age (< 55 years). A lthough hereditary prostate cancer accounts fo r 
10% of all prostate cancers, it is implicated in 43%  of prostate cancers 
d iagnosed before 55 years o f age [13] Hereditary prostate cancer is a 
com plex problem  and the presence of genetic locus heterogeneity makes 
d iscovery o f prostate cancer susceptib ility genes a challenging process.
1.2.2 Genetic Polym orphism s
G ene polym orphism s are inherited variations in gene sequences which 
m ay result in altered function. M olecular epidem io logical studies have 
discovered a num ber o f associations between specific gene 
polym orphism s and risk o f developing prostate cancer.
Androgen Receptor (AR) Polym orphism s
Tw o polym orphism s of the AR gene appear to influence the risk of 
prostate cancer. Exon 1 contains a trinucleotide (CAG)n repeat that 
encodes polyglutam ine [15] The length o f the polym orphic repeat is 
inversely related to the transcriptional activity o f the AR gene [16,17] Long 
CAG repeats are associated w ith androgen insensitivity in patients w ith 
sp inobu lbar m uscular atrophy [Kennedy’s disease]. Short CAG repeat 
lengths are hypothesized to result in enhanced AR m ediated activity and
increased suscep tib ility to benign prostatic hyperplasia and prostate 
cancer. CAG repeat lengths less than 18 are linked to a 1.5- fold relative 
risk o f prostate cancer com pared w ith those with repeat lengths >26 [18] 
Shorter CAG lengths were associated with a higher risk o f advanced stage 
(relative risk-2.2) and high grade (relative risk-1.9) disease. In studies of 
men w ithout prostate cancer, the prevalence o f short CAG repeat lengths 
was highest in A frican Am ericans, interm ediate in non-H ispanic whites, 
and lowest in Asians [19]. These data could account in part fo r the 
observed ethnic differences in prostate cancer incidence. However M ir et 
al [20] found no corre lation between the AR CAG repeat length and the 
age o f onset, stage and grade o f prostate cancer. S im ilarly Correa-Cerro 
et al (1999) did not find an association between CAG and GGN repeats in 
the human androgen receptor gene and susceptib ility fo r prostate cancer 
In a French-G erm an population. It Is possible that AR  polym orphism s have 
very little clinical s ignificance in prostate cancer.
5a-reductase Type 2 G ene (SRD5A2) Polym orphism s
SRD5A2 polym orphism s appear to result in increased enzym atic activity 
and risk o f prostate cancer, possibly via increased conversion of 
testosterone to DHT [21,22] The 3 ’ untranslated region (UTR) o f SRD5A2 
contains the polym orphic d inucleotide repeat (TA)n . A frican-Am erican 
men tend to have longer TA  alleles (17 or more repeats) than do other 
ethnic groups [21] However th is observation has not been found in all
10
s tudies [22,23]. Two other SRD5A2 polym orphism s have been described 
[24,25] In one variant, alanine at codon 49 is replaced with threonine 
(A49T). This is m ost com m on in African-Am ericans. This allele has 5-fold 
higher enzym atic activity than the wild type enzyme. V89L is another 
SRD5A2 polym orphism  in which valine is substituted by leucine. This 
allele is more com m on in Asian-Am ericans than in African-Am ericans [26] 
This allele is less effic ient in converting testosterone to DHT and these 
genetic variations could partly explain the lower risk o f prostate cancer in 
Asians vs African Am ericans.
Cytochrom e P459C17a (CYP17) Polym orphism
The 17 a- hydroxylase and 17, 20 lyase enzym es are involved in the 
biosynthesis o f testosterone. The 5 ’UTR of CYP17 contains a single base 
polym orphism  which differentiates two alle lic variants- A1 and A2. Men 
hom ozygous fo r the A1 allele were found more com m only in a Swedish 
prostate cancer patient population than in a control population, suggesting 
that th is allele may increase prostate cancer risk [27] The A1 allele is 
believed to encode a m ore active enzym e than A2. W om en carrying two 
A2 alleles were reported to be at higher risk o f developing breast cancer 
[22] Each o f the described polym orphic variations supports the general 
hypothesis that increased androgen production m ay correlate with 
prostate cancer risk.
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1.2.3 Androgens
Circula ting androgens are produced prim arily in the form  of testosterone 
by Leydig cells in the testes. The adrenal cortex also secretes androgens 
predom inantly androstenedione and dehydroepiandrosterone. These 
adrenal androgens are not as potent as testosterone in activating 
androgen receptors nor are they present in such high concentrations. The 
production o f androgens by Leydig cells is regulated prim arily via the 
hypothalam ic-pitu itary-gonadal axis.The hypothalam us secretes 
gonadotropin-re leasing horm one (GnRH) in pulses every 90-120 minutes. 
GnRH stim ulates the anterior p itu itary to release Luteinizing horm one (LH) 
and fo llicu lar stim ulating horm one (FSH). LH stim ulates the production of 
androgens by the Leydig cells in the testes. Androgens in turn have a 
negative feed back effect and inhibit the secretion of GnRH and LH.
The androgen receptor is a phosphoprotein tha t m ediates the actions of 
testosterone and d ihydrotestosterone (DHT) by acting as a transcription 
facto r [28] The androgen receptor is a m em ber of the steroid nuclear 
receptor superfam ily [29] and m aps to band q11-12 o f the  X  chrom osom e 
[30,31]. The androgen receptor (figure 5) has three m ajor dom ains nam ely
•  An N-term inal transcription activation domain
• A  central DNA binding dom ain
•  A  C-term inal ligand binding domain.
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Figure 5: Androgen receptor
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In the prostate the AR is expressed in both epithelial and stromal cells. 
Once testosterone enters the cell, it is converted to dihydrotestosterone by 
the Sa-reductase enzymes. Whilst the AR is capable of binding both 
testosterone and DHT, DHT has a 2-10 fold higher affinity than 
testosterone and is the primary androgen bound to the AR under normal 
physiological conditions. Prior to ligand binding the AR appears to be in an 
inactive state stabilized by the heat shock proteins bound to it. Following 
ligand binding a conformational change takes place and the heat shock 
proteins (hsp90, hsp70 and hsp56) [32] dissociate from the AR. 
Subsequently the AR interacts with co-activators, such as AR associated
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160-kd pro teins, ARA70, ARA55, ARA54, and cyclic adenosine 
m onophosphate (cAMP) response element-binding protein-binding protein 
(CBP). The AR  then form s a hom odim er and is fu rther phosphorylated. 
Reversible phosphorylation appears to play a role in both ligand- 
dependent and ligand-independent AR activation [28] Finally the AR 
binds to a specific DNA binding site (androgen response element) in the 
prom oter o f androgen-responsive genes, to activate transcription o f these 
genes.
Prostate cancer initiation and progression appears to be influenced by 
androgen concentrations. Prostate tum ours are extrem ely sensitive to 
m ale sex horm ones and they regress after horm one deprivation by 
medical or surgical castration. Studies carried out to investigate the 
relationship between circulating androgen levels and risk o f prostate 
cancer have reported conflicting results.
A frican Am ericans have a higher incidence o f prostate cancer and also 
elevated levels o f circulating androgen [33]. A  study carried out by Ross et 
ai [21] reported that young African Am erican men had 15% higher total 
circulating testosterone levels than white men. On the other hand Guess 
and colleagues [34] In the ir prospective study found no relationship 
between testosterone, sex horm one binding globulin [SHBG, which binds 
to and inactivates testosterone] or 5a-reductase activity and risk o f 
prostate cancer.
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A  recen t m eta-analysis o f previously published studies on horm onal 
predictors of prostate cancer risk [35] suggests tha t men whose total 
testosterone level is in the h ighest quartile are 2.34 tim es more likely to 
develop prostate cancer.These studies indicate tha t people w ith higher 
levels o f serum testosterone are at risk o f developing prostate cancer. 
However th is is a contentious issue as there are a num ber o f technical 
and theoretical issues in these studies. For exam ple circulating 
testosterone levels have a significant diurnal variation and this affects 
m easurem ent o f overall androgen levels. It is d ifficu lt to m easure the 
degree o f exposure o f the prostate to endogenous testosterone. It is not 
known w hether early versus late exposure to androgens during a m ans life 
or a change in the concentration over tim e is im portant [36].
1.2.4 Insulin-Like Growth Factor I [IGF-I]
insulin like gro\wth fac to r-1 has both m itogenic and antiapoptotic effects on 
norm al and transform ed prostate epithelial cells [37,38,39]. IGF-1 is 
im plicated in both in itiation and progression o f prostate cancer. Chan and 
colleagues [40] studied IGF and IGFBP (IGF-binding protein) levels in 
prospectively collected sera and found a strong association between 
raised serum IGF levels and developm ent o f prostate cancer. Men with 
IGF levels in the highest quartile had a 4.3 fold higher risk o f prostate 
cancer com pared w ith men in the lowest quartile. S im ilarly W olk et al [41] 
m easured serum  IGF-1 and IGFBP-3 levels in 210 Swedish patients w ith
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newly diagnosed pros tate cancer and in 224 controls. Increased serum 
IGF levels were sign ificantly associated with prostate cancer, especially in 
men younger than 70 years (relative risk 2.93). These studies provide 
considerable evidence to suggest that the IGF axis could play an 
im portant role in the developm ent o f prostate cancer. Latif et al [42] 
studied circulating IGF, IGFBP-3, PSA and C-reactive protein 
concentrations in patients with BPH as well as prostate cancer. They 
found that IGF and IGFBP-3 concentrations were sim ilar in both BPH and 
prostate cancer patients. There was no corre lation between the ir 
concentrations and stage o f prostate cancer. These findings are 
contradictory to those reported in previous studies.
1.2.5 Dietary Factors
People who m igrate from  one area to another will eventually assum e the 
cancer rates of the ir host population. This suggests tha t d ietary habits 
could be playing an im portant role in modulating the risk of prostate 
cancer developm ent. However Asian-Am erican men have a lower prostate 
cancer incidence than white  or African-Am erican men indicating that 
genetic factors still play an im portant role in determ ining prostate cancer 
predisposition. M igration studies have shown an increased incidence of 
prostate cancer in first generation im m igrants from  Japan and China to 
Am erica [43,44] There has been considerable interest in evaluating the 
link between diet and prostate cancer.
16
Fat
Fat is the d ietary com ponent m ost frequently associated with prostate 
cancer. Several epidem iological studies have shown a corre lation 
between dietary fa t and prostate cancer risk. G iovannucci et al [46] 
prospectively studied the relationship between diet and prostate cancer in 
men. Men who consumed a high fat d iet had an increased risk o f 
developing advanced prostate cancer (Relative risk 1.6). Countries such 
as Am erica where dietary fa t consumption is high, have a high incidence 
of prostate cancer, whereas Japan, with one of the lowest rates o f fat 
consum ption has a low incidence rate. Fat m ay increase the risk of 
prostate cancer by altering androgen levels. Men who consum e less fa t 
have lower plasm a testosterone levels [46].
Essential fatty acids are derived from  the diet and are all unsaturated 
(LInoleic, Linolenic & arachidonic acids). They affect prostaglandin 
synthesis. Linoleic acid stim ulates the growth o f an androgen- 
unresponsive prostate cell line whereas the derivatives o f linolenic acid 
have an inhib itory effect [47,48,49]. Arachidon ic acid is a polyunsaturated 
fa tty acid that can stim ulate gro\A4h of prostate cancer cells in vitro. It is 
converted into 5-hydroxyeicosatetraenoic acid (5-HETE). Inhibition o f 5- 
HETE specifically inhibited growth o f prostate cancer cells. This suggests 
that 5-HETE may be involved in prostate cancer form ation or growth 
[50,51,52] In the future, d ietary m anipulation may be a valid com ponent in 
the prevention o f prostate cancer.
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Lycopene
Lycopene is a carotenoid antioxidant present at high concentrations in 
tomatoes. [53,54] reported that high lycopene intake was associated with 
a 21%  lower risk o f prostate cancer. The m echanism by which lycopene 
m ay decrease prostate cancer risk is not known. It m ay block IGF- 
m ediated cellu lar proliferation by blocking Tyrosine phosphorylation o f IGF 
receptor [55], however at present th is remains unsubstantiated.
Selenium
Selenium  is a trace m ineral and a com ponent o f the antioxidant 
g lutath ione peroxidase enzym e that protects the cell from  oxidative 
dam age. A  prospective random ized study that was carried out to 
determ ine if selenium  supplem entation could reduce the risk o f skin 
cancer [56] found no effect o f Selenium on skin cancer, but incidentally 
found a dram atic reduction in the incidence o f prostate cancer. [57] found 
a sim ilar reduction o f prostate cancer incidence in men with a high levels 
o f selenium  in the ir toe nails. Further studies are underway to clarify the 
protective role o f selenium  in the  developm ent of prostate cancer.
Vitam in E (a- tocopherol)
Vitam in E is a m ajor in tracellu lar antioxidant w ith anticancer properties. 
V itam in E protects cell m em branes from free-radical damage. In vitro 
studies have shown a pro-apoptotic and antipro liferative effect o f vitam in E
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on pros tate cancer cells [58] A  Finnish study [59] carried out to assess 
the effect o f V itam in E supplem ents on the incidence o f lung cancer in 
sm okers showed a 32% decrease in prostate cancer incidence and a 41%  
decrease in prostate cancer mortality com pared w ith placebo. No 
reduction in the incidence o f lung cancer was found. An Am erican 
SELECT trial (Selenium  V itam in E chem o-prevention trial) is being 
conducted, which is a double-blinded randomized study to assess the 
efficacy o f Selenium and V itam in E in preventing prostate cancer, initial 
results are expected in 2012.
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1.3 Surgical Anatomy Of The Prostate
The prostate is a fibromuscuiar and glandular organ lying just below the 
urinary bladder. There are three zones in the prostate [60] namely 
peripheral, central and transitional zones. Seventy percent of the prostate 
volume is formed by the peripheral zone, 25%  by the central zone and the 
remaining 5% by the transitional zone (Figure 6). The majority of prostate 
cancers (60-70% ) arise in the peripheral zone, 10-20% in the transitional 
zone, and 5-10%  in the central zone [61] Conversely benign prostatic 
hyperplasia (BPH) almost always develops in the transitional zone.
Figure 6- zonal anatomy of the prostate
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Sagittal) and frontal view of the histological zones. Peripheral PZ = zone, 
CZ = central zone, TZ  = zone of transition, E = ejaculatory channels, UD = 
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1.4 Pathology Of Prostate Cancer
1.4.1 Prostatic intraepithélial neoplasia (PIN)
Pros tatic intraepithélial neoplasia consists of architecturally benign 
prostatic acini or ducts lined by cytologically atypical cells w ith prom inent 
nucleoli. Pathologists cannot reproducibly d ifferentiate low-grade PIN and 
benign prostate tissue [62] Hence low-grade PIN should not be 
com m ented on in d iagnostic reports. Several studies have noted an 
increase in high grade PIN in the peripheral zone o f the prostate, where 
70%  of prostatic adenocarcinom as arise. High grade PIN is most critical 
when found on needle b iopsy o f the prostate. A  23%  to 35% risk of 
prostate cancer is reported a fte r repeat biopsy in patients with High grade 
PIN [63,64] High grade PIN is associated w ith invasive carcinom a of 
prostate in approxim ately 80%  o f cases. High grade PIN appears to be a 
precursor lesion to m any peripheral adenocarcinom as of the prostate. 
However PIN need not be present fo r carcinoma to arise.
1.4.2 Pathological typing of prostate cancers
M ore than 95% of prostate cancers are adenocarcinom as and arise from  
the epithelium  lining the  prostatic acini. O f the remaining 5%, 90% are 
transitional cell carcinom as [65] and the rest are neuroendocrine 
carcinom as [66], sm all cell carcinom as [67], prostatic duct
adenocarcinom a [68], squam ous carcinoma [69] and sarcom as [7 0 ].
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1.4.3 Gleason G rading O f Prostate Cancer
The Gleason grading system  [71,72] is the most w idely used num eric 
grading system fo r evaluating prostatic adenocarcinom a and is based on 
the low-power m icroscopic appearance o f the prostatic g landular 
architecture. G rades from  1 to 5 are assigned, w ith increasing num eric 
values denoting increasing ded ifferentiation o f the carcinoma. Due to the 
high degree o f variation in grade observed w ith in prostatic carcinomas, 
pathologists com m only assign a prim ary grade to the pattern o f cancer 
that is most com m only observed and a secondary grade to the second 
m ost com m only observed pattern in the tissue specimen. The num bers of 
the two m ost w idely represented grades are added together to produce 
the G leason score or sum ranging in value from  2 to 10. W ell d ifferentiated 
tum ours have a G leason sum of 2-4; m oderately differentiated tum ours 
have a G leason sum of 5-7; and poorly d ifferentiated tum ours have a 
G leason sum o f 8-10, The Gleason score or sum provides useful 
prognostic inform ation.. G leason scores above 4 are associated w ith an 
increased risk o f m ore rapid d isease progression, increased m etastatic 
potentia l and decreased survival.
1.5 Patterns of Progression of Prostate Cancer
The pattern o f progression o f prostate cancer is well defined. Small and 
well d ifferentiated cancers are usually confined to the prostate, whereas 
large volum e (>4cm^) or poorly differentiated cancers are more often
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locally advanced or m e tastatic to regional lymph nodes or bones [73]. 
Penetration o f the prostatic capsule by prostate cancer often occurs along 
perineural spaces. Sem inal vesicle involvem ent by prostate cancer can 
occur by e ither d irect extension or haem atogenous spread [74] and is 
associated w ith a high likelihood o f regional or d istant disease. Locally 
advanced carcinom a o f prostate can cause ureteral obstruction by 
invading the trigone of the bladder. Involvement o f the rectum is rare as 
Denonvillier’s fascia acts as a strong barrier. Lymph node m étastasés are 
m ost often identified in the obturator lymph node chain. O ther groups o f 
lymph nodes tha t are frequently involved are the common iliac, presacral 
and periaortic lymph nodes. The axial skeleton is the m ost usual site of 
d istant métastasés. The lum bar vertebra is the m ost common site fo llowed 
by, in decreasing order, the proxim al femur, pelvis, thoracic spine, ribs, 
sternum, skull, and hum erus [75] Bone m étastasés are typica lly 
osteoblastic. Lung, liver, and adrenal gland are the m ost frequent s ites of 
visceral métastasés.
1.6 Clinical Presentation of Prostate Cancer
There has been a significant shift in presentation o f prostate cancer in 
m ost countries in the last decade. Traditionally, m ost men presented w ith 
a com bination o f w eight loss, bone pain, lethargy and b ladder outflow  
obstruction, as a result of locally advanced or m etastatic disease. 
Increasingly the disease is being diagnosed in younger, asym ptom atic 
patients, with much less advanced disease [9,76] This earlier
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presen tation of prostate cancer has posed the m edical profession with 
d ifficu lt d ilem m as concerning m anagement. Prostate cancer patients may 
present with a variety of sym ptoms. They could present w ith sym ptom s of 
b ladder outflow  obstruction such as frequency, hesitancy and poor flow  or 
sym ptom s resulting from  local extension o f the tum our, such as 
haematuria, haem osperm ia, erectile dysfunction, bilateral ureteric 
obstruction etc. W orldw ide, m any men still present w ith m etastatic 
disease. The m ost com mon presenting sym ptom s are low back pain, 
anaem ia and weight loss. Pathological fractures m ay also occur, 
particularly affecting the neck o f the femur. M étastasés w ith in the 
vertebrae can lead to spinal cord com pression and paraplegia [77,78]. 
Spread of prostate cancer to the lymph nodes could cause bilateral 
ureteric obstruction and renal fa ilure secondary to lymph node 
enlargem ent.
1.7 Early Detection of Prostate Cancer
The m ajority o f the patients in whom  prostate cancer is suspected are 
identified on the basis o f abnormal findings on DRE (Digital rectal 
exam ination) or, more com monly, by raised serum  PSA levels.
1.7.1 Digital Rectal Exam ination
Not all tum ours are palpable on DRE, either due to an anterior location of 
the cancer or due to the fact that not all are large or hard enough to  be
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palpa ted. [79] reported that approxim ate ly 50% o f palpable lesions on 
DRE were cancerous on histological exam ination afte r prostate biopsy. 
M ost other series report an overall detection rate of less than 40%  for an 
abnorm al DRE [80,81].
1.7.2 Prostate Specific Antigen
PSA is a glycoprotein (34kDa) protease secreted exclusive ly from  the 
epithelia l cells that line the acini o f the prostate. PSA is recognized as the 
m ost useful tum our m arker available in clinical practice fo r diagnosis, 
staging and monitoring o f prostate cancer [82] The approxim ate chance 
of cancer on prostate biopsy is 1 in 50 fo r men w ith PSA levels below 
4ng/m l; 1 in 4 fo r PSA of 4-10 ng/ml; and 1 in 2 fo r PSA greater than 
10ng/m l [83,84,85] The early detection o f prostate cancer is feasib le 
using PSA screening which advances the diagnosis of the disease by 5-10 
years [86]. W hether prostate cancer screening w ill reduce prostate cancer 
m orta lity currently rem ains unknown and the application of screening 
rem ains controversial
1.7.3 Transrectal U ltrasound (TRUS) And Prostate Biopsies
Patients with an DRE, elevated PSA, or both are offered prostate biopsies. 
[87] first reported that TRUS guided sextant prostate biopsy was better 
than digital guidance, since then this technique has becom e a standard
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procedure fo r d iagnosing pros tate cancer. As m ost cancers are 
im palpable or invisible on TRUS, system atic biopsies m ust be taken.
1.8 Clinical Staging of Prostate Cancer
The firs t clinical staging system  for prostate cancer was introduced by [88] 
and modified by [89]. The Am erican Joint Com m ittee fo r Cancer Staging 
and End Results Reporting (AJCC) introduced the tumour, node, 
m étastasés (TNM) staging system. In 1992, the AJCC and the UlCC 
(International Union Against Cancer) adopted a new TNM classification 
system fo r prostate cancer which was further modified in 1997 as follows:
T1-Nonpalpable tum our (Incidental Prostate Cancer)
T la -^ 5 %  of tissue resected (TURP) fo r benign disease has cancer
T1b->5%  of tissue resected (TURP) fo r benign disease has cancer
T ic -D e te c te d  from  elevated PSA alone (normal DRE and TRUS)
T2-Palpable or v isib le tum our confined to the prostate
T2a-Tum our palpable or visib le by TRUS and it involves one lobe or less
T2b-Tum our palpable or visible by TRUS and it involves both lobes
13- Palpable tum our beyond the prostate
T3a- Extracapsular extension o f the tum our on one or both sides
T3b-Tum our involves the sem inal vesicles
T4-Tum our is fixed or invades adjacent structures
T4a-Tum our invades b ladder neck and/or external sphincter and/or rectum
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T4b-Tum our invades leva tor m uscles and/or is fixed to pelvic wall 
N-Regional Lymph nodes [obturator, internal & external 
iliac,presacral]
NO-No regional lym pti node m étastasés
N1 -M étastasés in single regional lymph node, ^2cm  in dim ension
N2- M étastasés in single[ >2 but < 5cm] or m ultiple nodes with none >5cm
N3- M étastasés in regional lymph node >5cm in dim ension
M -D istant M étastasés
MO-No evidence o f d istant m étastasés
M 1a-M etastases in non-regional lymph nodes
M 1b-M etastases to bone
M 1c-M etastases to other sites
1.9 Role of Axial Imaging ( CT, MRI) & Bone Scan In 
Prostate cancer
Once the diagnosis o f prostatic adenocarcinom a is histologically 
confirm ed an accurate assessm ent of stage is essential to predict 
prognosis and select appropriate therapy. The extent of the disease 
corre lates directly w ith prognosis in men with newly diagnosed prostate 
cancer. Cross-sectional imaging o f the pelvis in patients w ith carcinom a of 
the prostate is selectively carried out to exclude lymph node m étastasés 
and sem inal vesicle involvem ent in high risk patients (PSA >20 ng/ml; 
G leason score 8-10) who are believed to be candidates for curative local
27
therapy (Radical prostatectom y or radical radiotherapy). The sensitivity o f 
CT and MRI fo r detecting nodal m étastasés is approxim ate ly 36% and the 
specific ity is 97% [90]. Radionuclide bone scanning is the m ost sensitive 
imaging technique to  detect skeletal métastasés. The isotope m ost 
com m only used is 99m T c-m ethylenediphosphonate. Overall, the 
sensitiv ity o f bone scans in skeletal m étastasés from  prostate cancer 
exceeds 95%.
1.10 Management of Prostate Cancer
1.10.1 Localized Prostate Cancer
The aim o f treating a patient w ith localized prostate cancer is to achieve 
cure. To achieve this, the selection of the patient is critical. Ideally, 
patients should have life expectancy o f at least 10 years. Men with 
localized disease do not experience significant d isease related m orbidity 
fo r several years after diagnosis, and curative trea tm ent itself could result 
in som e morbidity. Those men w ith a shorter life expectancy would benefit 
least from  such treatm ent. The treatm ent options fo r localized prostate 
cancer are watchful waiting, radical prostatectom y (retropubic, perineal 
and laparoscopic) and radical radiotherapy (external beam or conform ai) 
or brachytherapy.
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W atchful W aiting
W a tchfu l waiting m ay be recom mended fo r o lder patients (>70 yrs) with 
low volume, well d ifferentiated tumours, particularly when other significant 
illnesses are also present. Patients should be counselled, reviewed and 
PSA levels m easured at regular intervals The deve lopm ent of m etastatic 
d isease during watchfu l waiting is believed to be 2.1%  per year in patients 
with well differentiated tum ours (Gleason scores 2-4), com pared to 13.5% 
per year in patients w ith aggressive tum ours (G leason scores 7-10). 
Patients w ith low-grade tum ours appear to have a disease specific 
survival o f 87% after 10 years com pared with only 26%  in patients with 
poorly differentiated tum ours [91]. However, if PSA levels start to rise or 
the cancer begins to cause sym ptoms, then initiation o f therapy should be 
considered.
Radiotherapy
External beam radiotherapy (XRT) is w idely used in the trea tm ent of 
localised prostate cancer. Survival rates are often com parable to those 
achieved by radical prostatectom y with reported 15 year survival rates of 
40-60% . One of the d isadvantages w ith XRT technique is, it fa ils to 
provide adequate coverage of the target volum e in 20-40%  of patients w ith 
prostate cancer. Improved imaging and use of 3-dim entional treatm ent 
planning software can now guarantee accurate coverage. Retrospective
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s tudies from  several centres suggest that acute toxicity is reduced w ith the 
use o f conform ai radiotherapy com pared with standard XRT [92,93].
Brachytherapy
This technique involves placing Iodine-125 seeds into the prostate via the
transperineal route under TR US (Transrectal U ltrasound) guidance. The
indications for brachytherapy are T ia  - T2a cancer w ith a gleason score
2-6, PSA <10 ng/ml, prostate vo lum e <60ml and urinary flow  rate >15ml/s.
The initial 10 year results showed a 66% biochem ical d isease-free 
survival, which was m ainta ined in the 12-year fo llow-up results [94].
Radical Prostatectom y
In USA, radical prostatectom y is the first line treatm ent option fo r men 
aged 70 years or less w ith clin ica lly localised prostate cancer [95]. W hen 
carried out on men with localised prostate cancer and a life expectancy of 
10 years or more, radical prostatectom y is considered an acceptable and 
effective treatm ent. Patients w ith organ confined prostate cancer have 10 
year d isease free survival ranging from  70% to 85% in several series [96] 
Principal adverse effects associated with radical prostatectom y are urinary 
incontinence (2-18% ) and erectile  dysfunction (30-100% ).
1.10.2 Locally Advanced Prostate Cancer
A  diagnosis o f locally advanced prostate cancer im plies that there is extra­
capsu lar spread o f prostate cancer but no evidence o f m étastasés to
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regional lymph nodes or d is tan t sites. External beam radiation therapy has 
been the m ainstay o f trea tm ent fo r clinical stage T3 disease. The 10 year 
survival rate is approxim ate ly 15-30% [97,98]. Neoadjuvant horm one 
deprivation therapy before radiotherapy has been studied in an attem pt to 
im prove local control and survival [99]. Local control and disease free 
survival rates at 5 years are superior in the neoadjuvant horm one 
deprivation group in com parison to the radiotherapy alone [100,101]. 
M onotherapy with the antiandrogen Bicalutam ide is currently licenced to 
trea t locally advanced prostate cancer with out métastasés.
1.10.3 M etastatic Prostate Cancer
In UK, around 30% o f prostate cancer patients currently present with 
m etastatic disease. M etastatic prostate cancer is associated w ith high 
m orta lity approxim ate ly 70%  with in 5 years [102]. Horm one deprivation 
therapy in the form  of surgical castration has been the gold standard since 
Huggins and Hodges dem onstrated that the prostate cancer is dependent 
on androgens [103] A  favourable response rate o f 70-80%  is expected 
w ith horm one deprivation treatm ent. Hormone deprivation can be 
achieved by surgical castration (bilateral orchidectomy), medical castration 
(estrogens, LHRH agonists), androgen receptor blocking agents (pure 
antiandrogens & steroidal antiandrogens) and maxim al androgen 
blockade.
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O rchidectom y
In 1941 Huggins and Hodges dem ons trated that castration slowed 
progression o f prostate cancer. Bilateral orchidectom y or bilateral 
subcapsular orchidectom y [104] are simple surgical procedures and carry 
little m orbidity. C linical responses (decreased bone pain and reduced PSA 
concentrations) are achieved in more than 75%  of patients. Because of 
the psychological and cosm etic effects o f orchidectomy, m any patients 
prefer treatm ent with LHRH analogues.
LHRH Analogues_(G osere lin  acetate, Leuprolide acetate)
Schally et al [105] isolated and described the structure of gonadotropin- 
releasing horm one which is active in stimulating the release o f FSH and 
LH by the pituitary. This d iscovery was honoured by the Nobel Prize.
LHRH agonists cause an initial stim ulation o f luteinizing horm one 
production w ith a rise in serum  testosterone (flare response) [106,107] 
W ithin 2 weeks, they cause an inhibition o f luteinizing horm one secretion 
resulting in castrate levels o f serum  testosterone. The principal side effect 
is tum our flare as a result of the initial increase in serum  testosterone. This 
could result in increased bone pain or worsening of sym ptom s o f b ladder 
outflow  obstruction [107]. There is also a potentia l risk o f spinal cord 
com pression.
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Antiandrogens
Meges tro l and cyproterone acetate are steroidal antiandrogens. W here as 
Flutam ide, Bicalutam ide and Nilutam ide are nonsteroidal antiandrogens. 
Steroidal antiandrogens have properties sim ilar to  progesterone and they 
cause suppression o f gonadotrophins resulting in decreased production of 
testosterone by Leydig cells. Nonsteroidal antiandrogens com petitive ly 
bind to the androgen receptor in the target tissue and prevent the action o f 
androgens. B icalutam ide or Cyproterone acetate are used to prevent the 
flare response that occurs follow ing initiation o f treatm ent with LHRH 
agonists. Seidenfeld et al [108] carried out a literature based m etaanalysis 
o f endocrine m onotherapy o f prostate cancer. Tw enty-four tria ls involving 
6600 patients were reanalysed. There was a trend towards shorter overall 
survival w ith nonsteroidal antiandrogens com pared w ith castration or LH­
RH agonists.
M axim um  Androgen B lockade [MAB]
Suppressing both testicu la r and adrenal androgens sim ultaneously is 
known as m axim al androgen blockage (MAB). This form  of treatm ent has 
been tried as an initial trea tm ent fo r m etastatic prostate cancer. However 
m etaanalysis o f 22 random ised trials where MAB was used did not find a 
significant im provem ent in 5 year survival (22.8%  fo r castration versus 
26.2%  for MAB) [109] over castration.
33
1.11 Androgen Independent Prostate Cancer [AIPC]
In 1941, Charles Huggins and Hodges [103] reported that castration or 
oestrogen adm inistration in patients w ith m etastatic prostate cancer 
induced regression o f the cancer. This was associated w ith a decrease in 
serum  acid phosphatase and alkaline phosphatate. Testosterone 
adm in istration in orchiectom ised patients resulted in stim ulation o f cancer 
growth and an increase in acid phosphatate levels. Huggins noted that 
orchiectom y was often more effective than oestrogen adm in istration and 
favourable responses occurred m ore frequently in patients having normal 
sized testes and those having well differentiated tumours. Since then 
horm one deprivation therapy has been the main therapeutic intervention 
for the treatm ent of m etastatic prostate cancer.
Seventy percent of patients w ith advanced prostate cancer respond to 
androgen deprivation therapy as measured by a decrease in serum PSA 
to norm al levels during the firs t 8 months o f therapy and m ost will relapse 
with in 2-3 years from  the initiation o f treatm ent [110]. In contrast, in the 
remaining 30% of the patients, serum PSA w ill fa il to decline to a plateau 
in the normal range, after an initial response to therapy, higher readings 
are observed, indicating early progression to androgen independent 
prostate cancer.
AI PC is incurable and system ic therapy fo r patients with horm one 
refractory prostate cancer has been disappointing. Chem otherapy has 
only a palliative role to play in the m anagem ent o f som e patients with
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A lPC  [111] The median tim e to progression after endocrine ablation 
therapy is around 18-24 months, w ith a median survival of 6-18 m onths 
from the tim e of developm ent of A lPC  [112,113],
Understanding the m olecular m echanism s that lead to HRPC is the m ost 
im portant step towards developing therapies capable o f treating this 
disease.
1.11.1 Prostate Cancer And The Androgen Receptor
Prostate cancer is a horm one dependant tumour, androgens prom ote 
cellu lar proliferation and down regulate apoptosis [114]. The m ajority o f 
prostate cancers in itially regress after androgen deprivation therapy, 
however m ost tum ours eventually begin to re-grow despite continuing 
androgen deprivation. Studies on prostate cancer specim ens show that 
AR  continues to be expressed in nearly all tum ours of the prostate before 
and after horm one deprivation therapy [115-118]. PSA, which is encoded 
by an androgen responsive gene, is also detected in alm ost all horm one 
refractory prostates cancers. Prostate cancer cells appear to have several 
possible m echanism s by which they could becom e hormone refractory 
[119]
1. M utations in the androgen receptor (AR) ligand binding dom ain or 
am plification of the AR  gene.
2. A lterations of in teractions between the AR  and its co-activators.
3. Activation of AR  by phosphorylation.
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4. Activation o f regulatory m olecules down stream  o f the AR 
(bypassing AR).
It is possible that more than one mechanism  will be utilized in each case 
o f hormone refractory prostate cancer. Certainly there is growing evidence 
that each m echanism  m ay prom ote hormone relapse in d ifferent patient 
sub-groups.
1.11.2 Androgen Receptor M utations
Normally, the AR  is specifically activated by testosterone and 
dihydrotestosterone, but androgen receptor m utations involving the ligand 
binding domain may allow  the receptor to bind and be activated by 
horm ones that are norm ally present in the body but do not norm ally cause 
substantia l activation of the androgen receptor (e.g: adrenal androgens 
such as dehydroepiandrosterone (DHEA) and androstenedione) [120].
Two androgen receptor m utants T877A and H874Y were identified in vitro 
[121]. T877A was in itially described in the LNCaP cell line, and H874Y is 
found in the horm one refractory prostate cancer xenograft CW R22. These 
m utations affect the ligand-binding domain of the AR  and enable the AR  to 
be activated by DHEA (several fold higher than that of w ild-type AR). 
M utant ARs that respond to adrenal androgens have also been identified 
in tum ours o f patients who have failed to respond to hormone deprivation. 
A lso other steroid horm ones (progestins, estrogens) and anti-androgens 
(Flutam ide) illicitly bind to the m utant AR and act as agonists [122]
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Pros tate cancer cells continue to proliferate and avoid apoptosis by 
utilizing DHEA when the level o f androgens is low.
Flutam ide is an AR antagonist. Hence it is used in the treatm ent of 
m etastatic prostate cancer, ‘F lutam ide w ithdrawal syndrom e’ is a condition 
where patients show clinical worsening w ith Flutam ide [123]. In such 
patients Flutam ide acts as an agonist and the A R ’s w ith T877A m utations 
are activated by Flutam ide. D iscontinuing Flutam ide results in initial 
tum our regression before the tum our starts to regrow.
M DA PCa 2a and 2b cell lines, derived from bone métastasés that 
developed after orchidectom y [124] also express ARs. Androgens 
stim ulate the ir growth and PSA expression. However the AR in these cell 
lines has reduced affin ity fo r androgens and the MDA cells are less 
sensitive to androgens than LNCaP cells [125]. Two m utations (T877A & 
L701H) in the AR  ligand binding dom ain were identified in these cell lines 
[125]. In the presence o f L701H mutation, the affin ity o f the AR  to bind and 
respond to DHT decreases [126]. This mutation enhances the binding of 
g lucocorticoids (cortisol and cortisone) to the AR. The T877A m utation has 
a synergistic effect by increasing the affinity o f the AR fo r g lucocorticoids 
by 300% m ore than the L701H alone. In th is doubly m utated AR, cortisol 
and cortisone function as AR  agonists. In tum our cells w ith th is m utation 
g lucocorticoids can substitute fo r androgens and prom ote horm one 
independent growth [126] A lthough there is a large body o f in vitro 
evidence supporting a role fo r AR  m utations in the developm ent of
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horm one refrac tory prostate cancer, the overall frequency o f AR  m utations 
in the clinical setting cannot account for the m ajority o f horm one refractory 
cancers. Gaddipati et al [127] reported T877A m utation in 6 out o f 24 
tum our sam ples (25%) from  patients with m etastatic prostate cancer 
indicating that the m utation is not uncommon in patients w ith HRPC.
1.11.3 Androgen R eceptor G ene Am plification
AR gene am plification occurs in 20-30%  of horm one refractory prostate 
cancers [128-130]. The resulting increase in AR  protein expression is 
thought to sensitise the cell to the residual am ounts o f androgens 
rem aining after androgen deprivation therapy, and in the presence o f anti 
androgens [129]. Xenograft studies have dem onstrated tha t an increase in 
AR  expression not only allows AR to be activated in the presence o f anti­
androgens, but converts the anti-androgens to a weak agonist [131] 
Edwards e t al [118] studied AR  gene am plification status and AR protein 
expression in a unique cohort o f matched hormone sensitive and hormone 
refractory tum ours from 51 patients. AR gene am plification was 
dem onstrated in 20% of the patients. The AR  protein expression 
increased as the d isease progressed to horm one refractory state. Eighty 
percent o f cases in which AR  am plification was observed, also exhibited 
an increase in AR protein expression.
AR gene am plification and increased AR  protein expression are 
associated with the deve lopm ent o f hormone refractory prostate cancer in
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a subgroup of pros tate cancer patients only. Therefore there m ust be 
alternative m echanism s causing hormone refractory d isease in the 
remaining prostate cancers.
1.11.4 Activation o f the Androgen Receptor by AR co-activators
A R  co-activators generally do not bind DNA, but are recruited to the 
prom oter region through protein protein interactions with AR, usually in a 
ligand dependent manner. These co-activator proteins interact w ith the 
androgen receptor and enhance androgen receptor dependent gene 
transcription
The function o f a co-activator is to act as a bridge and facilita te assem bly 
of transcription factors into a stable pre-initiation complex. Included in this 
group are the glucocorticoid receptor-interacting protein 1, steroid receptor 
coactivator-1 (SRC-1) and the receptor-associated co-activator-3. These 
co-activator proteins interact w ith the N-term inal activation domain o f the 
androgen receptor [132] or bind to the c-term inal ligand binding dom ain o f 
the androgen receptor and thereby enhance AR-m ediated transcription of 
target genes [133]. It is also possible that an increase in the protein levels 
o f the p i 60 co-activators may allow  adrenal androgens to function as AR 
ligands [119]
In addition to the ir bridging function, som e coactivators including steroid 
receptor coactiva tor-1 (SRC-1), cAMP response elem ent binding protein 
binding protein (CBP), and p3D0 can also remodel chrom atin by
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ace tylating histones and recruiting the p300/CBP associated factor which 
harbours intrinsic histone acetyltransferase activity [134]. Therefore, when 
the ligand bound AR  binds to the ARE, co-activators and p300/CBP 
associated factor are recruited. This loosens the nucleosom e structure of 
the gene, by targeting h istone acétylation, and in itiates the stable 
assem bly o f the pre initiation com plex via the ir bridging function. The end 
result is an enhanced rate o f transcription initiation by RNA polym erase II. 
In addition AR co-activators m ay act to a lter the specific ity o f the ligand 
activation of the androgen receptor. These co-activators include the AR- 
associated proteins ARA54, AR A55 and ARA70 [135-137]. ARA55 and 
ARA70 allow activation o f the  AR  by 17(3-estradiol [136-137] and the 
antiandrogen hydroxyflu tam ide [136,138]
Thus an increase in these co-activator levels or m utations in co-activators 
could provide a way fo r horm one refractory prostate cancer to develop. 
AR m utations in com bination with co-activators tha t a lter the steroid 
specific ity can result in activation o f the androgen receptor and the 
deve lopm ent o f horm one independence. However there is currently no 
d irect evidence o f altered expression levels o f the co-activators or of 
altered interactions between the co-activators and the androgen receptor 
in hormone refractory prostate cancer.
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1.11.5 Activation o f the Androgen receptor by protein kinases
Dihydro testosterone binds to AR and it protects it from  proteolytic 
degradation by recruiting protein kinases resulting in hyperphosphorylation 
o f the AR [139,140]. Follow ing phosphorylation both the stability and 
transcriptional activity o f the AR  protein increase. The transcriptional 
activity o f the AR  has also been shown to corre late strongly w ith 
phosphorylation o f specific serine residues [140-144]. Factors tha t induce 
androgen receptor transcriptional activity by mediating phosphorylation 
may therefore provide a m echanism  for horm one dependent prostate 
cancer to develop into horm one refractory disease.
Several proteins, e.g. M itogen activated protein kinase [140,142,145,146] 
and AKT or protein kinase B (PKB) [140,142,145-147], phosphorylate AR  
in vitro  in the absence o f androgens. This phosphorylation m ay facilita te 
the deve lopm ent o f horm one refractory disease.
In the absence of d ihydrotestosterone, AR activity increases in response 
to phosphorylation suggesting that the AR is activated in the absence of 
the natural ligand [145]. It is m ore likely that, in vivo, phosphorylation of 
AR by kinases, sensitizes the AR  to low circulating levels o f adrenal 
androgens during horm one deprivation therapy. It has been dem onstrated 
that follow ing DHT binding, phosphorylation in the N-term inal dom ain of 
the AR  by MAP kinase results in enhanced transcription. MAP kinase and 
Akt (protein kinase B), regulate AR activity via phosphorylation at serine 
515 and serine 213 respectively, and modulate the function o f the AR.
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There is no evidence that AR phosphorylation can induce dim erization of 
the AR, resulting in AR  translocation to the nucleus to induce transcription 
[148]. Current evidence therefore suggests that phosphorylation o f AR 
m ay influence the deve lopm ent o f hormone escape by sensitisation to 
circulating androgens.
1.11.5.A  Ras /  R af /  MAP kinase Pathway
Cell growth, d ifferentiation and program med cell death are m ediated by 
the activation o f the Ras/ Raf /  MAP kinase cascade. N-Ras, H-Ras and 
K-Ras are three different genes, which share hom ology and encode Ras 
G TPase proteins [148]. Raf is a serine / threonine protein kinase. Ras is 
known to interact and activate Raf in a GTP dependent m anner [149]. Raf 
is recruited to the plasma m em brane where it binds to Ras, causing RAF 
phosphorylation conform ational changes and activation [150]
The im m ediate downstream  target of Raf is MAP kinase kinase (MEK) 
w hich is im plicated in invasion, m etastasis and angiogenesis [150]. Both 
m etastatic and non m etastatic prostate cancer cell lines express Raf [151]. 
M EK activates MAP kinase by phosphorylation at specific tyrosine and 
threonine sites [150]. Activated MAP kinase stim ulates various 
transcription factors including AR, Activa tor p ro te in -1 and c-myc [118].
The MAP kinase pathway is im plicated in the deve lopm ent of hormone 
escape
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[147]. AR  is phosphorylated by MAP kinase, which results in an increase 
in transcription of target genes, helps in recruitm ent o f co-factors and 
increases growth stim ulation [145]. MAP kinase has the ability to activate 
other transcription factors, which prom ote proliferation, independent o f AR  
activation.
Activation o f AR  via phosphorylation by MAP kinase has been 
dem onstrated in prostate cancer cell line studies. MAP kinase activity is 
elevated in androgen independent prostate cancer tissue [152]. Activated 
MAP kinase also corre lates w ith advanced stage and grade in prostate 
cancer [153], and cell line studies have dem onstrated that MEK and MAP 
kinase are expressed and activated during prostate cancer progression 
[154].
Cell line studies also dem onstrated that transfection w ith Ras results in 
increased expression and activation of MAP kinase resulting in the 
developm ent of horm one escape [118,153], also dem onstrated 
am plification of m em bers o f the Ras/MAP kinase pathway w ith the 
developm ent o f clinical horm one escape.
It appears that activation of MAP kinase may stim ulate prostate cancer 
cell growth in the absence o f androgens via phosporylation o f AR. 
However in-vitro studies cannot rule out increased proliferation due to 
activation o f transcription factors that bypass the AR e.g. AP-1 and c-m yc 
[152]. In a clinical setting, where low levels of circulating androgens are 
present, phosphorylation o f the AR  by MAP kinase could induce androgen
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hypersensitivity, and this has been dem onstrated in vivo using LNCaP 
cells [153] W hatever the route that the MAP kinase pathway takes to 
prom ote prostate cancer growth, it is evident that it is involved in the 
deve lopm ent of horm one escape.
It has also been reported that the MAP kinase pathway m ay increase AR 
activity by phosphorylating AR  co-factors (SRC-1) independent o f AR  
phosphorylation [155,156] This offers another route fo r the MAP kinase 
signal transduction to in fluence the developm ent o f horm one escape 
[156].
1.11.5.B PI3 K inase/AKT pathw ay
The AKT fam ily (AKT 1 -3 or Protein kinase B) is a group o f serine / 
threonine protein kinases that inhibit apoptosis by phosphorylating targets 
such as BAD, procaspase-9 and the forkhead fam ily o f transcription 
factors [157,158]. AK Ts are also involved in regulation of cell 
d ifferentiation and/or proliferation via c-Myb, a sequence specific DNA- 
transcriptional activator.
AKT-1 and AKT-2 directly phosphorylate AR at Ser 210/213 and Ser 
790/791 [147]. P13K (phosphotidylinosito l-3-kinase) generates PIP3 
(phosphotidylinosito l-3,4 ,5-triphosphate) which activates AKTs.
In vitro studies suggest tha t the PI3K/AKT pathway can prom ote prostate 
cancer cell survival via phosphorylation o f the AR or by bypassing the AR 
and activating BAD, procaspase-9 [159]. AKT is constitutively activated in
44
both LNCaP and PC-3 cells [160] and over expression o f activated AKT-1 
in LNCaP cells dram atically accelerates xenograft tum our growth [161]. 
Prostate cancer cell line studies have also dem onstrated tha t the activity 
o f AKT increases as cells progress to androgen independence [162].
In contrast to MAP kinase, phosphorylation of AR  by AKT decreases AR 
trans-activation in LNCaP, PC3 and DUI45 cells. Phosphorylation of AR 
by AK T prevents binding o f co-activators and hence decreases AR trans­
activation. So if PI3K/AKT pathway is not regulated, trans-activation of AR 
by DHT is greatly dim inished. This reduction in AR  trans-activation results 
in a decrease in AR regulated genes activity tha t norm ally induce 
apoptosis e.g. p21. This results in an increase in prostate cancer cell 
survival [163]
It has also been dem onstrated that the PI3K/AKT pathway is required fo r 
basal and DHT induced AR  expression [164] Therefore activation o f the 
PI3K/AKT pathway could result in up-regulation of AR protein and 
increased sensitivity to low circulating levels of DHT, thus providing a 
pathway to horm one relapse. S im ilar to MAP kinase, phosphorylation of 
AR  by AKT, increases AR  transcriptional activity with subsequent increase 
in PSA, cell proliferation in androgen independent cell lines and xenografts 
has been reported [118,165] identified am plification o f several m em bers of 
the AKT pathway in prostate cancer tissue using gene array technology. 
These data suggest that a lterations of AKT function could be a key to the 
deve lopm ent o f horm one relapse prostate cancer.
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1.11.5.C JAK/STAT3 pathway
In terleukin-6 can activate signal transducer and activators of transcription 
(STATs) such as STATS (signal transducer and transactivator of 
transcription-3), via the Janus kinase pathway (JAK). Activation o f the 
JAK/STAT3 pathway via the IL-6 receptor has also been reported as one 
prom oting possible m echanism  to the developm ent o f horm one escape 
[156,163,166] C linical data has shown that serum IL-6 levels are elevated 
in men w ith horm one refractory prostate cancer and tha t these high levels 
w ere accom panied by high levels o f serum PSA [167,168]. Activation of 
the IL-6 receptor results in activation o f both the MAP kinase pathway and 
/ or the JAK/STAT3 pathway. IL-6 receptor activation results in activation 
o f JAK, and which inturn activates STATS. Activated STATS form s a 
hom odim er prior to entering the nucleus [156]. In LNCaP cells the STATS 
hom odim er binds to the AR  and then enters the nucleus and thus 
facilita ting AR  translocation to the nucleus in the absence of androgens 
[166]. The AR /STAT3 com plex can activate transcription and elevate PSA 
expression in the absence of androgens, and can therefore possibly offer 
a route to horm one escape [156,166].
1.11.6 AR activation by c-Jun
Transcription factors are constitutive proteins that are d irectly responsible 
fo r the ‘sw itching on ’ o f genes. They are usually the end targets of several 
signaling pathways. AP-1 is com posed of c-Jun and c-Fos heterodim ers or
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c-Jun hom odim ers [169]. c-Fos is known to inhibit AR  transcriptional 
activity [170]. W here as c-Jun can either stim ulate or inhibit AR  activity.
The c-Jun m onom er is reported to function as an AR co-activator by 
binding to the N-term inal dom ain at am ino acids 503-555 [171]. This 
dom ain is involved in the dim erization of the AR  and it contains the AF-1 
region [145] . The AF-1 region contains m any consensus phosphorylation 
sites and is critical fo r ligand independent transactivation of the AR [145]. 
Binding of c-Jun to the NTD allows the AR to form  a hom odim er (an AR N- 
C domain interaction) which allows the AR to  translocate into the nucleus 
and bind to the DNA in a sequence specific m anner and hence act as a 
transcription factor [172]. This action of c-Jun is independent o f c-Jun 
phosphorylation, c-Fos and AP-1 DNA binding and ligand binding [172] 
However the AR  c-activator action o f c-Jun is inhibited by phosphorylation 
o f c-Jun and the presence o f c-Fos [172]. In prostate cancer cell lines, c- 
Jun alone can increase AR  activation [172].
In androgen independent cell lines and in the absence of androgens, 
transcriptional activaton o f AR  is increased by over expression of c-Jun 
[173]. AF-2 region of LBD is involved in ligand dependent transactivation 
o f the AR  [145]. It is thought that c-Jun can act in conjunction w ith the co­
activator TIF2 which acts at the AF-2 region to potentiate AR 
transactivation. The effects of c-Jun and TIF2 binding to the AR  on AR 
transactivation is additive [172]. Therefore c-Jun and TIF2 function 
together by targeting d ifferent regions o f the AR.
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O verexpression of c-Jun in horm one refrac tory prostate cancer offers a 
route by which the AR  m ay be activated in the absence of androgens, or 
m ay potentiate AR  activity when circulating levels o f androgens are low. In 
vivo studies are needed to investigate the involvem ent of c-Jun in the 
deve lopm ent o f clinical horm one refractory prostate cancer.
1.11.7 Progression to AlPC Via Bypassing the Androgen Receptor
Although the AR plays a m ajor role in the progression to horm one- 
refractory prostate cancer, prostate cancer cells m ay use other pathways 
fo r proliferation independent of the AR in the absence of androgens.
1.11.7.A Neuroendocrine differentiation
The prevalence of neuroendocrine (NE) cells in prostate adenocarcinom a 
varies from  30-100%  depending on the sources o f tum our sam ples and 
the m ethods used to detect NE cells. NE cells becom e more prevalent 
after long-term  anti-androgen therapy both in vitro and in vivo [174]. These 
NE cells are non-m itotic and do not express the AR. As the NE cells do 
not proliferate, they are relatively resistant to radiation therapy and 
endocrine therapy [175]. The prevalence of proliferating carcinom a in the 
v icin ity of the NE cells [176,177] suggests that these NE cells may play a 
role in the growth of horm one refractory prostate cancer.
NE cells produce a num ber o f products such as parathyroid horm one- 
related protein. Serotonin, bombesin, calcitonin, chrom agranin A,
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neuro tensin and thyroid stim ulatory horm one which may play a role in the 
progression to horm one refractory prostate cancer [178,179]. Cell line 
studies have dem onstrated that IL-6 treatm ent induces LNCaP and PC-3 
cells to undergo NE differentiation [180,181]. IL-6 induced NE 
d ifferentiation in LNCaP cells via activation of PI3K (Phosphatidylinosito l 3 
Kinase). This can be blocked by a dom inant-negative m utant form  of Etk. 
STAT3, one o f the downstream  targets of Etk [182] m ediates IL-6 induced 
NE differentiation in LNCaP and PC-3 cells [183]. Thus IL-6 induces NE 
differentiaton in prostate cancer cell lines by activating PI3K [184], Etk and 
STAT3. There is no in vivo data to account fo r the increase in NE cells 
after androgen ablation therapy. It is possible that elevated serum levels of 
IL-6 in patients with horm one refractory disease [167] activate the PI3K- 
Ekt-STAT3 signalling pathway to cause NE differentiation in prostate 
tum ours.
1.11.7.B Anti-apoptotic signaling Pathways
W ithdrawal o f androgen triggers apoptosis in both normal and m alignant 
androgen-dependent prostate epithelial cells. However, androgen- 
refractory prostate cancer cells do not undergo apoptosis [185]. PI3 
K inase and related pathways tha t activate anti-apoptotic signaling 
pathways should be critical fo r the survival o f horm one refractory prostate 
cancer cells.
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PIS Kinase is activated by a num ber o f survival factors, such as IL-6 etc. 
PIS Kinase phosphorylates phosphatidylinosito l to generate D-3 
phosphatidylinosito l, including phosphatidylinosito l-3,4,5- triphosphate and 
phosphatidylinosito l-3,4- biphosphate, both o f which activate protein 
kinase B (AKT). Protein kinase B is one of the key regulatory m olecules 
involved in the protection o f cells against apoptosis [186,187]. The tum our 
suppressor gene, phosphatase and tensin hom ologue deleted on 
chrom osom e 10 (PTEN) is a lipid phosphatase whose prim ary function is 
to negatively regulate PI3-Kinase / AKT signaling. PTEN is inactivated in 
m any cancers, including prostate, brain, breast, endom etrium , and kidney 
[188]. in prostate cancer loss of PTEN function can result from  a num ber 
of m echanism s such as deletion, mutation and in a xenograft model, 
méthylation [189-192]. The frequency of PTEN mutation in prostate cancer 
is relatively low overall, but inactivation o f PTEN is more frequent in 
advanced stages o f the tum our [190,193,194] ). Thus, loss of PTEN 
function may favour tum our cells survival in the environm ent resulting 
from  androgen ablation therapy. Loss o f PTEN and activation of P13K / 
AKT could favour Bcl-2 and Bcl-XL proteins which are inhibitors of 
apoptosis. In the normal prostate, Bcl-2 is expressed in the basal epithelial 
cells but not in the lum inal epithelial cells [195,196] Bcl-2 is over­
expressed in early stage disease, but most studies have shown higher 
frequencies o f over-expression in advanced prostate cancer [197] . 
Apoptosis in LNCaP cells as a result o f androgen w ithdrawal is prevented
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by forced expression o f Bcl-2, which enables cells to be less dependent 
on androgens [198]. Over-expression o f Bcl-2 is implicated in the 
conversion o f horm one-dependent to hormone refractory prostate cancer 
[197,198].
1.11.7.C.C“Jun and c-Fos expression in prostate cancer
The Activa tor Protein 1 (AP-1) is a transcription factor involved in control 
o f cell growth and differentiation. Its activity is modulated by growth 
factors, cytokines and Protein kinase c (PKC) [199]. c-Jun and c-Fos are 
encoded by c-Jun and c-Fos proto oncogenes. Jun/Fos heterodim ers 
have higher stability than Jun hom odim ers which accounts fo r the ir 
increased DNA binding activities [200]. Formation o f either d im er requires 
c-Jun phosphorylation at serine residues 63 and 73 by c-Jun N-term inus 
kinase (JNK), which is activated by PKC or MAP Kinase cascades. 
D imérisation is m ediated via the leucine zipper domain of both proteins 
[201]. The basic region adjacent to the leucine zipper on Jun and Fos 
proteins m ediates AP-1 DNA binding activity [202,203] AP-1 induces 
transcriptional activation by binding to the TPA (12-o-tetradecanoyl- 
phorbol-13 acetate) response elem ent (TRE) [201]. TREs are recognized 
by both the AP-1, c-Jun hom odim ers nd c-Jun /  c-Fos heterodim ers 
[110,204] Activa tion o f AP-1 via PKC or the Raf/MAP kinase pathway 
has been reported to be involved w ith the developm ent of androgen 
escape [172,204,205]. AP-1 influences the developm ent of horm one
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escape by com pe ting w ith the AR to alter expression o f AR  regulated 
genes [172,204].
AR  and AP-1 are capable o f binding to each other, this protein-protein 
interaction prevents e ither from  being able to bind to DNA and hence 
decreases gene transcription [110, 204]. However evidence also 
suggests that AP-1 can increase expression o f androgen regulated genes 
by binding to a TRE w ith in the prom oter region [204]. Therefore the effect 
o f AP-1 on androgen regulated gene expression depends on the ratio of 
AR to AP-1 and the ability o f AP-1 to bind to specific prom oter regions 
w ith in the androgen regulated genes [110,204]. Such com petition could 
influence the ability o f AP-1 to increase androgen regulated genes 
expression in the absence o f androgens and hence m ight influence the 
deve lopm ent of androgen escape [110]. This is especially im portant in 
androgen regulated genes which contain m ultiple TREs in the prom oter 
region e.g. PSA and PSMA [110]. In a situation where the ratio o f AP-1 to 
AR  is high (e.g. in the absence o f androgens), there would be less AR  
available to in itiate transcription by binding to the AR E [204]. There would 
be excess AP-1 available fo r binding to an alternative TRE, resulting in an 
increase in androgen regulated gene expression. Therefore it is 
conceivable that such a situation could influence the developm ent of 
androgen escape via increases in androgen regulated gene expression in 
the absence of androgens. In vitro studies dem onstrate that in PC3 cells, 
the in tracellu lar concentration of c-Jun and c-Fos is 7 fold greater than in
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LNCaP [204]. This suggests that AP-1 influences androgen escape in 
PC-3 cell line [206]. A lthough cell line work suggests tha t AP-1 could be 
involved in the deve lopm ent o f androgen escape, little w ork has been 
conducted to investigate its action in vivo.
The role o f AP-1 is fu rther com plicated by the fact that c-Jun can act as 
an AR  co-factor. In addition to interactions between AP-1 and AR, there is 
evidence that the c-Jun m onom er m ay also influence the developm ent of 
A tPC by functioning independently o f AP-1. c-Jun acts as an AR  co­
activator binding to the N-term inal domain at am ino acids 503-555 [171], 
th is prom otes AR dim érisation and gene transcription [193] . This action 
o f c-Jun is independent o f c-Jun phosphorylation, c-Fos, AP-1 DNA 
binding and AR ligand binding [193,207].
The potentia l role of c-Jun and AP-1 in A lPC  is therefore highly complex, 
w ith c-Jun being an AR  co-activator, wh ilst phosphorylated c-Jun m ay 
both inhibit AR  activation via AP-1 binding to AR  and prom ote A lPC  via 
AP-1 m ediated gene transcription.
1.11 .7 .0  Protein kinase C (PKC)
The protein kinase c fam ily o f enzym es prom ote lipid hydrolysis. 
D iacylglycerol and phorbol esters are potent PKC activators [208]. 
Receptor tyrosine kinases or non-receptor tyrosine kinases can cause 
diacylg lycerol production by either activating specific  phospholipase C or
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phospholipase D [209-211]. Protein kinase C (PKC) is an isozyme fam ily 
with at least eleven m amm alian m embers that play im portant roles in cell 
growth regulation and differentiation [212]. D iacylglycerol and phorbol 
esters cause PKC to translocate to m embranes. All isozymes of PKC 
require phosphatidylserine located on the cytoplasm ic face o f cell 
m em branes and some isozym es require Ca^^ fo r its optim al activity [] 
[213,214].
Phorbol-ester is a tum our promoter, which indicates PKC involvem ent in 
tum origenesis [212,215]. In vitro studies have dem onstrated involvem ent 
of PKC in androgen regulated transcription. Transfection studies have 
shown enhancem ent o f AR-induced transactivation by PKC activator 
phorbol 12-m yristate 13-acetae (PMA) [216]. No changes in AR 
expression levels, DNA binding, or phosphorylation were observed. The 
effect of PMA was attributed to the activation by PKC of proteins 
downstream . Two well studied proteins activated by PKC are c-Jun and 
c-Fos [169,172] dem onstrated that c-Jun stim ulates hAR activity w ithout 
altering hAR expression or DNA binding and they suggested that PKC 
activation o f c-Jun m ay be responsible fo r the PMA effect on AR 
transactivation. They also dem onstrated c-Fos as a negative regulator of 
c-Jun action on the AR.
Activation o f AP-1 via PKC or the Raf/MAP kinase pathway has been 
linked to the deve lopm ent of androgen escape [172,204,205]. AP-1
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influences the developm ent o f horm one escape by com peting w ith the AR 
to a lter expression o f AR  regulated genes [172,204].
PKC-a is selectively over-expressed in androgen independent human 
prostate cancer cell line (PC3- 8 fold & DU 145- 40 fold) in com parison to 
LNCaP [207]. Activation o f the isozyme PKC-a results in apoptosis o f 
LNCaP cells [218,219]. Androgen- independent hum an prostate cancer 
cell lines DU 145 and PC3 do not suffer apoptosis in response to phorbol 
esters [219,220]. Chelerythrine is a highly selective PKC inhib itor which 
elicits apoptoic response in androgen-independent human prostate 
cancer cell lines tha t express constitutively active PKC but not in LNCaP, 
which do not express constitutive PKC activity [211]. It appears that 
constitutive PKC-a activity is required fo r survival and growth o f androgen 
independent human prostate cancer cells [215].
1.11.7.E C y c lo o xyg e n a se  2 (COX-2)
Cyclooxygenase (COX), is also known as prostaglandin (PG) 
endoperoxide synthase. It is a key enzym e in the conversion of 
arachidonic acid to PGs. There are two isoform s o f COX. COX-1 is 
constitutively expressed in m ost tissues and m ediates the synthesis of 
PG required for normal physiological functions. COX-2 is not detectable 
in m ost normal tissues, but is inducible by trauma, growth factors, tum our 
prom oters and cytokines, and is involved in inflamm ation and 
proliferation. Increased COX-2 expression has been described in a
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num ber o f human cancers including colonic, breas t and prostate cancers 
[222-226]. O verexpression and persistence of COX-2 has been linked to 
prom otion o f tum origenesis, resistance to apoptosis and defective 
regulation of cell-cycle [228]. COX-2 is also implicated in tum our 
progression and there is a strong link between COX-2 expression and 
hypoxia induced tum our ang iogenesis [228]. COX-2 induced PGE2 has 
been reported to stim ulate angiogenesis [229]. Both androgen sensitive 
LNCaP and androgen independent PC-3 cell lines express COX-2 protein 
. Treated both cell lines w ith a selective COX-2 inhib itor NS-398, resulted 
in apoptosis [230-231].
Ceram ide is a novel lipid second messenger. It is formed when the 
m em brane phospholip ids sphingomyelin undergoes hydrolysis by 
sphingom yelinase (SMase). Subbaram aiah et al [223] dem onstrated 
enhanced prostaglandin E2 synthesis and increased COX-2 protein 
expression in human m am m ary epithelial cells following trea tm ent of 
these cells w ith neutral sphingom yelinase. The induction of ceram ide was 
inhibited by calphostin C, an inhib itor o f protein kinase C. Stim ulation of 
ceram ide pathway also resulted in increased expression o f extracellu lar 
signal-regulated kinase (ERK), c-Jun N-term inal kinase (JNK) and M APK 
activities. Inhibition o f M APK kinase blocked the induction o f COX-2 by 
SMase. Overexpressing ERK1, JNK or MAPK led to several fold 
increases in COX-2 prom oter activity. A  dom inant negative fo r c-Jun 
inhibited the activation o f COX-2 prom oter activity by ceram ide. Hence in
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response to ceram ide, increased M APK signalling activates c-Jun, which 
in turn induces COX-2 gene expression via the cAM P response elem ent 
in the COX-2 promoter. Therefore it appears that both PKC and MAPK 
can induce COX-2 expression by activating c-Jun.
1.12 HYPOTHESIS & AIMS / OBJECTIVES OF THE STUDY
Study hypothesis- AP-1 transcription factor related proteins are 
dysregulated in the em ergence of androgen independent prostate cancer. 
A im s of the study-
1. To establish a paired clin ical cohort o f patients in which prostate cancer 
tissue is available at d iagnosis o f prostate cancer and also follow ing the 
deve lopm ent o f androgen independence in order to test the hypothesis by 
im m unohistochem istry.
2. To evaluate the expression o f AP-1 related proteins in androgen 
sensitive and androgen independent prostate cancer, by 
im m unohistochem istry.
To test the hypothesis, expression of AP-1 transcription factor related 
proteins- c-Jun, phosphorylated c-Jun, c-Fos, Protein kinase c, COX-2 
and AR  in paired prostate cancer tissue specim ens will be evaluated using 
im m unohistochem istry. Imm unohistoscoring w ill be carried out by two 
independent observers. An increase or decrease in expression o f AP-1
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rela ted proteins with the deve lopm ent o f androgen independence will be 
determ ined.
An increase or decrease in expression of AP-1 transcription factor related 
proteins will be correlated w ith tim e to developm ent o f horm one relapse 
and also duration o f survival from  relapse.
A lso a change in the expression o f one protein w ill be corre lated w ith other 
AP-1 related proteins to determ ine if AP-1 pathway is involved in the 
em ergence o f androgen independent prostate cancer.
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CHAPTER 2
MATERIALS AND METHODS
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2.1 Patient Selection
2.1.1 Ethical Approval
E thical approval was obtained from the M ulti-centre Research Ethics 
com m ittee [M REC] fo r Scotland in Edinburgh. MREC approval has to be 
obtained if the study would be undertaken in five or m ore LREC sitesAs 
the study was retrospective and m ajority o f the patients were not alive at 
the tim e of the study, it was not possible to obtain written consent from 
patients whose prostate cancer tissue was studied. This aspect was made 
clear to the MREC, which gave approval for the study to be carried out. All 
together It took 5 months fo r getting MREC approval.
Subsequently Local Research Ethics Com m ittee [LREC] approval was 
sought from  each hospital involved. It was tim e consum ing and It took 
several m onths before approval could be obtained from all the LRECs. 
One LREC did not give approval fo r the study as it was not possible to 
obtain written consent from  patients and they suggested a prospective 
study to be carried out w ith written consent taken from  the patients.
2.1.2 Recruitm ent o f Patients
A fter having obtained ethical approval to carry out the research project, 
pathology departm ents o f each hospital involved in the study were 
contacted. The project was discussed with them  in detail. From the 
pathology data base, a list of prostate cancer patients who had two
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procedures carried ou t on the ir prostate [either TURP or Prostate biopsies] 
was obtained first. From this list of prostate cancer patients, the ir m edical 
records were accessed.
If all of the follow ing criteria were satisfied then the patients w ere included 
in the study.
1. Patients diagnosed to have carcinom a o f the prostate.
2. Prostate cancer tissue available at the tim e o f d iagnosis.
3. Patients should have received hormonal trea tm ent and have the ir 
PSA values monitored.
4. Evidence o f response to  hormonal treatm ent as indicated by 
decreasing levels of serum PSA.
5. Subsequently developed horm one relapse disease as indicated by 
rising PSA levels in spite of continuing horm onal treatment.
6. Had TURP for sym ptom s of bladder outflow  obstruction after 
developing relapse and the ir prostate cancer tissue available.
Prostate cancer patients who did not satisfy all of the above criteria were 
excluded from  the study.
A  total of 51 patients out o f 1021, who satisfied all the above criteria were 
selected for the study. Full clinical fo llow-up was retrieved from  patient 
m edical records. A ll the relevant details were entered into an anonym ised 
database protected w ith a password and kept w ithin the University 
Departm ent o f Surgery. The details that were recorded include date o f 
birth, date of diagnosis, serial PSA values through out follow-up, results o f
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s taging investigations such as CT scan, Bone scan, horm onal treatm ent 
received, date of relapse, date o f last visit and date of death where 
applicable.
In our study Androgen independent prostate cancer was defined as rising 
levels o f PSA inspite of horm onal treatm ent after having a good initial PSA 
response to horm onal treatm ent.
2.2 Preparation of silanised slides
To study protein expression by IHC, tissue sections were mounted on 
Silanised slides. Plain glass slides were coated with silane using the 
follow ing procedure.
S lides were loaded into racks and placed in acetone fo r 5 m inutes and 
then in 2% v/v Am inopropyltriethoxysilane in acetone fo r another 5 
m inutes in a fum e hood. Slides were washed in running tap w ater fo r 25 
m inutes and then dried overnight in a fume hood. They were then labeled 
and stored in dated boxes fo r no more than 6 months.
2.3 Tissue sections
Archival form alin fixed, paraffin-em bedded tissue blocks were cooled by 
placing them  on a cooled stage (Tissue TEX II) prior to sectioning. 4 pm 
sections were cut using a m icrotom e (Leica RM 2135). The cut sections 
were transferred into a warm  w ater bath at 50°C and then mounted on to
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Am inopropyltrie thoxysilane-treated glass slides o r non-silanised slides. 
The slides with tissue sections were then loaded into slide holding racks 
and placed in an oven at 56°C overnight to allow the tissue to fix. 
S ilanised slides were used fo r IHC and non- silanised slides were used for 
haem atoxylin and eosin staining.
2.4 Haematoxylin and Eosin staining
For histological exam ination and identification o f tum our areas
Haem atoxylin and Eosin staining was perform ed using the follow ing
protocol.
1. Removal of wax from  the sections Before any staining procedure is 
carried out it is necessary to remove the wax from  the sections. This 
was done by placing the slides in Xylene fo r 6 m inutes twice.
2. Rehydration o f tissue sections- The sections were gradually rehydrated 
through graded alcohols (100% alcohol fo r 4 m inutes, repeat; 90% 
alcohol fo r 2 m inutes & 70% alcohol fo r 2 minutes. Then the sections 
were washed in running tap w a te r fo r 2 minutes.
3. Staining o f sections: sections were placed in Haematoxylin stain fo r 3 
m inutes, washed in running tap water. They were then rinsed in Scott’s 
tap w ater untill blue and cleared in acid alcohol. Sections were then
63
rinsed in running tap water. They were then placed in eosin fo r 3 
m inutes and again rinsed in running tap water.
4. Dehydrating and mounting the sections- The sections were then 
dehydrated through a series of alcohols (70% alcohol fo r 30 seconds, 
90% alcohol fo r 30 seconds & 100% alcohol fo r 30 seconds) and 
cleared in Xylene. The sections were then covered with glass cover 
slips using DPX m ountant (contains dibutyl phthalate, xylene).
The slides were viewed using a light m icroscope.
2.5 Immunohistochemistry 
2.5.1 General Principles
Im m unohistochem istry (IHC) is a technique fo r localising and visualising 
an antigen in a tissue section by using an antibody specific fo r the tissue 
antigen. The procedure consists o f tissue preparation, antibody 
incubation, and a series o f detection reactions. There are a num ber of 
d ifferent IHC techniques. All aim to attach a visib le m arker to the prim ary 
antibody tha t w ill specifica lly recognise the antigen o f interest.
The visualisation m ethod we used is known as indirect IHC, which is m ore 
sensitive than the direct method that em ploys labelling the antibody w ith a 
substance that can be visualised. In indirect IHC another antibody 
(secondary antibody) is used to am plify the signal and enhance the 
detection of the antigen. The secondary antibody would be raised in a 
species different to that of the prim ary antibody. If the prim ary antibody is
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m ade in the m ouse then the secondary antibody would be made in a 
horse or a rabbit. The secondary antibody is labelled w ith the m arker (e.g. 
peroxidase). The peroxidase label would then be visualised with DAB 
(diam inobenzidine). The advantage o f using th is procedure is greater 
sensitivity. Each prim ary antibody will end up with several secondary 
antibodies attached. Therefore we get m ore peroxidase m olecules 
attached to each antigen.
The procedure w e used was slightly more com plicated and is known as 
Avid in Biotin Peroxidase Com plex procedure (ABC). This is a 3-step 
procedure, the first two are sim ilar to the indirect method, but the 
secondary antibody is labelled not with the peroxidase but with biotin. 
Biotin has a very high affin ity fo r avidin (present in high am ounts In egg 
white  and acts as an antib iotic by removing biotin from  any bacteria that 
could infect the egg), which is a large m olecule and can be labeled with 
m any peroxidase m olecules. So an avidin-peroxidase conjugate form s the 
third layer.
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Figure 7; Avidin biotin peroxidase complex
Ag- Antigen; P Ab- Primary antibody; S Ab- Secondary antibody; B- Biotin; 
A- Avidin labelled with peroxidase; DAB- Diamino benzidine.
2.5.2 Quality control for immunohistochemistry
When demonstrating the antigen of interest in tissue using IHC 
techniques, it is essential to include appropriate control sections (positive 
and negative) for quality control. Negative controls serve as “blanks” and 
any staining on this specimen is nonspecific. The primary antibody is 
added to the positive control section and an isotope matched IgG is added 
to the negative control section. A positive reaction with the positive control
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sec tion indicates tha t the antibodies are working properly and tha t the 
procedure has been carried out correctly. A  negative reaction w ith the 
positive control indicates that the fixatives may have reduced access of 
antibody to antigen, the antibody m ay be too dilute, the secondary 
antibody m ay not be recognising the prim ary antibody or the 
enzym e/substrate system is defective or incompatible. A  positive reaction 
with the negative control indicates e ither a technical m istake or non­
specific staining as a result o f secondary antibody binding non specifically 
to the tissue. Therefore a negative control slide m ust always be included.
2.5.3 Primary Antibodies
Prim ary antibodies may be either polyclonal or monoclonal. Polyclonal 
antibodies are produced by in vivo imm unisation usually o f m amm als such 
as a goat, sheep, m ouse or a rabbit. Polyclonal antibodies are derived 
from a variety o f B-cells that d iffer in the genetic m aterial that encodes fo r 
antibody production. In a polyclonal sam ple som e o f the antibodies w ill be 
specific fo r the antigen with which the animal was im m unised. The 
rem aining antibodies are produced from interaction with other antigens 
tha t the animal was exposed to throughout its lifetime.
M onoclonal antibodies are derived using a more com plex process. Here, a 
mammal, an inbred mouse, is immunised w ith an antigen. A fter repeated 
im m unisations, the spleen o f the animal is removed. The spleen is 
responsible fo r B-cell production and so the spleen cells contain the
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gene tic inform ation tha t gives rise to antibody production. But these 
spleen cells cannot be cultured. So they are fused with "im m ortal" 
m yelom a cells, so-called because o f their ability to proliferate in vitro. The 
resulting fused cells, called hybridom a cells, are screened by enzym e- 
linked im m unoabsorbant assay (ELISA) using the antigen in question. 
This assay allows selection of hybridoma cells that produce antigen- 
specific antibodies. Because a given hybridoma cell is derived from  a 
single B-cell, it produces a “m onoclonal” cell population producing the 
required antibody. Once a single hybridom a line is selected, it is injected 
into a healthy mouse. Hybridom a cells, like m yelom a cells, have the ability 
to produce tumors. A fte r injection w ith a hybridom a line, a tum or grows 
inside the host mouse. W hen this tum or grows, it produces ascites, a fluid 
that is rich in m onoclonal antibodies. These days this is being carried out 
by culturing hybridom as in-vitro
2.5.4 Immunohistochemistry procedure
The steps described below are only general principles in carrying out IHC. 
A fte r optim ising the IHC technique fo r each antibody the follow ing steps 
were tailored accordingly. The steps taken to optim ise the IHC technique 
for each antibody is described in detail separately.
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Step I Rem oval of w ax and rehydration of tissue sections
The wax was dissolved from  paraffin em bedded tissue by placing the 
slides in Xylene (Fishers chem icals) fo r 6 m inutes and th is was repeated. 
Xylene is m iscible w ith alcohol. The sections were gradually rehydrated 
through graded alcohols (100%  alcohol fo r 4 m inutes,repeat; 90% alcohol 
fo r 2 m inutes & 70% alcohol fo r 2 minutes. Then the sections were 
washed in running tap w ater fo r 2 minutes.
Step II Quenching o f endogenous peroxidase activity
Some cells, especially red blood cells, m uscle cells, granulocytes, 
m onocytes, kidney and liver contain high concentrations of peroxidase 
enzym es. If endogenous peroxidase is not destroyed, it could result in 
staining of the negative control and tissue sections due to nonspecific 
oxidation o f DAB. Endogenous peroxidase is generally inactivated by 
incubating tissues w ith H2O 2. Sections are treated w ith 0.3% H2O2 (VW R 
International lim ited; supplied at concentration of 30%) fo r 10 m inutes in a 
staining dish using a m agnetic stirrer and then rinsed in distilled w ater to 
rem ove excess FI2O 2 .
Step III Retrieval o f Antigen
After form alin fixation and paraffin em bedding o f tissues, m any antibodies 
react only weakly or not at all with the ir antigen(s). This is because 
solvents, heat and fixatives denature proteins, and prom ote protein protein 
and protein nucleic acid cross linking, these alterations can m ask antigens 
by obscuring the epitope recognised by the antibody.
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Form aldehyde fixes tissue by reacting w ith the basic am ino acid lysine to 
form  cross-linking m ethylene bridges. This may result in the partial loss of 
the characteristic 3D protein structure so that the change in physical 
shape o f the antigen m eans that it will not be recognised by its 
corresponding antibody: therefore antigen retrieval. If the form aldehyde 
cross-links d irectly w ith the epitope in question it m eans that its chem ical 
characteristics are altered and again it w ill not be recognised by its 
antibody until unmasked. Trypsin exposes the antigenic determ inant by 
cleaving argin ine and lysine residues. M icro waving or pressure cooking in 
EDTA at pH 8 is the latest antigen retrieval method and although the exact 
m echanism  is unknown, it is thought that the fixative protein cross-linking 
is broken thus restoring the proteins physical and chem ical characteristics 
and therefore antigenic properties.
Antigen retrieval was carried out by one o f the follow ing techniques that 
were under use in our laboratory, depending upon the antibody used.
1. M icrowave/ pressure cooking- Tris EDTA buffer solution (0.37g sodium 
EDTA-BDH Laboratory supplies and 0.55g Tris base-Sigm a, made up to 1 
litre w ith distilled water, pH 7.5) was warm ed fo r 13.5 m inutes on full 
pow er and the sections were m icrowaved in a pressure cooker fo r 2 
m inutes to bring it to pressure and fo r another 5 m inutes under pressure. 
Then the weight on the pressure cooker was lifted to allow  the steam to 
escape and the lid was finally removed. The sections were allowed to cool
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for 20 m inu tes, washed in w a ter and then transferred to a staining dish 
with water.
2. Trypsin antigen retrieval technique-
Sections were incubated in 80 mis o f 0.1% Trypsin calcium  chloride 
solution (0.08 gm of Trypsin (Sigma) in 80 mis o f 0.1% C aC ^ (Sigma) 
solution ) fo r 25 m inutes in a w ater bath at 37°C. Subsequently the slides 
were washed in w ater and transferred to a staining dish with water.
Step IV-Blocking non-specific back ground staining
Non specific background staining was blocked by incubating the sections 
in normal horse se rum (Vector) at a concentration of 15pl/ml fo r 15 
m inutes. A fter incubation tim e the serum was tapped off the sections.
Step V- Blocking o f endogenous Biotin
Some tissues m ay bind avidin, biotinylated peroxidase or other 
Biotin/Avidin system  com ponents w ithout prior addition of biotinylated 
antibody because Biotin is a recognised enzym e co-factor in normal 
physiology. This binding m ay be due to endogenous biotin or biotin 
binding proteins, lectins, or non-specific binding substances present in the 
section.
If a high background was present using the ABC reagents (Vector) in the 
absence of biotinylated secondary antibody, pre-treatm ent of the tissue 
w ith avidin, followed by biotin (to block the remaining binding sites on the
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avidin), was required . The sections were incubated w ith Avidin for 15 
m inutes, rinsed in Tris Base solution (pH 7.5 and 100 m is of 10 tim es TBS 
in 900 mis o f distilled water), then incubated with Biotin fo r 15 m inutes and 
fina lly rinsed in Tris Base solution.
Step V I- Incubation w ith Prim ary antibody
Excess serum was blotted from the sections and then incubated w ith the 
prim ary antibody in a hum idified cham ber or in a cold room (4°C) 
depending upon the antibody used .The concentration o f the prim ary 
antibody and Incubation period varied, depending on the antibody. A fte r 
incubation the sections were washed in Tris Base saline solution fo r 2 x 5 
m inutes.
Step VII- Binding with the secondary antibody
The sections were incubated w ith the biotinylated secondary antibody 
solution (15j.ll o f normal serum + 5|al o f secondary antibody per ml of Tris 
Base saline solution) fo r 30 m inutes and washed in Tris Base saline 
solution fo r 2 X 5 m inutes.
Step V lii- Avidin I biotin labelled peroxidase binding
The avidin and peroxidase labeled biotin must be allowed to interact fo r at 
least 30 m inutes before being applied (to the sections), resulting in the 
form ation o f a large and highly labelled complex, the labeled m olecules 
(peroxidase) being shared by several biotin molecules.
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The proportion of avidin to labelled biotin must be such that some binding 
sites on the avidin are left free to attach to the biotin o f the secondary 
antibody. Avidin has an extraord inarily high affin ity for biotin making 
binding of avidin to  biotin essentia lly irreversible. In addition, avidin has 4 
binding sites fo r biotin and peroxidase can be conjugated w ith several 
m olecules o f biotin resulting in a very sensitive detection system.
The sections were incubated with ABC solution (Vectastain Elite ABC 
reagent- 20pl o f Reagent A  added to 1 ml o f Tris Base saline solution, 
m ixed, then 20pl o f Reagent B added and m ixed again) fo r 30 m inutes 
and washed in Tris Base saline solution for 2 x 5 m inutes.
Step IX- Localizing peroxidase using D iam inobenzidine
Diam inobenzidine tetrahydrochloride (DAB) is a chrom ogen used to 
localise peroxidase in the tissue sections. DAB in the presence o f 
peroxidase will polym erize to form  a visible insoluble brown precipitate 
which is insoluble in alcohol and clearing agents, allow ing sections to be 
perm anently mounted. DAB is poisonous and a known carcinogen 
therefore precautions m ust be taken. The sections were incubated with 
DAB (Vector Laboratories) solution (2 drops o f buffer stock added to 5 ml 
of saline, m ixed, then 4 drops o f DAB added, m ixed and fina lly 2 drops of 
hydrogen peroxide is added and m ixed) fo r 2-10 minutes__until brown 
colour developed and washed in running water fo r 10 m inutes.
73
Step X - Counterstaining
It is helpful to use a nuclear counter stain, which will produce a colour 
contrast w ith the labelled antigen. W ith the deep brown colour produced 
by the DAB and peroxidase, haematoxylin produces a satisfactory blue 
counter stain.
The sections were counter stained with heamatoxylin fo r 60 seconds and 
then washed in water. The sections are then immersed in Scotts tap water 
till they appear blue and then immersed in acid alcohol and then washed 
in running tap water.
Step XI- Dehydrating and m ounting
The sections were then dehydrated through a series o f alcohols (70% 
alcohol for 1 minute; 90% alcohol fo r 1 m inute and 100% alcohol fo r 2 
m inutes), cleared in xylene (2 m inutes) and mounted in a synthetic resin 
(DPX- xylene, dibutylphthalate). The protein in tissue sections, the 
synthetic resin and the glass slides all have sim ilar refractive index thus 
producing the m axim um  resolution when viewed down the m icroscope.
2.5.5 Choice of Antibodies
In the present study c-Jun, Phosphorylated c-Jun, c-Fos, Protein Kinase 
C, AR, PSA and COX-2 protein expressions were studied 
im m unohistochem ically.
An antibody is defined as an im m unoglobulin capable o f specific 
com bination with the antigen tha t caused its production in a susceptible
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animal. The classical Y shape of IgG is composed of the two variable, 
antigen specific F(ab) arms, which are critical fo r actual antigen binding, 
and the constant Fc “ta il” tha t binds immune cell Fc receptors and also 
serves as a useful “handle” fo r m anipulating the antibody during most 
im m unochem ical procedures.
Imm unochem ical techniques capita lize upon the extrem e specificity, at the 
m olecular level, of each im m unoglobulin fo r its antigen, even in the 
presence o f high levels o f contam inating m olecules. The m ultivalancy o f 
most antigens and antibodies enables them to interact to form  a 
precipitate.
In our study all the antibodies used were m onoclonal. In general 
monoclonal antibodies are reported to provide more specific 
im m unostaining results than those obtained w ith polyclonal antibodies. 
A lso they give much lower background staining than polyclonal antibodies. 
They also provide highly reproducible results. In v iew  of these advantages 
m onoclonal antibodies w ere used in our study. These antibodies were 
shown to be effective in staining tissue em bedded in paraffin wax. 
Im m unohistochem ical protein expressions of c-Jun, phosphorylated c-Jun, 
c-Fos, Protein K inase C, AR, PSA and COX-2 using these m onoclonal 
antibodies have been reported in various studies and the results were 
encouraging.
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2.6 c-Jun Immunohîstochemistry
c-Jun IHC was perform ed using the DK4 m ouse monoclonal c-Jun 
antibody (lgG 1) specific to the human c-Jun oncoprotein (Novocastra 
laboratories). DK4-c-Jun has been reported to be effective on frozen 
tissue as well as paraffin w ax em bedded tissue. The data sheet fo r this 
antibody recom m ended a typical working dilution between 1:40 to 1:80, 
Trypsin digestion of paraffin sections and over night prim ary antibody 
incubation at 4°C fo r IHC. Reconstituted antibody was frozen at -20°G  and 
stored in a freezer. W orking dilutions of the antibody was prepared on the 
day o f use.
As a large proportion o f breast cancers express c-Jun protein, breast 
cancer sections were used in the work up o f this antibody in the initial 
stages. Subsequently prostate cancer tissue was used fo r the study. 
Antibody concentrations of 1:40, 1:50, 1:60, 1:70, 1:80, 1:90, 1:100 & 
1:120 were incubated fo r 30 or 60 m inutes at room tem perature and at 
4°C in a cold room overnight and the optimum antibody concentration was 
found to be at a dilution o f 1:70 (40 pi of reconstituted prim ary antibody in 
2800 pi o f DAKO antibody diluent). The optimum duration o f incubation 
was overnight at 4°C in a cold room. Negative control sections did not 
dem onstrate any background staining. However to reduce the background 
staining in the positive slides DAKO antibody d iluent w ith background
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reducing com ponen ts was used. The following protocol was used fo r c~ 
Jun IHC.
2.6.1 IHC protocol for c-Jun
Clone DK4, NCLc-JUN 
M ouse m onoclonal antibody lgG i 
NovoCastra Laboratories
A) Dewax & rehydrate
1. Dewax the slides-2 x 4 m inutes in Xylene
2. Re hydrate-2 x 2 m inutes in 100% alcohol, 2 m inutes in 90% alcohol 
and 2 m ins in 70% alcohol
3. R inse in w ater
4. Treat w ith 0.3% Hydrogen peroxide fo r 10 m inutes on a m agnetic 
stirrer (30% Hydrogen peroxide- 5 mis in 500 m is o f d istilled water)
5. R inse in water
B) Antigen Retrieval
1. Make up 0.1 % Ca Cl 2 (0.08g in 80ml o f distilled water)
2. Incubate sections in 0.1 % Trypsin in 80 mis of CaCI2 solution fo r 25 
m ins at 37°C
3. Rinse in water
4. T ransfer to a staining dish w ith w ater (slides can be stored like this)
5. Keep TBS ready. (1 in 10 TBS -  200 mis in 2 litres o f distilled W ater)
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C) Staining
1. Ring the sections w ith DAKO pen to create a barrier.
2. Horse serum - incubate the sections fo r 15 m inutes
(Vector ABC Kit- add 15 pi o f horse serum per 1 ml o f TBS- buffer; i.e.
0.5m l per slide)
3. Blot serum from  sections
4. Prim ary antibody- Incubate the sections w ith c-Jun m onoclonal 
antibody (1 in 70 dilution) over night in a cold room at 4°C. Use DAKO 
solution fo r dilution
(Use isotope m atched IgG antibody fo r negative control ie 5 pi of 
serum in 500 pi o f DAKO solution)
5. W ash in TBS- 2 X 5  m inutes, (use m agnetic stirrer)
6. Secondary antibody- Incubate the sections w ith secondary antibody fo r 
30 m inutes. (15 pi o f serum + 5 pi o f secondary antibody per 1 ml TBS)
7. W ash in TBS- 2 X 5  minutes, (use stirrer)
8. ABC reagent- Incubate fo r 30 m inutes.(20 pi of A, 20 pi o f B per 1 ml of 
TBS)
9. W ash in TBS- 2 X 5  m inutes.(use m agnetic stirrer)
10. DAB- Incubate the sections w ith DAB until co lour develops ie fo r 2-10 
m inutes.(5 m is o f distilled w ater + 2 drops o f buffer stock & mix, 4 
drops o f DAB stock & mix, 2 drops o f hydrogen peroxide & mix)
11. W ash in w a ter fo r 10 m inutes
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D) Counter Staining
1. Stain in haematoxylin fo r 60 seconds
2. Rinse in running tap w ater
3. Place the slides in Scots tap w ater substitute till they appear blue
4. R inse in running tap w ater
E) Dehydrating & m ounting
1. 1 m inute 70% alcohol
2. 1 m inute 90% alcohol
3. 2 x 1  m inutes 100% alcohol
4. 2 X 1 m inutes xylene & m ount in DPX
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2.7 Phosphorylated c-Jun I m mu nohistochemistry
A  m ouse m onoclonal lgG i antibody raised against a peptide 
corresponding to am ino acids 56-69 of c-Jun of human origin was used for 
IHC. Phosphorylated c-Jun (KM-1) antibody reacts with c-Jun p39 
phosphorylated on Ser-63 of mouse, rat and human origin. No cross 
reactivity w ith Jun B or Jun D phosphorylated on the analogous serine 
residues or with c-Jun non-phosphorylated at Ser-63. It is a product o f 
Santa Cruz B iotechnology, Inc (p-c-Jun (KM-1): sc-822). The data sheet 
fo r th is antibody recom m ended a dilution range of 1:100-1:1000 for 
western blot analysis. Recomm ended starting dilution was 1:100. Each 
vial contained 200pg lgG i in 1.0 ml of PBS containing 0.1% sodium azide 
and 0.2% gelatin. The antibody was stored at 4°C in a cold room. Prostate 
cancer tissue was used to work out the antibody. 1:100 dilution was tried 
to start with. Negative control sections did not dem onstrate any 
background staining. Satisfactory staining was observed with this dilution. 
The follow ing protocol was used fo r p-c-Jun IHC.
2.7.1 IHC protocol for p-c-Jun
p-c-Jun (KM-1): sc-822 
M ouse m onoclonal antibody lgG i 
Santa Cruz B iotechnology,Inc.
A) Dewax & réhydraté
1. Dewax the slides-2 x 4 m inutes in Xylene
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2. Rehydrate-2 x 2 m inutes in 100% alcohol, 2 m inutes in 90% alcohol 
and 2 m ins in 70%  alcohol
3. R inse in water
4. Treat with 0.3% Hydrogen peroxide for 10 m inutes on a m agnetic 
stirrer (30% Hydrogen peroxide- 5 mis in 500 m is o f distilled water)
5. Rinse in water
B) Antigen Retrieval
1. Make up 0.1 % CaCI 2 (0.08g in 80ml o f distilled water)
2. Incubate sections in 0.1% Trypsin in 80 mis of CaCI2 solution fo r 25 
m ins at 37°C
3. W ash in water
4. T ransfer to a staining dish w ith w ater (Slides can be stored like this)
5. Keep TBS ready. (1 in 10 TBS -  200 mis in 2 litres o f distilled W ater)
C) Staining
1. Ring the sections with DAKO pen to create a barrier.
2. Horse serum - Incubate the sections fo r 15 m inutes
(Vector ABC Kit- add 15 pi o f horse serum per 1 ml o f TBS- buffer; i.e. half 
ml per slide)
3. B lot serum from sections
4. Prim ary antibody- Incubate the sections w ith phosphorylated c-Jun 
m onoclonal antibody (1 in 100 dilution) over night at 4°C. Use DAKO 
solution fo r dilution (Use isotope matched IgG antibody fo r negative 
control i.e. 5pl o f serum in 500 pi o f DAKO solution)
5. W ash in TBS- 2 X 5  m inutes (use m agnetic stirrer)
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6. Secondary antibody- Incubate the sections w ith secondary antibody fo r 
30 m inutes (15 pi o f serum  + 5 pi o f secondary antibody per 1 ml TBS)
7. W ash in TBS- 2 X 5  m inutes (use stirrer)
8. ABC  reagent- Incubate w ith it fo r 30 m inutes (20 pi o f A, 20 pi o f B per 1 
ml o f TBS)
9. W ash in TBS- 2 X 5  m inutes (use m agnetic stirrer)
10. DAB- Incubate the sections w ith the DAB until co lour develops i.e. fo r 
2-10 m inutes (5 mis o f distilled w ater + 2 drops o f buffer stock & mix, 4 
drops o f DAB stock & mix, 2 drops o f hydrogen peroxide & mix)
11. W ash in water fo r 10 m inutes.
D) Counter Staining
1. Stain in haematoxylin fo r 60 seconds
2. R inse in running tap w ater
3. Place the slides in Scots tap w a te r substitute till they appear blue
4. Rinse in running tap w ater
E) Dehydrating & m ounting
1. 1 m inute 70%  alcohol
2. 1 m inute 90% alcohol
3. 2 x 1  m inutes 100% alcohol 
4 . 2 x 1  m inutes xylene & m ount in DPX
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2.8 c- Fos Immunohîstochemistry
A m ouse m onoclonal an tibody lgG i was used fo r c-Fos IHC. The antibody 
is m anufactured by B ioG enex using c-Fos 88 clone. This antibody 
specifically localizes c-Fos protein in form alin-fixed, paraffin-em bedded 
tissue sections. It is sourced from  ascites and diluted in phosphate 
buffered saline, pH 7.6, containing 1% BSA and 0.09%  sodium azide. The 
data sheet recom m ends to  storing the antibody at 2-8°C. Antigen retrieval 
was tried by m icrowave pressure cooking as recom m ended In the data 
sheet. Due to inconsistency in staining, Trypsin digestion technique was 
used fo r antigen retrieval. Breast cancer tissue as well as prostate cancer 
tissue were used fo r working up the antibody. The data sheet fo r the 
antibody recom mended a dilution of 50-100, incubation tim e of 30 m inutes 
at room temperature. Satisfactory staining was achieved with 1:50 dilution. 
The follow ing protocol was used fo r c-Fos IHC.
2.8.1 IHC protocol for c-Fos
c-Fos M ouse m onoclonal antibody lgG i
Ab N0.348M
Biogenex
A) Dewax & rehydrate
1. Dewax the slides-2 x 4 m inutes in Xylene
2. Rehydrate-2 x 2 m inutes in 100% alcohol, 2 m inutes in 90%  alcohol 
and 2 m ins in 70%  alcohol
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3. R inse in w ater
4. Treat with 0.3%  Hydrogen peroxide fo r 10 m inutes on a m agnetic 
stirrer (0.3% Hydrogen peroxide- 5 m is in 500 m is o f distilled water)
5. R inse in w ater
B) Antigen Retrieval
1. Make up 0.1% CaCI 2 (0.08g in 80ml of distilled water)
2. Incubate in 0.1% Trypsin in 80 m is of CaCI2 solution for 25 m ins at 
37°C
3. W ash in w ater
4. Transfer to a staining dish with w ater (Slides can be stored like this)
5. Keep TBS ready (1 in 10 TBS -  200 mis in 2 litres o f distilled W ater)
C) Staining
1. Ring the sections w ith DAKO pen to create a barrier
2. Horse serum - Incubate the sections fo r 15 m inutes
(Vector ABC Kit- add 15 pi of horse serum per 1 ml o f TBS- buffer; i.e. half
ml per slide)
3. Blot serum from  sections
4. Prim ary antibody- Incubate the sections w ith c-Fos m onoclonal 
antibody (1 in 50 dilution) over night in a cold room at 4°C. Use DAKO 
solution fo r dilution. (Use isotope matched IgG antibody fo r negative 
control i.e. 5 pi o f serum  in 500 pi o f DAKO solution)
5. W ash in TBS- 2 X 5  m inutes (use m agnetic stirrer)
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6. Secondary antibody- Incubate the sections with secondary antibody for 
30 m inutes (15 pi o f serum + 5 pi of secondary antibody per 1 ml TBS)
7. W ash in TBS- 2 X 5  m inutes (use m agnetic stirrer)
8. ABC reagent- Incubate w ith it fo r 30 m inutes (20 pi o f A, 20 pi o f B 
per 1 ml o f TBS)
9. W ash in TBS- 2 X 5  m inutes (use m agnetic stirrer)
10. DAB- Incubate the sections w ith the DAB until co lour develops i.e. fo r 
2-10 m inutes (5 m is of distilled w ater + 2 drops of buffer stock & mix, 4 
drops o f DAB stock & mix, 2 drops o f hydrogen peroxide & mix)
10. W ash in w a ter fo r 10 m inutes.
D) Counter Staining
1. Stain in haematoxylin fo r 60 seconds
2. Rinse in running tap w ater
3. Place the slides in Scots tap w ater substitute till they appear blue
4. Rinse in running tap water.
E) Dehydrating & m ounting
1. 1 m inute 70%  alcohol
2. 1 m inute 90% alcohol
3. 2 x 1  m inutes 100% alcohol
4. 2 X 1 m inutes xylene & m ount in DPX.
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2.9 Protein Kinase C Immunohistochemistry
PKC IHC was carried ou t using a mouse m onoclonal lgG2a antibody 
against purified bovine brain protein kinase C. The antibody (anti-protein 
kinase C ab31) is a product o f abeam limited. It has cross reactivity w ith 
mouse, rat and human PKC. It was synthesized from  MC5 clone and 
P3x63. This antibody recognizes alpha, beta and gam m a PKC isoforms. 
The data sheet recom mended storage o f the antibody at 4°C. For long 
term  (>6 months) storage the recommended tem perature is -20°C.
Trypsin digestion technique was in itially tried fo r antigen retrieval. This did 
not work. Hence pressure cooking technique was tried subsequently. This 
worked well. D ifferent d ilutions o f the primary antibody were tried (1:100, 
1:200, 1:300 & 1:400). Optim um  concentration o f the prim ary antibody 
was found to be at 1:200.
The follow ing protocol was used fo r PKC IHC.
2,9.1 IHC protocol fo r PKC
PKC M ouse m onoclonal antibody lgG2a 
Anti Protein Kinase C ab31 
Abeam Limited
A) Dewax & rehydrate
1. Dewax the slides-2 x 4 m inutes in xylene
2. Rehydrate-2 x 2 m inutes in 100% alcohol, 2 m inutes in 90% alcohol 
and 2 m ins in 70%  alcohol
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3. R inse in w ater
4. Treat with 0.3% Hydrogen peroxide fo r 10 m inutes on a m agnetic 
stirrer (0.3% Hydrogen peroxide- 5 m is in 500 m is o f distilled water)
5. R inse in w ater
B) Antigen Retrieval
1. Make up Tris EDTA buffer, pH 8 (0.37g EDTA+0.55G Tris Base + 1 
Litre distilled water)
2. M icrowave on full power for 13.5 m inutes to warm the solution
3. Add the slides and close the lid and m icrowave on full power fo r 2 
m inutes to bring to pressure
4. M icrowave fo r 5 m inutes under pressure
5. Carefully remove the weight to allow the steam to escape, and remove 
the lid. Cool it fo r 20 m inutes
6. W ash the slides in water
7. Transfer to a staining dish w ith water (Slides can be stored like this)
8. Keep TBS ready (1 in 10 TBS -  200 mis In 2 litres o f distilled W ater)
0 ) Staining
1. Ring the sections with DAKO pen to create a barrier & Keep incubator 
ready
2. Horse serum - Incubate the sections with it fo r 15 m inutes
(Vector ABC Kit- add 15 pi o f horse serum per 1 ml of TBS- buffer [i.e. half 
ml per slide)
3. Blot serum from  sections
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4. Blocking step- Avid in- fo r 15 m inutes, quick rinse in TBS; B iotin-for 15 
m inutes, quick rinse in TBS (No dilution of Avidin/B iotin)
5. Primary antibody- Incubate the sections w ith PKC monoclonal antibody 
(1 in 200 dilution) over night in a cold room at 4°C. Use DAKO solution 
for dilution.
(Use isotope matched IgG antibody fo r negative control i.e. 5 pi o f 
serum  in 500 pi o f DAKO solution)
6. W ash in TBS- 2 X 5  m inutes (use m agnetic stirrer)
7. Secondary antibody- Incubate the sections w ith secondary antibody for 
30 m inutes (15 pi o f serum + 5 pi o f secondary antibody per 1 ml TBS)
8. W ash in TBS- 2 X 5  m inutes (use m agnetic stirrer)
9. ABC reagent- Incubate w ith it for 30 m inutes (20 pi o f A, 20 pi o f B per 
1 ml o f TBS)
10. W ash in TBS- 2 X 5  m inutes (use magnetic stirrer)
11. DAB- Incubate the sections w ith the DAB until co lour develops i.e. fo r 
2-10 m inutes (5 m is o f distilled w ater + 2 drops of buffer stock & mix, 4 
drops of DAB stock & mix, 2 drops o f hydrogen peroxide & mix)
12. W ash in w ater fo r 10 m inutes.
D) Counter Staining
1. Stain in haematoxylin fo r 60 seconds.
2. R inse in running tap water.
3. Place the slides in Scots tap w ater substitute till they appear blue.
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4. R inse in running tap water.
E) Dehydrating & m ounting
1. 1 m inute 70% alcohol
2. 1 m inute 90% alcohol
3. 2 x 1  m inutes 100% alcohol
4. 2 X 1 m inutes xylene & m ount in DPX.
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2.10 COX-2 Immunohistochemistry
I used a m ouse m onoclonal (CX229) an tibody a product o f Cayman 
chem ical USA. Our laboratory has previous experience in using this 
antibody in breast cancer and prostate cancer samples. I followed this 
protocol w ithout any m odifications as described below.
2.10.1 IHC protocol for COX 2
COX 2 Mouse m onoclonal antibody IgG I
CX229 clone
Cayman Chemical, USA.
A) Dewax & rehydrate
1. Dewax the slides-2 x 4 m inutes in Xylene
2. Rehydrate-2 x 2 m inutes In 100% alcohol, 2 m inutes in 90% alcohol 
and 2 m ins in 70%  alcohol
3. Rinse in w ater
4. Treat w ith 0.3% Hydrogen peroxide fo r 10 m inutes on a m agnetic 
stirrer (0.3%  Hydrogen peroxide- 5 mis in 500 mis o f distilled water)
5. Rinse in w ater
B1 Antigen Retrieval
1. Make up Tris EDTA buffer, pH 8 (0.37g EDTA+0.55G Tris Base + 1 
Litre distilled water)
2. M icrowave on full power fo r 13.5 m inutes to warm  the solution
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3. Add the slides and close the lid and m icrowave on full power fo r 2 
m inutes to bring to pressure
4. M icrowave fo r 5 m inutes under pressure
5. Carefully remove the w e igh t to allow the steam to escape, and remove 
the lid. cool it fo r 20 m inutes
6. W ash the slides in w ater
7. Transfer to a staining dish w ith w ater (slides can be stored like this)
8. Keep TBS ready (1 in 10 TBS -  200 mis in 2 litres o f distilled W ater)
0 )  Staining
1. Ring the sections with DAKO pen to create a barrier.
2. Horse serum - Incubate the sections fo r 15 m inutes
(Vector ABC Kit- add 15 pi o f horse serum per 1 ml of TBS- buffer; i.e. 
half ml per slide)
3. Blot serum from  sections and incubate with prim ary antibody at room 
tem perature fo r 30 m inutes
(Use isotope matched IgG antibody fo r negative control i.e. 5 pi o f 
serum in 500 pi o f DAKO solution)
4. W ash in TBS- 2 X 5  m inutes (use m agnetic stirrer)
5. Add yellow  link solution and incubate fo r 30 m inutes
6. W ash in TBS- 2 X 5  m inutes (use stirrer)
7. Add red streptavidin solution and incubate for 1 hour
8. W ash in TBS- 2 X 5  m inutes (use m agnetic stirrer)
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9. DAB- Incubate the sections w ith the DAB until co lour develops i.e. fo r 
2-10 m inutes (5 m is o f distilled w ater + 2 drops of buffer stock & mix, 4 
drops of DAB stock & mix, 2 drops o f hydrogen peroxide & mix)
10. W ash in w ater fo r 10 m inutes
D) Counter Staining
5. Stain in haematoxylin fo r 60 seconds.
6. Rinse in running tap water.
7. Place the slides in Scots tap w ater substitute till they appear blue.
8. Rinse in running tap water.
E) Dehydrating & m ounting
5. 1 m inute 70%  alcohol
6. 1 m inute 90% alcohol
7. 2 X 1 m inutes 100% alcohol
8. 2 X 1 m inutes xylene & m ount in DPX.
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2.11 Androgen Receptor Immunohistochemistry
A  mouse m onoclonal (clone 2F12) lgG1 antibody was used fo r AR  IHC. It 
is available from  Novocastra Laboratories Ltd (NCL-AR-2F12). The data 
sheet recom m ends high tem perature antigen unm asking technique and 60 
m inutes prim ary antibody incubation at 25°C. W ork up of the antibody was 
carried out using prostate cancer sections. The reconstituted antibody is 
stable fo r at least two m onths when stored at 4°C and fo r long-term 
storage, a liquots o f the antibody are frozen at -20°C. A  prim ary antibody 
dilution o f 1:100 gave optim al staining. The follow ing protocol was used for 
A R IH C .
2.11.1 IHC protocol for AR
AR M ouse m onoclonal (clone 2F12) antibody lgG1 
NCL-AR-2F12
Novocastra Laboratories Ltd
A) De w ax & re hydrate
1. Dewax the slides-2 x 4 m inutes in Xylene
2. Rehydrate-2 x 2 m inutes in 100% alcohol, 2 m inutes in 90% alcohol 
and 2 m ins in 70% alcohol
3. Rinse in w ater
4. Treat w ith 0.3%  Hydrogen peroxide fo r 10 m inutes on a m agnetic 
stirrer (0.3% Hydrogen peroxide- 6 mis in 500 m is o f distilled water)
5. Rinse in w ater
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B) Antigen Retrieval
1. M ake up Tris EDTA buffer ,pH 8 (0.37g EDTA+0.55G Tris Base + 1 
Litre distilled water)
2. M icrowave on full power fo r 13.5 m inutes to warm  the solution
3. Add the slides and close the lid and m icrowave on fu ll power fo r 2 
m inutes to bring to pressure
4. M icrowave for 5 m inutes under pressure
5. Carefully remove the w e igh t to  allow  the steam to escape, and remove 
the lid Cool it fo r 20 m inutes
6. W ash the slides in w ater
7. T ransfer to a staining dish w ith w ater (slides can be stored like this)
8. Keep TBS ready (1 in 10 TBS -  200 mis in 2 litres o f d istilled W ater)
C) Staining
1. Ring the sections w ith DAKO pen to create a barrier.
2. Horse serum - Incubate the sections fo r 15 m inutes
(15 pi o f horse serum per 1 ml o f TBS- buffer; i.e. 0.5 per slide)
3. Blot serum from sections
4. Blocking step- Avid in- fo r 15 m inutes, quick rinse in TBS; B iotin-for 15 
m inutes, quick rinse in TBS (No dilution o f Avidin/B iotin)
5. Prim ary antibody- Incubate the sections w ith prim ary antibody (1 in 100
dilution) fo r 30 m inutes. Use DAKO solution fo r dilution
(Use isotope m atched IgG antibody fo r negative control i.e. 5 pi of 
serum  in 500 pi of DAKO solution)
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6. W ash in TBS- 2 X 5  m inutes (use m agnetic stirrer)
7. Secondary antibody- Incubate the sections w ith secondary antibody 
fo r 30 m inutes (15 pi o f serum  + 5 pi of secondary antibody per 1 ml 
TBS)
8. W ash in TBS- 2 X 5  m inutes (use stirrer)
9. ABC reagent- Incubate w ith it fo r 30 m inutes (20 pi o f A, 20 pi o f B per 
1 ml o f TBS)
10. W ash in TBS- 2 X 5  m inutes (use m agnetic stirrer)
11 .DAB- Incubate the sections w ith the DAB until co lour develops i.e. for 
2-10 m inutes (5 m is of d istilled w ater + 2 drops o f buffer stock & mix, 4 
drops of DAB stock & mix, 2 drops of hydrogen peroxide & mix)
11 .W ash in w ater fo r 10 m inutes.
D) Counter Staining
1. Stain in haematoxylin fo r 60 seconds.
2. R inse in running tap water.
3. Place the slides in Scots tap w ater substitute till they appear blue.
4. R inse in running tap water.
E) Dehydrating & m ounting
1. 1 m inute 70% alcohol
2. 1 m inute 90% alcohol
3. 2 x 1  m inutes 100% alcohol
4. 2 X 1 m inutes xylene & m ount in DPX.
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2.12 PSA Immunohistochemistry
A  m onoclonal an tibody (A 0562) to human PSA was used. It is available 
from  DAKO laboratory, Denmark. A  1:200 prim ary antibody dilution was 
used fo r IHC. Satisfactory staining was observed w ith this dilution. The 
follow ing protocol was used for PSA IHC.
2.12.1 IHC protocol for PSA
PSA human monoclonal 
A  0562
Dako Laboratories Ltd
A) Dewax & re hydrate
1. Dewax the slides-2 x 4 m inutes in Xylene
2. Rehydrate-2 x 2 m inutes in 100% alcohol, 2 m inutes in 90% alcohol and 
2 m ins in 70% alcohol
3. R inse in w ater
4. T reat with 0.3%  Hydrogen peroxide fo r 10 m inutes on a m agnetic stirrer 
(0.3% Hydrogen peroxide- 5 mis in 500 m is o f distilled water)
5. R inse in w ater
A) Antigen Retrieval
1. M ake up Tris EDTA buffer, pH 8 (0.37g EDTA+0.55G Tris Base + 1 
Litre distilled water)
2. M icrowave on full power fo r 13.5 m inutes to warm  the solution
3. Add the slides and close the lid and m icrowave on full power fo r 2
m inutes to bring to pressure
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4. M icrowave for 5 m inutes under pressure
5. Carefully remove the weight to allow  the steam to escape, and remove 
the lid. Cool it fo r 20 m inutes
6. W ash the slides in w ater
7. T ransfer to a staining dish with w ater (Slides can be stored like this)
8. Keep TBS ready (1 in 10 TBS -  200 mis in 2 litres o f distilled W ater)
B) Staining
1. Ring the sections w ith DAKO pen to create a barrier.
2. Horse serum - Incubate the sections fo r 15 m inutes
(Vector ABC Kit- add 15 pi o f horse serum per 1 ml o f TBS- buffer i.e. half 
ml per slide)
3. Blot serum from  sections
4. Blocking step- Avid in- for 15 m inutes, quick rinse in TBS; B iotin-for 15
minutes, quick rinse in TBS (No dilution of Avidin /B iotin)
5. Prim ary antibody- Incubate the sections with prim ary antibody (1 in 200
dilution) 30 m inutes. Use DAKO solution for dilution
(Use isotope m atched IgG antibody fo r negative control i.e. 5 pi of
serum  in 500 pi o f DAKO solution)
6. W ash in TBS- 2 X 5  m inutes (use m agnetic stirrer)
7. Secondary antibody- Incubate the sections w ith secondary antibody fo r 
30 m inutes (15 pi o f serum  + 5 pi o f secondary antibody per 1 ml TBS)
8. W ash in TBS- 2 X 5  m inutes (use stirrer)
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9. ABC reagent- Incubate with it fo r 30 m inutes (20 pi o f A, 20 pi o f B 
per 1 ml o f TBS)
10. W ash in TBS- 2 X 6  m inutes (use m agnetic stirrer)
11. DAB- Incubate the sections w ith the DAB until colour develops i.e. for 
2-10 m inutes (5 m is o f distilled w ater + 2 drops o f buffer stock & mix, 4 
drops o f DAB stock & mix, 2 drops o f hydrogen peroxide & mix)
11. W ash in w ater fo r 10 m inutes.
0 ) Counter Staining
1. Stain in haem atoxylin fo r 60 seconds
2. Rinse in running tap w ater
3. Place the slides in Scots tap w ater substitute till they appear blue
4. Rinse in running tap w ater
D) Dehydrating & m ounting
1. 1 m inute 70%  alcohol
2. 1 m inute 90% alcohol
3. 2 x 1  m inutes 100% alcohol
4. 2 X 1 m inutes xylene & m ount in DPX.
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2.13 Scoring Principles
Scoring was perform ed independen tly by two observers (NSK- N Sa rath 
Krishna and JE- Dr Joanne Edwards). The percentage of cells labelled 
and the labelling intensity were estim ated by scoring the percentage of 
tum our cells falling into negative, weakly positive, m oderately positive and 
strongly positive, intensity, distribution and pattern of im m unostaining 
were recorded. If there was a d iscrepancy between the observer scores, a 
consensus was reached after fu rther evaluation. For exam ple in a tum our 
section, 50% of the cells are negative (no brown staining i.e. 0), 20% 
weakly positive (light brown staining i.e. 1+), another 20% are m oderately 
positive (brown staining i.e. 2+) and the rem aining 10% are strongly 
positive (dark brown staining i.e. 3+). To calculate the histoscore, each 
percentage is multiplied by staining intensity (50 X 0=0; 20 X 1=20; 20 X 
2=40; 10 X  3=30). The sum o f these gives the histoscore (20+40+30=90). 
So the histoscore in this case is 90. Maximum histoscore that could be 
obtained is 300. The m eans o f the two observer’s scores were used for 
analysis. Protein expression was defined as increased or decreased in the 
tum ours sections only if there was a difference between paired pre and 
post horm one refractory prostate cancer sam ples o f greater than 2 X the 
mean observer variation in scores.
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2.14 Statistics
2.14.1 Inter-observer variation
Mean his toscores fo r each protein assigned by the two observers (NSK & 
JE) were compared. Intra-class correlation coefficient (ICCC) and Pearson 
corre lation coeffic ient were calculated. The Pearson corre lation coefficient 
is a m easure o f linear association, rather than of agreement. A  correlation 
coeffic ient o f +1.00 signifies a perfect positive relationship. W hile  -1 .0 0  
signifies a negative relationship. The ICCC is a true index o f agreem ent 
between m easurements. The criteria for assessing the degree o f 
agreem ent were: ICCC<4- poor; ICCC > 0.4 but <0.59-fair; ICCC > 0.6 but 
< 0.74- good; ICCC o f > 0.75 is regarded as excellent.
Analysis of agreem ent fo r each set of m easurem ents was conducted 
using the m ethods o f Bland and Altm an.This plot provides a direct 
im pression o f the agreement, d istribution of the differences and detection 
o f possible outliers. The m ean difference between the two sets o f 
m easurem ents was obtained. This mean difference would be zero fo r 
optim al agreem ent between the m easurements. 95% confidence intervals 
fo r the mean were calculated to assess the precision o f the estim ate of 
mean difference.
The differences between the two sets of m easurem ents were assessed to 
determ ine that they fo llowed a normal distribution. On establishing
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norm ality , the 95% limits o f agreem ent (mean difference ± 2 SD) the lim its 
w ithin which 95% o f the differences would be expected to lie in the 
population were calculated.
This inform ation was displayed graphically by plotting the differences 
against the m eans o f the two sets of measurements. The mean difference 
and 95% lim its o f agreem ent were displayed on the graphs. Random 
scattering of the points above and below the mean line reflects no 
system atic bias between observers.
Scatter plots of one set of m easurem ents against the other further 
illustrated the relationship between the two sets of m easurements.
2.14.2 Correlation of Protein Expression
Spearm an’s rank test was used to correlate protein expression w ith in the 
two groups (hormone sensitive and hormone refractory tumours). 
Spearm an’s rho is a m easure o f the linear relationship between two 
variables. W ilcoxon signed rank tests were used to com pare expression 
between pre and post A lPC s.
The prim ary end points o f the study tim e to relapse (measured from  the 
tim e of response to treatm ent) and the tim e to death from  relapse. The 
principal m ethods of analysis were of tim e to events. Univariate analyses 
used the log rank test with life table analysis o f overall survival and tim e to 
death from relapse perform ed using Kaplan-M eier estimates.
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2.14.3 Power Calculation
S tatistical power is the probability o f getting a statistically significant result 
given that there is a biologically real effect in the population being studied. 
If a particular test is not statistically significant, is it because there is no 
effect or because the study design makes it unlikely that a b iologically real 
effect would be detected? Power analysis can distinguish between these 
alternatives, and is therefore a critical com ponent of designing 
experim ents and testing results.
Power analysis is m ost useful when planning a study. Such "prospective" 
power analyses investigate the relationship between the range of sam ple 
sizes that are thought to be feasible, effect sizes thought to be biologically 
important, levels o f variance that could exist in the population (usually 
taken from the literature or from pilot data), and desired levels of a and 
statistical power. The result is a decision about the sam ple size and a 
level that will be used in the study, and the target effect size that will be 
"detectable" with the given level o f statistical power. A fte r the study is 
com pleted and the results analyzed, a "retrospective" power analysis can 
also be useful if a statistically non-significant result was obtained.
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Protein SD of difference in 
histoscore  
[Between Pre and  
Post AlPC]
Pow er to detect specified difference at 5%  
significance level for n=51 paired sets of 
m easurem ents
Difference  
= 10
Difference  
= 20
Difference  
= 30
Difference  
= 40
c-Jun 64 .9 19 .0% 57.9 % 89.9 % 99.1 %
P c-Jun 47.4 31 .5% 84.0 % 99.3 % 100.0 %
c-Fos 62.5 20.2 % 61.1 % 9 1 .9% 99.4 %
PKC 39.7 42.3 % 94.2 % 100.0 % 100.0 %
Cox-2 45.9 33.2 % 86.3 % 99.6 % 100.0 %
AR 61.8 20.5 % 62.0 % 92.5 % 99.5 %
W ith 51 paired sets o f m easurem ents (51 patients), a difference o f 40 in 
the histoscores fo r each protein tested would be statistically s ignificant 
with a power of 99%.
W ith a sim ilar paired num ber o f measurem ents, a difference o f 30 in the 
histoscores fo r each protein tested would also be statistically significant 
w ith a power of 90%.
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A  generic power calcula tion was performed to estim ate the size of the 
difference in protein expression between pre and post A lPC s that the 
study could reasonably be expected to detect. To perform  this calculation 
it was assum ed that the standard deviation o f the d ifference in histoscores 
was 50 units fo r all proteins (based on pilot data) and that statistical 
significance would be assessed at the 5% level using Student’s paired t- 
test.
No. of 
paired  
sam ples
Power to detect specified difference a t 5% significance  
level assum ing a standard deviation o f 50 histoscore
units
Difference = 
10
Difference = 
20
Difference = 
30
Difference = 
40
30 18.5 56.3 88.8 98.9 %
40 23.5 69.4 95.9 99.9%
50 28.4 79.2 98.6 100.0%
60 33.2 86.2 99.6 100.0%
70 37.9 91.0 99.9 100.0%
80 42.4 94.2 100.0 100.0%
90 46.7 96.4 100.0 100.0%
100 50.8 97.7 100.0 %
If the paired sam ple size is 40 or more and the difference in histoscore for 
each paired sam ple is over 30, then the difference would be statistically 
significant w ith a pow er o f 95.9%.
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CHAPTER 3
RESULTS
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3.1 Patient information
3.1.1 Patient Inclusion Criteria
Based on the inclusion and exclusion criteria only 51 out of 1021 patients 
were suitable fo r the study. If all o f the following criteria were satisfied 
then the patients were included in the study.
1. Patients diagnosed to have carcinoma of the prostate.
2. Prostate cancer tissue available at the tim e of diagnosis.
3. Patients should have received horm onal trea tm ent and have their 
PSA values monitored.
4. Evidence o f response to hormonal treatm ent as indicated by 
decreasing levels o f serum PSA.
5. Subsequently developed hormone relapse disease as indicated by 
rising PSA levels in spite o f continuing horm onal treatment.
6. Had TURP for sym ptom s o f bladder outflow obstruction after 
developing relapse and the ir prostate cancer tissue available.
A  total of 960 patients were excluded as they did not satisfy all o f the 
above criteria. In total 102 (51 pairs) prostate cancer tissue sam ples were 
analysed.
The m edian age o f the patients at diagnosis was 69 yrs (41-83 years). 
Median fo llow-up o f the patients was 4.57 years (2.9-6.65) and median 
tim e to horm one relapse was 2.46 years (1.47-4.63).
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3.1.2 Descriptive patient data
S tudy number, age o f the patients, gleason sum, type o f biopsy at 
diagnosis and at relapse, PSA nadir, PSA at relapse, PSA velocity, time 
to relapse, tim e from  relapse to second biopsy, presence o f bone 
m étastasés at d iagnosis and developm ent of bone m étastasés are 
illustrated below (Table 1-4).
T ab le l Descriptive Patient Data
Study no Age (yrs) Gleason sum 
at diagnosis
Type of biopsy a t 
Diagnosis Reiapse
AR1&2 72 8 TURP TURP
AR3&4 78 7 TRUCUT TURP
AR5,6 69 5 TRUCUT TURP
AR8&9 70 7 TURP TURP
AR14&15 71 5 TURP TURP
AR16&17 72 6 TURP TURP
AR18&19 74 4 TURP TURP
AR23-24 54 7 TURP TURP
AR29&30 71 9 TURP TURP
AR31 &32 66 10 TURP TURP
AR33&34 62 9 TRUCUT TURP
AR35&36 83 10 TRUCUT TURP
AR37&38 67 8 TRUCUT TURP
AR41&42 76 8 TRUCUT TURP
AR43&44 68 9 TURP TURP
AR45&46 76 7 TURP TURP
AR47&48 69 6 TURP TURP
AR49&50 64 8 TURP TURP
AR61&52 70 6 TURP TURP
AR55&56 73 9 TURP TURP
AR57&58 79 7 TURP TURP
AR59&60 63 7 TURP TURP
AR61&62 81 7 TURP TURP
AR63&64 77 7 TURP T U R P
AR65&66 75 9 TURP TURP
Table 2 Descriptive Patient Data
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Study no Age (yrs) Gleason sum 
at diagnosis
Type of biopsy at 
Diagnosis Relapse
AR67&68 73 9 TURP TURP
AR69,70 67 8 TRUCUT TURP
AR72&73 63 7 TRUCUT TURP
AR74&75 49 6 TURP TURP
AR76&77 68 6 TRUCUT TURP
AR78&79 68 6 TRUCUT TURP
AR80&81 75 4 TURP TURP
AR82&83 70 8 TURP TURP
AR84&85 70 9 TURP TURP
AR86&87 68 6 TURP TURP
AR-88&89 67 7 TRUCUT TURP
AR90&91 63 6 TURP TURP
AR92&&93 74 8 TURP TURP
AR96&97 74 7 TRUCUT TURP
AR100&101 80 9 TRUCUT TURP
AR102&103 98 10 TURP TURP
AR104.105 70 6 TURP TURP
AR107&108 68 9 TURP TURP
AR109&110 73 9 TURP TURP
AR111,112 67 6 TURP TURP
AR114,115 63 8 TURP TRUCUT
AR116,117 41 7 TRUCUT TURP
AR118,119 59 9 TRUCUT TURP
AR120.121 59 10 TURP TURP
AR122.123 68 8 TURP TURP
AR124.125 62 7 TRUCUT TURP
Table 3 Descriptive Patient Data
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Study PSA PSA at PSA Time to Time from Bone Métastasés
no Nadir
ng/mi
Reiapse
ng/ml
Velocity
ng/ml/yr
Relapse
(days)
PSA relapse 
to 2"'^  biopsy 
in days
at
Diagnosis/Relapse
AR1&2 1 ■, 4.97 836 108.00
AR3&4 37 470 216 184 0.00
AR5,6 1.2 6.4 1.16 1914 9.00
AR8&9 1.3 64 62.7 24 6.00
AR14&15 7.6 19.4 11.8 1451 102.00
AR16&17 6.4 39.3 14.65 2062 35.00
AR18&19 0.9 29 29.2 2051 156.00 +
AR23-24 1 6 1.66 2069 18.00 +
AR29&30 13.4 38 45.25 1678 22.00
AR31 32 15.6 43.7 21 861 323.00
AR33&34 7.9 30.6 9.24 1237 22.00
AR35&36 0.8 2.6 3.9 537 28.00
AR37&38 5.5 7.2 1.3 3027 4.00
AR41&42 85.2 796.4 683.6 678 8.00 + +
AR43&44 0.5 6.4 7.75 834 20.00
AR45&46 126 243 43.6 820 94.00
AR47&48 1.9 7.7 1.15 605 109.00 +
AR49&50 35 384 107.2 365 62.00 + +
AR51&52 7.5 16.6 11.7 85 268.00 +
AR55&56 26 101 39 692 252.00
AR57&58 0.1 19.8 4.9 1641 14.00
AR59&60 14.5 106 238.1 1189 313.00
AR61&62 2.0 58 11 957 129.00 +
AR63&64 10.7 29 20.8 496 389.00 4-
AR65&66 0.1 1.3 29.9 1305 147.00
Table 4 Descriptive Patient Data
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Study no PSA
Nadir
ng/ml
PSA at 
Relapse 
ng/ml
PSA
Velocity
ng/ml/yr
Time to 
Relapse 
In days
Time from 
PSA relapse 
to 2"*^  biopsy 
in days
BoneMetastases
at
Diagnosis/Relapse
AR67&68 0.6 20.0 36.2 329 119.00 + +
AR69.70 0.2 3.1 28.8 1091 308.00
AR72&73 0.1 2.2 8.6 2032 543.00 +
AR74&75 1.6 4.5 12.5 792 1216.00
AR76&77 0.9 2.6 32.2 546 602.00 + -H
AR78&79 0.1 1.9 2.9 3202 215.00
AR80&81 4.1 6.1 8.4 431 74.00
AR82&83 1.3 8.7 11.8 467 140.00 + +
AR84&85 6.1 25.5 8.6 1746 81.00 +
AR86&87 5.0 31.8 24.3 415 77.00
AR-88&89 2.0 13.1 8.6 5306 81.00 +
AR90&91 1.0 7.0 15.9 1689 118.00
AR92&&93 0.8 4.5 1.9 899 172.00
AR96&97 0.4 1.5 1.4 1500 1174.00
AR100&101 4.9 22.7 50.2 100 172.00
AR102&103 7.6 261 252.4 421 10.00
AR104,105 0.1 1.2 0.67 3400 1.00
AR107&108 3.3 33.6 34.5 646 361.00
AR109&110 1.7 27.1 24.2 857 58.00
AR111,112 18.2 34.3 11.2 4230 0.00
AR114,115 29 114 247.2 47 183.00 + +
AR116,117 4.8 22.4 12.7 902 322.00
AR118,119 3.9 33.4 61.7 425 45.00 +
AR120.121 11.1 41.4 30.3 306 35.00 +
AR122.123 8.1 24 125.3 1087 175.00 +
AR124,125 2.5 5.6 489.8 576 32 + +
110
3.1.3 Statistical Association Between PSA and Time to Relapse & 
Survival
There was a statistically significant difference in time to relapse in prostate 
cancer patients whose PSA level at diagnosis was >10ng/ml compared to 
those with PSA <10ng/ml (p= 0.037) (Figure 8a).
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Figure 8a- Kaplan-Meier Plot showing time to relapse in Prostate cancer 
patients with PSA levels <10ng/ml and >10ng/ml at diagnosis. Patients 
with PSA >10ng/ml at diagnosis relapsed earlier compared to those with 
PSA <10ng/ml (P= 0.037).
I l l
PSA levels at diagnosis did not have a significant effect on overall survival 
(p=0.076) (figure 8b).
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Figure 8b- Kaplan-Meier Plot showing over all survival in Prostate cancer 
patients with PSA levels <10ng/ml and >10 ng/ml at diagnosis. No 
significant difference was observed (p=0.076).
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3.1.4 Statistical Association Between Gleason sum  and Tim e to 
Relapse & Survival
Mean Gleason sum at diagnosis was 7.63 (STDEV=1.40) and after the 
developm ent o f androgen independent disease it was 8.44 (STD EV=1.16). 
G leason sum in androgen sensitive tum ours was significantly lower than in 
androgen independent tum ours (p<0.001) (Table 5).
Table 5 G leason sum  in androgen sensitive and androgen  
independent prostate tum ours
Gleason sum Num ber of androgen 
sensitive prostate 
tum ours
Num ber of androgen 
independent prostate 
tum ours
p-value
^6 24%  (12/51) 4%  (5/51)
=7 27%  (14/51) 12% (7/51)
>8 49%  (25/51) 78% (40/51) <0.001
W e also correlated G leason sum at diagnosis with tim e to relapse as well 
as overall survival. There was no significant d ifference in tim e to relapse 
i.e. developm ent o f androgen independent prostate cancer (figure 8c).
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Figure 8c- Kaplan-Meier Plot showing no difference in time to relapse, in 
patients with Gleason sum <7, =7 or >7 at the time of diagnosis of prostate 
cancer (p=0.075).
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Gleason sum however had a significant effect on overall survival. Those 
patients with gleason sum >7 had a shorter overall survival that was 
statistically significant (p=0.05).
Gleason
100 1
80
(0.>I 60CO0)O)B^
 40 -
g
S.
20
102 4 120 6 8
° gleason>7
t
° gleason=7
° gleason<7 
+ p=0.0535
Overall surviva In years
Figure 8d- Kaplan-Meier Plot showing overall survival in prostate cancer 
patients who had different Gleason sum at diagnosis (Gleason <7 ,=7 & 
>7). The difference in survival in the three groups was significant (p=0.05).
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3.2 Protein location and expression in prostate tumours.
3.2.A Site o f protein expression in prostate tum ours
c-Jun and c-Fos pro teins expression was observed in the cytoplasm  and 
nucleus of the tum our cells. However phosphorylated c-Jun and AR 
expression was observed only in the nucleus. PKC and COX-2 protein 
expression was observed only in the cell cytoplasm  (Figures 11a-f).
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3.2.B Inter-observer variation
3.2.B.1 Correlation o f histoscores assigned by two independent 
observers
Evalua ting in ter-observer variation was a specific objective o f the study. 
Intensity o f protein expression was scored by two independent observers 
(NSK and JE). The scores assigned by the observers w ere then 
compared. The mean difference plus 2 standard deviations, the inter-class 
correlation coeffic ient (ICCC) and Pearson correlation coeffic ient (PCC) 
fo r each protein investigated are shown in Table 6.
The ICCC is a true index o f agreem ent between the scores assigned by 
both observers. All the proteins that were investigated had ICCC’s greater 
than 0.75, which is regarded as an excellent correlation (Table 6). 
However fo r AR the ICCC was 0.68 which is regarded as a good 
correlation.
The PCC was gained from scatter diagram which illustrates the 
relationship between protein histoscores assigned by the two observers. 
The square root of r  ^ indicates correlation between the histoscores 
assigned by the two observers (figures 9a-f).
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Table 6- Mean difference plus 2SD o f histoscores assigned by tw o  
independent observers, ICCC & PCC are shown
Protein Mean difference 
plus 2 standard deviations
ICCC PCC
c-Jun 57.7 0.79 0.82
P c-Jun 64.78 0.90 0.90
c-Fos 58.1 0.90 0.91
PKC 16.6 0.87 0.86
COX-2 33.4 0.89 0.90
AR 29.98 0.68 0.87
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c-Jun Histoscores Assigned By Two independent Observers
Figure 9a-Scatter plot250
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p-Jun Histoscores Assigned by Two independent
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The above scatter diagrams Illustrate the relationship between protein histoscores 
assigned by the two observers. PCC is the square root of r^  and it indicates correlation 
between the histoscores assigned by the two observers. It is a measure of linear 
association.
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c-Fos Histoscores Assigned By Two Independent
Observers
Figure SC-Scatter Plot250 yO.9158x-2.32G 
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Scatter Diagram Of PKC Histoscores Assigned By Two 
Independent Observers
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The above scatter diagrams illustrate the relationship between protein histoscores 
assigned by the two observers PCC is the square root of r^  and it indicates correlation 
between the histoscores assigned by the two observers. It is a measure of linear 
association.
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Scatter Diagram Of COX-2 Histoscores Assigned By
Two Independent Observers
Figure 9e300 y = 0.9276X ♦ 12.834
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Scatter Diagram of AR Histoscores Assigned By Two 
Independent Observers
Figure 9f250
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The above scatter diagrams Illustrate the relationship between protein histoscores 
assigned by the two observers. PCC is the square root of and it indicates correlation 
t>etween the histoscores assigned by the two observers. It is a measure of linear 
association.
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3.2.B.2 Analysis o f agreem ent for each set o f h istoscores assigned  
by the two independent observers
This was conduc ted using the methods o f Bland and Altman. The 
inform ation is displayed graphically. The differences between histoscores 
assigned by observers are plotted against the m eans o f the observer’s 
histoscores. If the points in the graph are random ly scattered above and 
below the zero line, then this reflects no system atic bias in the method. 
The graph provides a d irect visual im pression o f the agreem ent between 
the observer’s scores, distribution of the differences in scores and 
detection of possible outliers. Bland and A ltm an plots fo r each protein 
investigated are shown in figures 10a-f.
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Bland And Altman Plot For c-Jun Histoscores
Figure 10a
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Bland And Plot For p-Jun Histoscores 
Figure 10b
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In the above Bland & Altman plots- mean histoscores of two independent observers are
randomly scattered above & tielow the zero line reflecting no systemic bias. The mean
difference + 2SD line is marked.
123
Bland And Altman Plot For c-Fos Histoscores
Figure 10c
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Bland And Altmann Plot For PKC Histoscores 
Figure lOd
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In the above Bland & Altman plots- mean histoscores of two independent observers are
randomly scattered above & below the zero line reflecting no systemic bias. The mean
difference + 2SD line is marked.
124
Bland And Altman Plot For COX-2 Histoscores
Figure lOe
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In the above Bland & Altman plots- mean histoscores of two independent observers are
randomly scattered above & below the zero line reflecting no systemic bias. The mean
difference + 2SD line is marked.
Figure l i a  c-Jun protein expression (brown staining in the cytoplasm and
nucleus)
i
*
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Figure 11 b Phosphorylated c-Jun protein expression (brown staining in the 
nucleus)
Figure l i e  c-fos protein expression (brown staining in the cytoplasm and
nucleus)
Figure l i d  PKC protein expression (brown staining in the cytoplasm
Figure l i e  Cox-2 protein expression (brown staining in the cytoplasm) 
W  ^  f  I ? mm.
Figure 11 f  AR protein expression (brown staining in the nucleus)
!
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3.3.A Distribution of the staining intensity (histoscores) for androgen  
sensitive and androgen independent prostate tum ours
The his tograms depicted below, dem onstrate the distribution o f staining 
intensity (histoscores) fo r androgen sensitive and androgen independent 
prostate tum ours fo r each protein investigated (Figures 12A-F). None of 
the protein expressions shown in the histogram s had a normal distribution 
in A!PC, therefore all statistical tests used in th is study w ere non 
parametric. The m edian histoscore and interquartile ranges (Sum m ary 
statistics) fo r each protein investigated are shown in table 7. No 
significant difference in c-Jun, p-Jun, c-Fos, PKC and COX-2 protein 
expression was observed fo r any o f the proteins investigated in the 
transition from  ASPC to  A lPC. There was a s ignificant increase in AR 
protein expression in the transition from  ASPC to A lPC.
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Figure 12 A- c-Jun Histoscores in Androgen Sensitive And Androgen
Independent Prostate Cancers.
c-Jun expression in ASPC & AlPC
c-Jm Histoscore
ASPC
AlPC
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Number of patients
The above histogram illustrates c-Jun histoscores in ASPC (Green bars) and AlPC 
(Pink). The distribution of histoscores was not a normal distribution.Increase in c-Jun 
expression was observed in 15.7%, no change in 64.7% and decrease in 19.6% at 
relapse (development of AlPC.) c-Jun histoscores scores are given in Appendix III.
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Figure 12 B p-Jun Histoscores in Androgen Sensitive And Androgen 
Independent Prostate Cancers.
P-Jun Expression in ASPC & AlPC
P-Jun Histoscores
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The above histogram illustrates p-Jun histoscores in ASPC (Green bars) and AlPC 
(Pink). The distribution of histoscores was not a normal distribution.Increase in p-Jun 
expression was observed in 7.8%, no change in 82.3% and decrease in 9.8% at relapse 
(development of AlPC.) p-Jun histoscores scores are given in Appendix IV.
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Figure 12 C c-Fos Histoscores in Androgen Sensitive And
Androgen independent Prostate Cancers.
C-Fos Expression in ASPC & AFC
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The above histogram illustrates c-Fos histoscores in ASPC (Green bars) and AlPC 
(Pink). The distribution of histoscores was not a normal distribution.Increase in c-Fos 
expression was observed in 13.7%, no change in 68.6% and decrease in 17.6% at 
relapse (development of AlPC.) c-Fos histoscores scores are given in Appendix V.
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Figure 12 D PKC-Jun Histoscores in Androgen Sensitive And
Androgen Independent Prostate Cancers.
PKC Expression in ASPC & AlPC
PKC Histoscores
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The above histogram illustrates PKC histoscores in ASPC (Green bars) and AlPC (Pink). 
The distribution of histoscores was not a normal distribution.Increase in PKC expression 
was observed in 27.5%, no change in 27% and decrease in 45% at relapse (development 
of AlPC.) PKC histoscores scores are given in Appendix VI.
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Figure 12 E COX-2 Histoscores in Androgen Sensitive And
Androgen Independent Prostate Cancers.
COX-2 Expression in ASPC & AlPC
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The above histogram illustrates COX-2 histoscores in ASPC (Green bars) and AlPC 
(Pink). The distribution of histoscores was not a normal distribution.Increase in COX-2 
expression was observed in 33.3%, no change in 39.2% and decrease in 27.5% at 
relapse (development of AlPC.) COX-2 histoscores scores are given in Appendix VII.
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Figure 12 F Androgen Receptor Histoscores in Androgen Sensitive 
And Androgen independent Prostate Cancers.
Androgen Receptor Expression In ASPC & AlPC
Figure 12F
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The atxjve histogram illustrates AR histoscores in ASPC (Green bars) and AlPC (Pink). 
The distribution of histoscores was not a normal distribution . I ncrease in AR expression 
was observed in 50.98%, no change in 39.2% and decrease in 9.8% at relapse 
(development of AlPC.) AR histoscores scores are given in Appendix VIII.
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Table 7 Protein expressions in androgen sensitive and independent 
prostate cancer
Pro tein
ASPC
median histoscore 
(1 ^ -  3""^  quartiie)
A lPC
median histoscore 
(ist_ 3 rd quartiie) p value
c-Jun 155 (129-185) 160 (143.75-181.75) 0.882
P c-Jun 101 (77.5-132.8) 105 (57.5-125) 0.388
c-Fos 111 (66.88-154.4) 100 (52-140) 0.642
PKC 172 (147.5-195) 164 (146.25-185) 0.125
COX-2 145 (122.5-175) 155 (132.5-170) 0.957
AR 94.5 (55-120) 132.5 (89.25-172.5) 0.000
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3,3.B Expression of c-Jun, c-Fos, Cox-2 & AR In BPH 
tissue
c-Jun, c-Fos, AR and COX-2 Pro teins were expressed in the BPH tissue 
on im m unohistochem ical exam ination. Median histoscores o f protein 
expressions are given in table 8.
Table 8 Expression of c-Jun, c-Fos, AR and COX-2 Proteins in BPH 
Tissue
NO 0 JUN
HISTOSCORE
CFOS
HISTOSCORE
AR
HISTOSCORE
COX 2
HISTOSCORE
BPH 1 140 170 105 105
BPH 2 60 185 65 115
BPH 3 110 195 135 195
BPH 4 60 180 60 60
BPH 5 110 190 120 190
BPH 6 100 170 130 135
BPH 7 150 195 170 170
BPH 8 130 205 130 170
BPH 9 130 170 100 155
BPH 10 130 160 120 65
Mean Histoscore 112 182 113.5 136
SD 31.19 14.37 32.91 48.64
Skewness -0.863 0.059 -0.274 -0.468
Median 120 182.5 120 145
Inter Quartiie 
range
90-132.5 170-195 91.25-131.25 95-175
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c-Jun, c-Fos, AR and COX-2 Pro tein expressions In BPH tissue and 
ASPC tissue were com pared (Median histoscores- c-Jun in B P H -112, 
A lP C - 160; c-Fos in BPH-182, AIPC-100; AR- in BPH-120, AIPC-132; 
COX-2 in BPH-145, AIPC-155). There was no significant correlation for c- 
Jun, c-Fos and COX-2 expression in BPH and A lPC  tissue. However 
Androgen receptor protein expression in BPH tissue and ASPC tissue 
corre lated well and it was statistically significant (p=Q.04).
3.3.C Relation of protein expression in androgen sensitive 
tumours to time to relapse.
W hen the protein expression fo r c-Jun, p-Jun, c-Fos, PKC and COX-2 in 
the prim ary androgen sensitive tum ours was investigated, we were unable 
to dem onstrate a significant correlation between any of the proteins 
investigated and tim e to relapse (table 9). T im e to progression (relapse) 
against c-Jun, p-Jun and PKC expression in ASPC are given as scatter 
plots (Figure-13 A-C).
Table 9 Protein Expressions In ASPC and Tim e To Relapse
Protein Spearm an’s rank order Correlation Coefficient P value
c-Jun -0.252 0.085
P c-Jun -0.242 0.095
c-Fos 0.062 0.678
PKC -0.248 0.086
COX-2 -0.099 0.500
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Figure 13-A Scatter Plot of Time to progression (Relapse) against
c-Jun protein Expression (Histoscores) in ASPC
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The above scatter plot clearly illustrates no correlation between c-Jun expression in 
androgen sensitive prostate cancers and time to relapse.
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Figure 13-B Scatter Plot of Time to progression (Relapse) against
p-Jun protein Expression (Histoscores) in ASPC
8(/)
Bm  200
c3
S'
■O
B
o 100 sz
CLCOo
CL
■■
p=0.095
11 14 160 3 5 8
Tim e to progression (years)
In the scatter plot there is no statistically significant correlation between p-Jun histoscores 
and time to relapse.
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Figure 13-C Scatter Plot of Time to progression (Relapse) against
PKC protein Expression (Histoscores) in ASPC
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Similar to c-Jun and p-Jun protein expression, PKC expression had no effect on time to 
progression.
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3.3.D Relation of high protein expression in androgen 
independent tumours to time to death from relapse
Pro tein expression was considered to be high in A lP C  tum ours if the 
histoscore was > 100. However fo r PKC and COX-2, so few  cases had 
histoscores o f less than 100 (1 fo r PKC and 5 fo r COX-2), it was not an 
appropriate cut off, therefore fo r these two proteins high expression was 
defined as a histoscore > 150. Using these defin itions it was noted that 
approxim ately 60%  o f patients had a high c-Jun, PKC, COX-2 and AR 
expression with the developm ent of A lPC  and (table 10). Approxim ately 
half of patients had high phosphorylated c-Jun expression and these 
patients were noted to have a significantly shorter period o f survival 
follow ing relapse in com parison to patients w ith low expression (figure 
14A). However high expression levels o f other proteins at relapse had no 
effect on duration of survival from  relapse (figures 14 B-F) & (Table 11).
Table 10 High Protein expression in AlPC
Protein High Protein Expression 
No of tum ours (%)
Low protein expression 
No of tum ours (%)
c-Jun 35 (68.6% ) 16 (31.3%)
P c-Jun 24(47% ) 27(52.9% )
c-Fos 20(39.2% ) 31(60.8% )
PKC 30(58.8% ) 21(41.2% )
COX-2 29(56.8% ) 22(43.2% )
AR 32(62.7% ) 19(37.3% )
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Figure 14-A Kapian-Meier survival plot of patients with High (— ) 
and low ) phosphorylated c-Jun expression in Androgen 
Independent prostate cancers
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Patients with high phosphorylated c-Jun expression survived for a significantly shorter 
period of time than those with low phosphorylated c-Jun expression (p=0.023, log-rank 
test)
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Figure 14-B Kaplan-Meier survival plot of patients with High (------ )
and low (------) c-Jun expression in AlPC.
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Patients with high and low c-Jun expression in AlPC had no difference in survival from 
relapse (p=0.98, log rank test).
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Figure 14-C Kaplan-Meier survival plot of patients with High (-
and low (— ) c-Fos expression in AlPC.
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Patients with high and low c-Fos expression in AlPC did not have significant difference in 
survival (p=0.464, log rank).
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Figure 14-D Kaplan-Meier survival plot of patients with High (— - )
and low (— ) PKC expression in AlPC.
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Duration of survival following relapse, in patients (AlPC) with high and low PKC 
expression did not have a significant difference in survival (p=0.07, log rank).
146
Figure 14-E Kapian-Meier survival plot of patients with High (— ) 
and low (----- ) COX-2 expression in AlPC.
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COX-2 expression in AlPC patients, either high or low did not effect survival from relapse 
(p=0.655, log rank test).
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Figure 14-F Kaplan-Meier survival plot of patients with High (— )
and low (— ) AR expression in AlPC.
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No correlation between androgen receptor protein expression (low or high) in AlPC 
patients and time to death from relapse was demonstrated.
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Table 11 Duration of survival after relapse in relation to high and low  
protein expression
Protein High protein expression 
M edian survival from 
relapse in yrs (Interquartile 
range)
Low protein expression 
Median survival from  
relapse in yrs (Interquartile 
range)
p value
c-Jun 2.5(0.78-4.1) 2.56(0.82-4.32) 0.978
P c-Jun 1.87(1.1-2.6) 5.5(1.07-9.9) 0.023
c-Fos 3.07(1.28-4.9) 2.1(1.30-2.99) 0.464
PKC 1.65(0.97-2.32) 3.6(3.0-4.2) 0.070
COX-2 3.0(1.1-4.9) 2.5(1.6-3.3) 0.655
3.3.E Changes in protein expression with the development 
of AlPC
W hen the changes in protein expression were investigated fo r each 
individual patient it was noted that sub groups of patients had increases, 
no changes or decreases in protein expression. A  real change in protein 
expression is defined as mean difference of in ter-observer variation plus 2 
standard deviations, table 2 gives the values in histoscores fo r each
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pro tein investigated. PCK and COX-2 \A/ere the 2 proteins with the highest 
rate of increase in expression. Approxim ately 1/3 o f patients had an 
increase in PKC or COX-2 expression with the developm ent of A lPC, 
while increases in expression of c-Jun and c-Fos were observed in less 
than 20%  of patients (table 12).
Table 12 Changes in protein expression with developm ent o f relapse
Protein Increase In 
expression (%)
No change in 
expression (%)
Decrease in 
expression (%)
c-Jun 8/51 (15.7% ) 33/51 (64.7%) 10/51 (19.6%)
P c-Jun 4/51 (7.8%) 42/51 (82.3%) 5/51 (9.8%)
c-Fos 7/51 (13.7%) 35/51 (68.6%) 9/51 (17.6%)
PKC 14/51 (27.5%) 14/51 (27%) 23/51 (45%)
COX-2 17/51 (33.3%) 20/51 (39.2% ) 14/51 (27.5% )
AR 26/51(50.98% ) 20/51(39.2% ) 5/51(9.8% )
An increase in PKC protein expression in the transition from androgen 
sensitive to  androgen independent prostate cancer resulted in a significant 
reduction in patient survival from  tim e to relapse (figure 15-A). For all other 
proteins investigated no significant difference in patient survival from  tim e 
to relapse was noted w ith an increase in protein expression (table 13) 
(figures 15C-F). W hen changes in protein expression with the 
deve lopm ent o f A lP C  were com pared to overall survival no significant 
observations were made.
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Figure 15-A Kaplan Meier Survival Plot of AlPC Patients with 
increase and decrease in PKC Expression
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An increase in PKC expression was associated with shorter patient survival from time to 
relapse when compared to those with no change or a decrease in PKC expression in 
AlPC patients (p=0.014, log rank).
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Table 13 Changes in protein expression and duration o f survival 
from tim e to relapse
Protein
Increase in expression 
Median survival from  
relapse in yrs 
(Inter quartile range)
No change or fa ll in expression. 
Median survival from  relapse in 
yrs
(Inter quartile range)
p value
c-Jun 3.45(0.29-6.62) 2.47(1.05-6.62) 0.301
P c-Jun 1.65(0.45-2.85) 30 (1 .7 -4 .3 ) 0.466
c-Fos 1.31(1.10-1.36) 2.47(0.79-4.14) 0.645
PKC 1.61(1.4-1.8) 3.5(28.4.1) 0.014
COX-2 1.33 (0.48-2.17) 3.08 (2.12-4.04) 0.112
It was noted that high levels o f phosphorylated c-Jun and an increase in 
PKC expression were both associated with shorter patient survival and 
that these represented to individual patient cohorts. W e therefore 
com bined these patient and we observed that those patients w ith high 
phosphorylated c-Jun expression or an increase in PKC expression with 
developm ent of A lP C  survived fo r a significantly shorter period o f tim e 
com pared to those w ith low phosphorylated c-Jun or no increase in PKC 
expression (figure 15-B, p=0.0036). Median survival changed from 5.5 
years (3.99-6.38) to 1.62 years (0.99-2.24 years), depending on changes 
in PKC expression and levels o f phosphorylated c-Jun.
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Figure 15-B Kaplan Meier Survival Plot of AlPC Patients with High
phosphorylated c-Jun and an increase in PKC expression
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The above graph shows that AlPC patients with high p-Jun and increased PKC 
expression survived for a significantly shorter penod of time than those with low or no 
change or a decrease in p-Jun / PKC expression (p=0.003, log rank).
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Figure 15-C Kaplan Meier Survival Plot of AlPC Patients with
increase and a decrease or no Change in c-Jun Expression
(O>
3
COo>cm-2c0>(_)
0>o_
1.0
9 increase in c-Jun
8 Decrease/no change in 
c-Jun —7
p= 0.3016
5
4
3
2
1
0.0
0 1000 2000 3000
Time To Death From Relapse
AlPC patients with an Increase, decrease or no change in c-Jun expression had no 
significant difference in survival from the time of development of hormone relapse 
(p=0.301, log rank).
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Figure 15-D Kaplan Meier Survival Plot of AlPC Patients with
Increase and a decrease or no Change in p-Jun Expression
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The above survival plot demonstrates no significant difference in survival in patients with 
increased p-Jun expression in comparison to those with a decrease or no change 
(p=0.466, log rank).
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Figure 15-E Kaplan Meier Survival Plot of AlPC Patients with Increase
and a decrease or no Change in COX-2 Expression
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The Kaplan Meier Survival Plot of AlPC patients with Increase and a decrease or no 
change in COX-2 Expression shows no significant difference in survival from time to 
relapse (p=0.112, log rank).
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Figure 15-F Kaplan Meier Survival Plot of AlPC Patients with
Increase and a decrease or no Change in AR Expression
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AlPC patients with an Increase, decrease or no change in AR expression had no 
significant difference in survival from the time of development of hormone relapse 
(p=0.081, log rank).
157
3.3.F Protein Correlation in Androgen Sensitive and 
Independent prostate cancer
c-Jun hom odim ers or he terodim ers of phosphorylated c-Jun and c-Fos 
form  the transcription facto r A P -1 . In our patient cohort protein expression 
of c-Jun, phosphorylated c-Jun and c-Fos all corre late in ASPC, however 
with the developm ent of A lP C  c-Fos expression no longer corre lates with 
c-Jun or phosphorylated c-Jun (table 14)
Table 14 Correlation between com ponents of AP-1
Phosphorylated c-Jun c-Fos
ASPC c-Jun 0.008 (c.c 0.396) 0.02 (c.c 0.343)
A lPC  c-Jun <0 . 0 0 0 1  (c.c 0.608) 0.083 (c.c 0.274)
ASPC c-Fos 0.027 (c.c 0.332)
A lP C  c-Fos 0.480 (c.c 0.113)
It was previously reported that PKC may phosphorylate and activate c-Jun 
and also increase expression of c-Fos. W e therefore correlated PKC 
expression in ASPC and A lPC  tum ours to c-Jun, phosphorylated c-Jun 
and c-Fos expression. In ASPC no correlations were seen with c-Jun and
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c-Fos and PKC, however fo llow ing the developm ent o f A lP C  c-Jun protein 
expression negatively corre lates with PKC protein expression (table 15).
Table 15, Protein correlations with c-Jun, c-Fos and PKC
Protein c-Jun Phosphorylate c-Jun c-Fos
ASPC PKC 0.662 
(c.c 0.067)
0.433
(c.c. 0.123)
0.280
(C.C.-0.165)
A lPC  PKC 0 . 0 1 2
(c.c.- 0.387)
0.877
(c.c - 0.025)
0.825
(cc - 0.037)
COX-2 has a consensus phosphorylation site fo r both PKC and A P -1 , in 
our patient cohort COX-2 protein expression correlated w ith PKC 
expression in both ASPC and A lPC  tumours however no correlations were 
observed fo r phosphorylated c-Jun (AP-1) in e ither ASPC or A lPC  
tum ours (table 16)
Table 16 Protein correlations w ith COX-2, PKC and phosphorylated  
c-Jun.
PKC Phosphorylated c-Jun
ASPC COX-2 0.014
(c.c. 0.387)
0.684 
(c.c. -0.59)
A lPC  COX-2 0 . 0 0 2
(c.c. 0.451)
0.262
(c.c.0.162)
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c-Jun may act as an AR  co-activator or compete w ith AR to regulated 
gene transcription, however in th is patient cohort AR  does not correlate 
w ith protein expression o f c-Jun in ASPC or A lPC  tumours. However AR 
corre lated w ith phosphorylated c-Jun in both androgen sensitive as well as 
androgen independent psostate tum ours (table 17).
Table 17 Protein correlations w ith AR, c-Jun, c-Fos and 
phosphorylated c-Jun
c-Jun Phosphorylated c-Jun c-Fos
ASPC AR 0.176 0.003 0.925
(c.c. 0.197) (c.c. 0.460) (c .c .-0 .0 1 6 )
A lPC  AR 0.799 0.07 0.408
(c.c. -0 .0 37 ) (c.c. 0.659) (c.c. 0.142)
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CHAPTER 4
DISCUSSION
161
4.1 Back Ground To The Study
Pros tate cancer is the second m ost common cancer in men in the UK, 
w ith more than 21 000 new cases diagnosed each year in the UK [232]. 
M ost men at diagnosis have early localised disease, but alm ost 30-35%  
are diagnosed with locally advanced or m etastatic disease [232].
S ince the landm ark experim ents by Huggins and coworkers (103,233] it 
has been known that prostate cancer can be treated by endocrine therapy, 
in itia lly endocrine therapy was accomplished by surgical orchidectom y 
and later by the use o f estrogens. However the main stay o f endocrine 
therapy in the modern era has been through the use o f long acting 
Luteinising hormone releasing hormone (LH-RH) analogues [234,235] 
they act to down-regulate the production of luteinizing horm one (LH) by 
the pituitary gland, resulting in castrate levels o f serum testosterone [236]. 
Serum  PSA levels fall (PSA < 4.0 ng/ml) in around 70-80%  of men after 
endocrine therapy, and that is maintained fo r a variable period of tim e 
[237,238]. The earliest m anifestation of relapse after endocrine deprivation 
therapy is a rise in serum PSA level, which usually precedes the 
developm ent of clinically detectable disease progression [239,240]. A t th is 
stage, such disease is often labelled as androgen independent prostate 
cancer (A lPC) or horm one refractory prostate cancer (HRPC). The median 
tim e to progression after endocrine ablation therapy is around 18-24
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mon ths, with a median survival o f 6-18 m onths from  the tim e of 
developm ent of A lPC  [78,112].
Currently, there is no standard approach to the treatm ent of A lPC . 
Treatm ent options include second-line endocrine therapy, chem otherapy 
w ith or w ithout endocrine agents and radiotherapy, depending on the site 
of relapse, sym ptom s at relapse, perform ance status of the patient, and 
presence or absence of co-morbid medical conditions [232]. They do not 
provide significant control o f the d isease but improve quality o f life [234]. 
Two phase III tria ls dem onstrated the efficacy o f M itoxantrone plus 
corticosteroid in A lPC  [241,242]. In both trials, a benefit in palliation was 
observed with out any survival benefit. How-ever two further randomised, 
phase 3 m ulti-centre studies (TAX 327 and SW OG 99-16) used taxane 
based chem otherapeutic agent, docetaxel [236] which binds to tubulin and 
causes disruption of the m icrotubular network essential fo r m itotic and 
interphase cellu lar functions. In the TAX 327 study [243] an actual median 
survival im provem ent of 2.4 m onths by com parison was observed (18.9 
m onths in docetaxel vs 16.5 months in m itoxantrone groups). In the 
SW OG 99-16 study [244] a sim ilar result to that observed with TAX 327 
was observed. In both the studies a 24% im provem ent in overall survival 
was dem onstrated. The efficacy o f docetaxel is not universally effective in 
all patients. The m edian survival benefit of 2.4 m onths is small. This 
suggests that A lPC  is a d ifficult d isease to trea t and none o f the currently 
available chem otherapeutic agents are able to improve survival
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significan tly. Due to lack o f proper understanding of the underlying 
m olecular m echanism s involved in the pathogenesis o f A lPC, there are 
only few  treatm ent options available.
Studies on human prostate cancer specim ens show that the androgen 
receptor (AR) is expressed in nearly all cancers of the prostate before and 
after hormonal therapy [115-117]. Prostate specific antigen (PSA) 
production by prostate tum ours is regulated by androgens initially, but w ith 
endocrine treatm ent the levels decline sharply. An early sign o f A lPC  is a 
rising PSA level that m ay eventually surpass the pre-treatm ent value 
(M iller et al, 1992; G leave et ai, 1996). These findings does suggest that 
the AR is still functional in an androgen independent m anner [245].To 
explain the progression o f androgen sensitive prostate cancer (ASPC) to 
A lPC , androgen receptor dependent and independent m olecular 
m echanism s have been postulated [119,246,247].
Androgen receptor dependent m echanism s include mutations in the 
androgen receptor (AR) ligand binding domain or am plification o f the AR 
gene, alterations of the interactions between the AR  and its co-activators 
and ligand independent activation of AR via AR  phosphorylation. 
Androgen receptor independent m echanism s com plete ly bypass the 
androgen receptor and they activate the regulatory molecules down 
stream  of the AR. It is possible that more than one m echanism  w ill be 
utilised in each case of horm one refractory prostate cancer.
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Androgen recep tor gene m utations are reported in both in-vitro  as well as 
in-vivo  studies. AR  m utations w ere reported in 10-25% of prostate cancer 
tissue specim ens [127,155] and they were more common in A lPC  in
AR  gene am plifications [118,128,129,130,250,251] are more com m on in 
A lPC  (0-5%) in com parison to ASPC (20-30%). An increase in AR  protein 
expression as a result o f AR  am plification is postulated to enables low 
circulating androgen levels after endocrine m anipulation, to activate AR 
promoting prostate cancer progression [249] However both AR m utations 
and am plification can explain developm ent of A lP C  only in a small 
subgroup of prostate tumours.
AR transcriptional activity depends on its phosphorylation status 
[252,253]. DHT binding to AR protects it from  proteolytic degradation by 
protein kinases resulting in hyperphosphorylation of the AR at m ultiple 
serine residues [139,140]. Several proteins phosphorylate AR in -vitro  in 
the absence of androgens. These include MAP kinase [140,142,145,146] 
and Akt [140,142,145-147]. Hence AR phosphorylation may offer a 
possible route for progression to A lPC.
Even though AR plays a m ajor role in the progression to A lPC, androgen 
independent prostate cancer cells may use other pathways fo r 
proliferation and survival via bypassing the AR entirely. Bcl-2 is a m em ber 
o f a fam ily consisting o f interacting pro-survival proteins e.g. Bcl-2 and 
pro-apoptotic proteins e.g. Bax [254,255]. Bcl-2 protects cells against
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apop tosis, however when it form s a d im er with pro-apoptotic protein BAX, 
the ability of Bcl-2 to block apoptosis is inhibited [256]. Bcl-2 has been 
shown in-vitro  and in -vivo  model system s to suppress apoptosis following 
androgen ablation [257]. Anim al studies have shown increased 
expression of Bcl-2 protein with the developm ent o f androgen escape after 
surgical castration [257].
P I3K (phosphatidylinosito l 3-kinase) also plays a critical role in ceil 
survival by inhibiting several downstream  pro-apoptotic proteins Bad, 
caspase-9 via a pathway that includes PIP (3) (3-phosphoinositide protein 
kinase-1 and 2) and Akt [119]. PTEN (phosphatase and tensin hom ologue 
deleted on chrom osom e 1 0 ) is a lipid phosphatate whose prim ary function 
is to negatively regulate PI3K/Akt signalling. So loss o f PTEN and 
activation of PI3K /Akt in prostate cancer cells m ight provide a favourable 
environm ent fo r Bcl-2 protein to function as inhib itor of apoptosis.
The role of activator protein 1 (AP-1) in the developm ent of A lPC  is more 
com plicated by the fact that it acts by two different m echanisms. In the 
first, c-Jun form s AP-1 transcription factor and actually com petes w ith the 
AR  to bind to AR  regulated genes [173,204]. In the other, instead of 
form ing AP-1 transcription factor, c-Jun m onom er acts as an AR co­
activator by binding to the N-term inal domain at am ino acids 503-555 
[171,172].
AP-1 is a transcription facto r whose com ponents are nuclear proteins 
encoded by c-Jun and c-Fos proto-oncogenes [169,204,258]. AP-1 is
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im plica ted in cell growth, d ifferentiation and development, its activity 
m odulated by growth factors, cytokines, oncogenes and protein kinase c 
(PKC) [204]. AP-1 can either be a c-Jun/ c-Jun hom odim er or a c-Jun/c- 
Fos heterodimer, the c-Jun/c-Fos heterodimer is m ore stable than the c- 
Jun/c-Jun hom odim er [204]. Formation of e ither d im er requires 
phosphorylation o f c-Jun by c-Jun N-term inal kinase (JNK), which is 
activated by e ither PKC / MAP kinase cascade [259] c-Jun hom odim ers 
and c-Jun/Fos heterodim ers are form ed through the leucine Z ipper 
dom ain of both_proteins [204,171]. AP-1 induces transcriptional activation 
by binding to the TPA-responsive elem ent (TRE or AP-1 DNA binding site 
[204].
Activation of c-Jun via PKC /  MAP kinase pathway is reported to be 
involved in the deve lopm ent o f A lPC  [172,204,205]. AP-1 influences the 
developm ent of A lPC  by com peting with the AR  to alter androgen 
regulated gene expression [172-204].
Cross ta lk between the androgen receptor and PKC signal transduction 
has been reported in prostate cells [170,204,260]. TPA increased AP-1 
activity inhibited androgen induced PSA prom oter activity in LNCaP cells. 
This was due to protein protein interaction between AR  and AP-1 [204. 
Mutual inhibition o f DNA binding by AR  and AP-1 resulted from form ation 
o f com plexes between the two proteins [204]. Hence the effect o f AP-1 on 
androgen regulated gene expression depends on the ratio of AR  to AP-1 
and the ability o f AP-1 to bind to specific promoter regions in the androgen
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regula ted gene [110,206]. Such AP-1 and AR protein protein interaction 
could influence the ability o f AP-1 to enhance androgen regulated gene 
transcription in the absence of androgens and hence m ight influence the 
developm ent of A lP C  [110,204]. In-vitro  work on PC3 cells (poorly
differentiated prostate cancer cells and are androgen independent)
dem onstrated a 7 fold greater intracellu lar c-Jun concentration than in
LNCaP cells that are androgen sensitive [204]. This suggests that AP-1 
influences androgen escape in PC-3 cells. Matrix m etalloprote inases 
(MMPs) degrade all of the protein com ponents o f the extracellu lar matrix 
such as collagens, proteoglycans, laminin, elastin, and fibronectin 
[261,262]). This is considered to be a prerequisite fo r tum our invasion and 
m étastasés. A lso MMPs contribute to angiogenesis, cellu lar differentiation, 
proliferation and apoptosis [261-263]. MMPs gene expression is prim arily 
regulated through AP-1 via m itogen activated protein kinase (MAPK) 
pathways [264-266]. dem onstrated inhibition o f MMP-2 and MMP-9 in 
DU 145 cell by EGCG (epigallocatechin-3-gallate) via inhibition of
activation of c-Jun and NF-kB.
The possible role of c-Jun and c-Fos in contributing to the developm ent of 
androgen independent prostate cancer in-vivo  using paired human 
prostate cancer tissue sam ples has not been studied before. W e had 
opportunity to study this in a unique cohort of prostate cancer patients who 
were horm one sensitive to start with and subsequently progressed to 
horm one relapse. Prostate cancer tissue at diagnosis and at relapse was
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available fo r the study. The present study was carried out to test the 
follow ing hypothesis
“AP-1 transcription factor related proteins are dysregulated in the 
em ergence of androgen independent prostate cancer” .
The aims of the study were
1. To establish a paired clinical cohort of patients in which prostate cancer 
tissue is available at diagnosis o f prostate cancer and also follow ing the 
deve lopm ent o f androgen independence in order to test the hypothesis by 
im m unohistochem istry.
2. To evaluate the expression o f AP-1 related proteins in androgen 
sensitive and androgen independent prostate cancer, by 
im m unohistochem istry.
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4.2 Study Results And Issues Raised
4.2.1 Scoring Criteria For Im m unohistochem ical Staining O f Protein  
Expression
W e inves tigated im m unohistochem ical expression of c-Jun, 
phosphorylated c-Jun, c-Fos, PKC, COX-2 and AR  in 51 paired prostate 
tum our samples, the first specim en in a pair was obtained when the 
tum our was androgen sensitive and the other at relapse. 
Im m unohistochem ical staining of protein expressed was quantified using 
intensity weighted histoscore method. This is a sem i-quantitative method 
o f scoring based on intensity o f staining and the proportion of cells stained 
[118,267,268].
Pertschuk et al [269] reported use of sim ilar Intensity weighted histoscore 
technique in scoring im m unohistochem ical AR expression in paraffin 
em bedded prostate cancer tissue specimens.
Regitnig et al [270] studied estrogen and progesterone receptor 
expression in breast cancer specimens by im m unohistochem ical 
technique. The expression o f these receptors was evaluated 
sem iquantitatively by estim ating the percentage and intensity o f stained 
nuclei.
Kerfoot et al [268] in the ir study to evaluate PKC a  im m unohistochem ical 
expression in advanced human breast carcinom a also reported the use o f
170
sim ilar in tensity weighted histoscore method to evaluate PKC 
immunostaining.
In our study intensity of protein expression was scored as negative (0), 
weak (1), m oderate (2), or strong (3). The proportion o f cells stained also 
noted. The histoscore was then calculated from  the following equation. 
H istoscore = (1 x % weak staining cells) + (2 x % m oderate staining cells) 
+ (3 x strong staining cells), with a m aximum score o f 300.
Two independent observer’s scores o f the sam ples and the mean of the 
scores was used. The inter-class correlation coefficients (ICCC) between 
the two independent observers were calculated as 0.79 fo r c-Jun, 0.90 fo r 
phosphorylated c-Jun and c-Fos, 0.87 fo r PKC, 0.89 fo r COX-2 and 0.68 
fo r AR. By defin ition an ICCC of 0.7 is regarded as an excellent correlation 
and an ICCC of >0.6 as a good correlation.
Changes in protein expression between ASPCs and AI PCs were defined 
based on the variation in scores between the two independent observers 
(NSK and JE), as the mean plus 2 standard deviations of the inter­
observer variation o f all sections scored. Therefore, an increase in 
h istoscore of more than 57.7 for c-Jun, more than 64.7 fo r phosphorylated 
c-Jun, more than 58.1 fo r c-Fos, more than 16.6 for PKC, more than 33.4 
for COX-2 and m ore than 29.98 for AR would represent a significant 
increase in protein expression in paired ASPC and A lPC  samples. Those 
cases in which an increase was dem onstrated were classed as having 
significant rise in protein expression fo r each protein investigated.
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4.2.2 Protein Expressions In Androgen Sensitive And Androgen  
Independent Prostate Cancer
c-Jun, phosphoryla ted c-Jun, phosphorylarted c-Jun, c-Fos, PKC, COX-2 
and AR protein expressions in ASPC and A lPC  paired sam ples were 
studied by im m unohistochem ical method.
Protein expressions in both groups o f tum ours were not norm ally 
distributed (ASPC- Skewness- c-Jun -134, phosphorylated c-Jun -.076, c- 
Fos -.185, PKC .741,COX-2 .442 and AR -.150; A lPC-Skewness-c-Jun - 
.942 phosphorylated c-Jun -.656, c-Fos -.184 , PKC -.031, COX-2 -.703 
and AR -.435)
Median expression of c-Jun, phosphorylated c-Jun, c-Fos, PKC, COX-2 
and AR proteins in androgen sensitive sam ples and at relapse were 
compared (table 7). There was no significant difference in the ir median 
protein expression between the two groups except fo r AR  expression 
(ASPC vs A lPC  median histoscores and p value- c-Jun 155 vs 160, 
p=0.88; phosphorylated c-Jun 101 vs 105, p=0.39; c-Fos 111 vs 100, 
p=0.64; PKC 172 vs 164, p=0.13; COX-2 145 vs 155, p=0.96; and AR 145 
vs 155, p=0.000).
c-Jun and c-Fos expression was observed in the nucleus and cytoplasm  
of the tum our cells (figure 11a and c). However staining fo r 
phosphorylated c-Jun and AR  was found in the nucleus (figure 11b and
172
11 f). PKC and COX-2 proteins were expressed only in the cytoplasm of 
the tum our cells (figures l i d  & e).
Changes in protein expression were investigated in our paired cohort of 
tumours. A  change in protein expression at relapse (between ASPCs and 
A lPCs) was defined, as the mean plus 2 standard deviations o f the inter­
observer (NSK and JE) variation of all sections scored. Therefore, an 
increase in histoscore of more than 57.7 for c-Jun, more than 64.78 
phosphorylated c-Jun, m ore than 58.1 for c-Fos, more than 16.6 fo r PKC, 
more than 33.4 fo r COX-2 and more than 29.98 fo r AR would represent a 
significant increase in protein expression in paired sam ples (table 6 ). 
Those cases in which an increase was dem onstrated were classed as 
having significant rise in protein expression for each protein Investigated 
(table 1 2 ).
A t relapse c-Jun protein expression was increased in 15.7%(8/51), 
Phosphorylated c-Jun in 7.8% (4/51), c-Fos in 13.7%(7/51), PKC in 
27.5% (14/15), COX-2 in 33.3% (17/51) and AR  50.98% (26/51). A  
decrease in protein expression was also noted at relapse (c-Jun in 19.6% 
[10/51]: phosphorylated c-Jun in 9.8% [5/51]; c-Fos in 17.6%[9/51]; PKC in 
45% [23/51; COX-2 in 27.5%  [14/51] and AR in only 9.8% [5/51].
W e also defined high and low protein expression by a tum our at relapse 
depending on the histoscore for that protein assigned by the observers. If 
the histoscore was over 1 0 0 , then it was considered that the protein 
expression by that tum our was high. Sim ilarly a low expression at relapse.
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if the histoscore was less than 100. But for PKC and COX-2, so few  
tum ours had a histoscores less than 100 (1/51 fo r PKC and 5/51 fo r COX- 
2 ), we felt that it was not an appropriate cut off, therefore fo r these 
proteins, a histoscore o f 150 was used to define high and low protein 
expression. Using these defin itions we noted that approxim ately 60%  of 
tum ours had a high c-Jun, PKC, COX-2 and AR  protein expressions (c- 
Jun 68.6% [35/51]: PKC58.8%  [30/51]; COX-2 56.8% [29/51]; AR [32/51]) 
w ith progression to A lPC  (table 10). A lso approxim ate ly 45%  had high 
phosphorylated c-Jun and c-Fos expression at deve lopm ent of relapse 
(phosphorylated c-Jun 47% [24/51]; c-Fos 39.2% [20/51]).
4.2.2.A  Role of Threshold Setting In Survival Analysis
Determ ination o f factors tha t predict outcome m easures such as tim e to 
relapse, survival tim e and probability of death from disease are referred to 
as prognostic variables. Several m ethods have been used to assess 
whether these variab les are genuinely associated w ith the outcome. Such 
prognostic variables can be entered directly into a proportional-hazards 
regression (e.g. Cox regression) or logistic regression. However m any 
practitioners choose a threshold value so that patients w ith values on one 
side o f the threshold are designated as high risk and the remaining 
patients as low risk. The final assessm ent and use of the m arker is then 
based on the low risk / high risk d ichotom y and not on the actual value of
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the marker. The method of choosing the threshold requires care. Not all 
studies report how the threshold has been determ ined. Keegan et al [298] 
reported that optim al threshold setting using several m ethods have 
serious statistical flaws tha t could underm ine conclusions o f the study. 
Som e of the flawed m ethods w idely used are, chosing the threshold value 
that yie lds the sm allest p-value when the groups above and below this 
value are com pared, using a hypothesis test such as a chi-squared or log- 
rank test which uses ju s t a single marker. All the above m ethods choose 
the threshold value on the basis o f the data; which is not legitim ate and 
can give p-values that have a large downward bias which can lead to 
m isrepresentation of the data. Hence m ethods such as proportional- 
hazards regression (e.g. Cox regression) or logistic regression should be 
regarded as the method of choice.
In our study we defined high and low protein expression by a tum our at 
relapse depending on the histoscore fo r that protein assigned by the 
observers. If the histoscore was over 100, then it was considered that the 
protein expression by tha t tum our was high. Sim ilarly a low expression at 
relapse, if the histoscore was less than 100. But fo r PKC and COX-2, so 
few  tum ours had a histoscores less than 100 (1/51 fo r PKC and 5/51 fo r 
CO X-2 ), we fe lt that it was not an appropriate cut off, therefore fo r these 
proteins, a histoscore o f 150 was used to define high and low protein 
expression. Using these defin itions we noted that approxim ate ly 60%  of 
tum ours had a high c-Jun, PKC, COX-2 and AR  protein expressions (c-
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Jun 68 .6% [35/51]; PKC58.8%  [30/51]; COX-2 56.8% [29/51]; AR 62.7%  
[32/51]) with progression to AlPG (table 10). A lso approxim ately 45%  had 
high phosphorylated c-Jun and o-Fos expression at developm ent of 
relapse (phosphorylated c-Jun 47%  [24/51]; c-Fos 39.2% [20/51]). W e also 
dem onstrated that high phosphorylated c-Jun expression was associated 
w ith shorter patient survival from  tim e to relapse.
4.2.2.B  c-Jun, phosphorylated c-Jun and c-Fos Proteins Expression
Our study was carried out in prostate cancer tissue clinical specimens. 
The findings presented here are based on im m unohistochem istry. Studies 
looking into im m unohistochem ical protein expressions of c-Jun, 
phosphorylated c-Jun, c-Fos in prostate cancer as well as other cancers 
like breast, bladder, lung, have been carried before [271-274]. The present 
study is unique as paired prostate cancer tissue sam ples were 
investigated.
T iniakos et al [272] showed c-Jun-specific imm unostaining in norm al and 
benign breast tissues, which was weaker and in fewer cells com pared to 
that observed in breast carcinomas. Ninety per cent o f all breast 
carcinom as studied showed c-Jun-specific nuclear staining. There were 
no statistically significant differences in the intensity o f c-Jun 
im m unoreactivity am ong different grades o f infiltrating ductal carcinomas.
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In ASPCs and A lPCc, we observed c-Jun staining in the nucleus and 
cytoplasm  of the tum our cells. c-Jun reactivity increased in 15.7% (8/51) of 
tum ours and was high in 6 8 % tum ours (38/51) at relapse. No relation to 
G leason sum was seen (p=0.098) in ASPCs.
c-Jun oncoprotein expression in transitional cell carcinom as (TCCs) o f the 
urinary b ladder using im m unohistochem istry and to determ ine its 
relationship to tum our grade and stage was investigated by T iniakos et al 
in 1994 (273) They found a positive association between intense c-Jun 
im m unoreactiv ity and m uscle invasive growth, and EGFR positivity in 
TCCs. N inety two (44/48) tum ours showed c-Jun specific nuclear 
im m unoreactivity o f variable intensity. The intensity o f c-Jun 
im m unostaining was significantly related to tum our stage and EGFR 
status. c-Jun expression was not related to clinical outcom e in term s of 
patient survival or rate o f tum our recurrence.
W alker et al [274] investigated c-Fos protein expression in both benign 
and m alignant human breast tissue using im m unohistochem istry. There 
was a greater degree o f staining in the carcinomas than in the normal and 
benign tissue. In all the instances, staining was nuclear. In our study, we 
also dem onstrated sim ilar nuclear and also cytoplasm ic staining fo r c-Fos 
in prostate cancer tissue specimens exam ined. Poorly differentiated 
breast carcinom as had a greater degree of reactivity, but this did not apply 
to well differentiated tumours. They could not find any clear relationship 
between c-Fos detection and proliferation or differentiation. However In
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the prostate tum ours we studied, c-Fos expression varied in both well and 
poorly differentiated androgen sensitive prostate tumours. No statistical 
significance was reached in relation to G leason sum (p=0.161). In both 
groups ASPC and AI PC, m edian c-Fos expression was not different 
(p=0.642).
Gavrilov et al [271] exam ined c-Jun and c-Fos expression in high-grade 
prostate cancers. Strong staining for c-Jun and c-Fos occurred in 
approxim ately 35% of cancers. No staining was detected in BPFI tissue. 
Remarkably, c-Jun and c-Fos staining was frequently localised to the 
cytoplasm of tum our cells. A lso PC3 cells were reported to exhibit 
cytoplasm ic staining. W here as we observed both nuclear and cytoplasm ic 
staining in our cohort of tumours.
4.2.2 0  COX-2 Protein Expression
COX-2 is a key enzym e in the conversion o f arachidonic acid to 
prostaglandins and it is highly expressed in a num ber of human cancers 
and cancer cell lines, including prostate cancer [275]. In-vivo  studies 
reported COX-2 expression in prostate tum ours by im m unohistochem ical 
analysis. In one study 87% o f the prostate tum our sam ples dem onstrated 
im m unoreactivity to COX-2 [275]. The enzyme was strongly expressed in 
sm ooth m uscle cells o f both the normal and cancerous prostate. Its 
expression in benign epithelial cells was limited to the basal cell layer. But 
it was expressed in epithelia l cells of high grade PIN and cancer.
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Madan et al [226] assessed COX-1 and COX-2 expression in human 
prostates. COX-2 expression was significantly greater in cancer compared 
to BPH Its expression was significantly higher in poorly differentiated 
tum ours (P=<0.001) The results were supported by im m unoblotting. In 
BPH there was m em branous expression of COX-2 in lum inal g landular 
cells and no strom al staining. In cancer the strom al expression was 
sim ilar, but the staining pattern changed from m em branous to  cytoplasm ic 
(p=<0.001). O ur study find ings were consistent w ith some of the findings 
in this study. COX-2 staining was cytoplasm ic in prostate cancer cells. 
However COX-2 expression was unrelated to tum our grade (Gleason 
sum) in ASPC s (p=0.278). High COX-2 expression was observed in 57% 
of tum ours at relapse. Median COX-2 expression in sensitive and 
independent prostate tum our groups was no different (p=0.957).
In-vitro  cell line studies [230,231,276,277] have dem onstrated COX - 2  
expression in both LNCaP and PC3 cells. Hsu et a l,(2000) com pared 
COX-2 expression in LNCaP and PC3 cells vs normal human prostate 
epithelial cells by western blot analysis. COX-2 expression was lower in 
normal prostate epithelia l cells than LNCaP and PC3 cells. Between the 
two cancer cell lines, LNCaP cells displayed a higher COX-2 level than 
PC3 cells in a ratio o f approxim ate ly 2:1.
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4.2.2.D PKC Protein Expression
Pro tein kinase c (PKC) is a fam ily o f serine/threonine protein kinases, with 
at least twelve m am m alian members that play an im portant role in cell 
growth and differentiation [278-280]. D ifferent isoforms of PKC are 
categorized under 3 main categories classic'novel and atypical according 
to cofactor requirem ents [281]. C lassic PKCs (a, p i, pz, and y) and novel 
PKCs (Ô, c, riand 0 ) can be activated in-vivo, by second m essenger 
diacylg lycerol and in-vitro  by phorbol esters. C lassic PKC isoenzym es 
are also dependent on calcium. In contrast atypical PKCs (Ç, X, p, and i)  
are calcium independent and are not activated by phorbol esters.
PKC a is present in both androgen sensitive LNCaP cells as well as 
androgen independent cells such as PC-3, PC-3M and DU 145 [217,282]. 
Androgen independent cells express 6-38 fold more PKCa m RNA and 4- 
16 fold less PKC p m RNA than LNCaP cells.( Powell et al, 1996; O ’Brian 
yet al, 1998). PKC a  protein expression was respectively 5, 8 , and 40 fold 
higher in PC3M, PC3, and DÜ145 cells compared with LNCaP [215,217]. 
They dem onstrated a selective over expression o f PKC a protein in 
androgen independent hum an prostate cancer cells.
Lahn et al [282] obtained 44 prostate cancer biopsy sam ples to com pare 
over all PKC a with phosphorylated PKC a expression using western 
im m unoblotting. PKC a was present in 100% of the sam ples where as
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phosphoryla ted PKC a  in 98%. They did not have inform ation w hether the 
tissue sam ples were from  ASPCs or A lPCs.
Jaggi et al [279] investigated PKCp activity in androgen independent C4-2 
cells and com pared it w ith LNCaP cells by im m unoblot analysis. A lso 
Im m unohistochem ical analysis o f prostate cancer tissue from  patients 
progressing to A lPC  was carried. PKCp expression was seen as diffuse 
cytoplasm ic staining in the tum our tissue. PKCp was decreased in 100% 
of androgen independent prostate cancers. This consistent down 
regulation in both cell line m odels and human prostate cancer tissue 
suggests a possible functiona lly s ignificant role fo r PKCp in progression to 
A lPC.
In our cohort of tum ours exam ined pan PKC im m unoreactivity was seen in 
both tum our groups. All the tum ours (100%) were positive for PKC 
staining. The staining was identified in the cytoplasm  of the tum our cells. 
These findings were consistent w ith the findings in other studies. 
Approxim ately 60% of tum ours in the androgen independent group had a 
high PKC expression (H istoscore >100). Comparison o f m edian pan PKC 
expression in ASPCs and A lPC s did not have any statistical significance 
(p=0.125).
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4.2.2.E AR Protein Expression
In our study AR  protein expression was dem onstrated in the nucleus of 
prostate cancer cells. Both androgen sensitive and androgen independent 
tum ours expressed AR  protein. AR  protein expression was significantly 
h igher in A lPC  when com pared to ASPC (p=0.000). Median histoscores 
fo r AR  protein expression in ASPC and A lPC  were 94.5 and 132.5 
respectively.
W e used AR  expression data to correlate with c-Jun, phosphorylated c- 
Jun and c-Fos expression. No correlations between A R  and c-Jun or c- 
Fos in A lPC s were detected. But a significant corre lation was observed 
between AR and AP-1 (p=0.003, cc=0.460 fo r phosphorylated c-Jun) in 
androgen sensitive tum ours (table 17). An increase in AP-1 form ation (in 
excess of AR) m ay represent change from androgen mediated to 
androgen independent tum our growth, allowing AP-1 to  function as an 
independent transcription factor.
The role of AP-1 is further complicated by the fact that c-Jun can act as 
AR  co-factor. In addition to interactions between AP-1 and AR, there is 
evidence that c-Jun m onom er could influence A lP C  developm ent 
independent of AP-1. c-Jun acts as AR co-activator by binding to N- 
term inal domain thus prom oting AR dimérisation and gene transcription 
[193]. This action o f c-Jun is independent of c-Jun phosphorylation, c-Fos, 
AP-1 DNA binding and AR  ligand binding [193,207].
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Ogreid e t al [295] studied AR  protein expression in prostate cancer 
biopsies before, after, during and after neoadjuvant androgen deprivation 
followed by radiotherapy. During androgen suppression and subsequent 
radiotherapy a gradual reduction in tissue im m unoreactivity fo r AR  was 
observed. The m ost striking observation was the com plete lack of AR 
stainability after com bined LHRH/radiotherapy. O f the 7 patients who had 
a long term  fo llow-up after radiotherapy, 1 patient was cancer negative on 
biopsy and w ithout AR  stainability. Six patients with cancer-positive on 
final biopsies had regained AR  stainability.
Gaston et al [296] reported racial d ifferences in AR  protein expression im 
men with clin ically localized prostate cancer. In black compared with white 
men m alignant nuclei were 27%  more likely to imm unostain fo r AR 
(P=0.005) and in im m unopositive nuclei AR  protein expression was 81% 
greater (p=0.002). V isual scoring o f m alignant nuclei revealed that AR 
im m unostaining was significantly increased in black vs white men (171 ±40 
vs 149 ±37, p=0.048).
Edwards et al [297] in the ir study on AR gene gene am plification and 
protein expression in horm one refractory prostate cancer reported a 
significantly higher AR protein expression in horm one resistant tum ours 
com pared to matched horm one sensitive tum ours from  the sam e tum our 
(mediam histoscore 130 vs 94.5, p=0.019) w ith or w ith out AR 
am plification.
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4.2.3. Involvementof AP-1 (c-Jun, Phosphorylated c-Jun , c- 
Fos) in progression to AlPC
W e observed in our androgen sensitive tum our cohort, c-Jun, 
phosphorylated c-Jun and c-Fos protein expressions correlated with each 
other significantly (table 14). c-Jun expression in ASPC correlated w ith 
phosphorylated c-Jun (p=0.008, correlation coeffic ient [cc]=0.396) and c- 
Fos expression (p=0.020, cc=0.343). A lso c-Fos and phosphorylated c- 
Jun expression correlated in androgen sensitive group o f tum ours 
(p=0.027, cc=0.332). However with progression to A lPCs, c-Fos 
expression no longer corre lated w ith e ither c-Jun (p=0.083, cc=0.274) or 
phosphorylated c-Jun (p=0.480, cc=0.113).
It is clear from  the above data that c-Jun, phosphorylated c-Jun and c-Fos 
proteins are expressed by both horm one sensitive and refractory prostate 
cancers. Protein com ponents o f AP-1 (c-Jun, phosphorylated c-Jun and c- 
Fos) expression in horm one sensitive group correlated w ith statistical 
significance. This explains involvem ent o f AP-1 activity in prostate 
tum ours that are horm one dependent. In tum ours that progressed to 
horm one independent status, still c-Jun and phosphorylated c-Jun had a 
correlation that was significant. But c-Jun and phosphorylated c-Jun 
expression did not corre late with c-Fos expression suggesting that, during 
deve lopm ent o f A lPC, the balance between phosphorylated c-Jun and c- 
Fos has changed. This may be the result of c-Jun becoming 
phosphorylatedand hence more stable at relapse. A lso a significant
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proportion o f tum ours expressed high levels (h istoscore >100) o f AP-1 at 
relapse (c-Jun 68.6% [35/51]; phosphorylated-cJun 24% [24/51]; c-Fos 
40% [20/51]).
W e used AR expression data to correlate with c-Jun, phosphorylated c- 
Jun and c-Fos expression. No corre lations between AR  and c-Jun or c- 
Fos in A lPC s w ere detected. But a correlation was observed between AR 
and AP-1 (p=0.003, cc=0.460 fo r phosphorylated c-Jun) in androgen 
sensitive tum ours (table 17). An increase in AP-1 form ation (in excess of 
AR) m ay represent change from  androgen m ediated to androgen 
independent tum our growth, allowing AP-1 to function as an independent 
transcription factor. This would result in increased cell proliferation and 
survival [204].
AP-1 induces transcriptional activation by interaction w ith AP-1 DNA 
binding site (TRE) [201,282]. This AP-1 DNA binding site is recognized by 
c-Jun hom odim ers and Jun/Fos heterodimers form ed by leucine zipper 
dom ain o f both proteins [171,201,283] AP-1 activity is increased by TPA 
and AP-1 inhibits androgen induced PSA prom oter activity in LNCaP cells. 
This was due to protein protein interaction between A R  and AP-1 [204]. 
AR  and AP-1 interaction prevents either protein from  DNA binding and 
hence transcription, as both AR and AP-1 together form  com plexes and 
m utually inhib it each o ther [204]. Hence the effect o f AP-1 on androgen 
regulated gene expression depends on the ratio o f AR  to AP-1 and the 
ability o f AP-1 to bind to specific prom oter regions in the androgen
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regula ted gene [110,206]. Such AP-1 and AR protein protein interaction 
could influence the ability o f AP-1 to enhance androgen regulated gene 
transcription in the absence of androgens and hence m ight influence the 
developm ent o f A lP C  [110,204]. In-vitro  work on PC3 cells which are 
poorly differentiated prostate cancer cells and androgen independent 
dem onstrated a 7 fold greater in tracellu lar concentration of c-Jun than in 
LNCaP cells that are androgen sensitive [204]. This suggests that AP-1 
may influence androgen escape in PC-3 cells.
Normal breast cells have high basal levels of A P -1 , while breast cancer 
cells have low basal levels [284,285]. Ludes-M eyer’s et al [285] 
investigated the role of AP-1 in controlling breast cell growth. They used 
normal breast cells, immortal breast cells and breast cancer cells to study 
the effect of AP-1 blockade on the ir growth using c-Jun dom inant negative 
mutant, TAM-67. The study dem onstrated highest basal transcriptional 
activity o f AP-1 in normal and im m ortal human m am m ary cells and the 
growth o f these cells was suppressed by AP-1 blockade. Therefore these 
cells require AP-1 transcriptional activity fo r the ir growth. Breast cancer 
cells had lower basal AP-1 transcriptional activity and hence were less 
sensitive to AP-1 blockade. O f the breast cancer cells tested, MCF7 cells 
were the m ost sensitive to growth suppressive effect o f the AP-1 inhibitor. 
W here as other breast cancer c e lls je s te d  were resistant. These results 
dem onstrate that the growth of som e breast cancer cells is inhibited by 
AP-1 blockade and AP-1 is a prom ising target fo r treatm ent o f breast
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cancer. S im ilarly it m ay be possible to target patients with high levels o f 
AP-1 expression in A lP C s .When c-Jun, phosphorylated c-Jun and c-Fos 
protein expression in the prim ary androgen sensitive tumours, was 
investigated, we were unable to dem onstrate a significant correlation 
between the proteins investigated and tim e to relapse (table 9).
In our study 47%  (24/51) o f patients w ith A lPC  had high levels o f 
phosphorylated c-Jun expression (histoscore >100 ) in the tumours. This 
group o f patients was noted to have a significantly shorter duration of 
survival (p=0.023) follow ing deve lopm ent o f horm one escape or relapse in 
com parison to those w ith low expression (figure 14A). The median 
duration of survival was 1.87 years (inter quartile range 1.1 years - 2.6 
years) in the high expression group and in the low expression group it was
5.5 years (interquartile range 1.07 years - 9.9 years).
These observations support the hypothesis generated by cell line studies 
that increased AP-1 expression results in prom otion of tum our growth 
[204,206] im plicating AP-1 in tum our progression to androgen 
independent status. Therefore, inhibition o f c-Jun activation m ay be a 
novel target fo r treating a subset o f hormone refractory prostate cancers. 
Gee et al [286] exam ined the activation of the AP-1 transcription facto r in 
human breast tumours. Phosphorylated c-Jun expression in 78 prim ary 
breast tumours. They observed correlations between high phosphorylated 
c-Jun expression and decreased over all survival and presence o f d istant 
métastasés. In addition, estrogen receptor positive tum ours that
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expressed high phosphoryla ted c-Jun expression developed progressive 
disease more rapidly than did tum ours expressing low phosphorylated c- 
Jun. These clinical data suggest that in a subset of breast tumours, AP-1 
transcription factor is activated and provide rationale to target AP-1 
transcription factor in the prevention and treatm ent o f breast cancer. 
c-Jun expression and its relationship with clinical statistics was studied in 
laryngeal cancer by Que et al [287]. The im m unohistochem ical expression 
o f c-Jun protein in laryngeal cancer (56.41+/-24.8% ) was not only 
significantly higher than that in vocal cord (32.48+7-1.78%) and laryngeal 
tissue (no expression), but also was correlated w ith the degree o f 
differentiation o f laryngeal cancer and lymph node metastasis (P<0.01). 
However the expression o f c-Jun was not associated w ith clinical staging 
(P>0.05). This study dem onstrated, that c-Jun protein was significantly 
increased in laryngeal cancer cells and its expression may be considered 
as an indicator fo r differentiating degree of tum our grade, neck lymph 
node m etastasis, and prognosis o f laryngeal cancer.
Observations from  our study and those from  others suggest that AP-1 
transcription factor expression is upregulated in a subset o f patients 
prom oting growth o f tumours. A lso AP-1 is a potentia l ta rget for therapy in 
a sub group of patients.
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4.2.4. Is PKC associated with c-Jun activation to AP-1 and 
progression to AlPC?
PKC is reported to phosphorylate and therefore activate c-Jun and also 
increase c-Fos expression. W e therefore investigated PKC expression in 
relation to c-Jun, phosphorylated c-Jun and c-Fos expression in both 
Androgen sensitive and independent tum ours (table 15). Pan PKC 
expression in androgen sensitive tum ours was not significantly different 
from  androgen independent tum ours (p=0.125). In ASPCs no significant 
corre lation was observed with c-Jun, phosphorylated c-Jun and c-Fos 
expression. However in A lPC s c-Jun expression and PKC expression 
corre lated in a negative m anner (p=0.012, cc= -.387).
In approxim ately 60%  of tum ours at relapse, pan PKC expression was 
high (histoscore >150) and in 28%  its expression was increased. Another 
interesting observation was an increase in PKC protein expression in the 
transition from ASPC to A lP C  resulted in a significant reduction in patient 
survival from  tim e to relapse (figure 14). The median survival in the group 
w ith increased PKC expression was 1.61 years (interquartile range 1.4 
years -  1 . 8  years) and in the group w ith a decrease or no change in 
expression it was 3.5 years (interquartile range 2.8 years - 4 .1  years).
As we noted tha t patients with high phosphorylated c-Jun and an increase 
in PKC expression were both had shorter survival from  relapse, we 
therefore com bined both these cohort of patients. This combined cohort 
had survived fo r a significantly shorter period o f tim e from  relapse (p=
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0 .0036) com pared to those w ith low phosphorylated c-Jun and no 
increase in PKC expression (figure 15B). Median survival changed from
5.5 years (interquartile range 3.99 -  6.38) to 1.62 years (interquartile 
range 0.99 -  2.24 years).
Powell et al [217] com pared PKC mRNAs in cultured LNCaP and 
androgen independent prostate cancer cell lines DU 145, PC3 and PC3M. 
A lP C  cell lines expressed more PKC m RNA (6-38 fold) and less PKCp 
m RNA (4-16 fold) than LNCaP cells. PKCa expression was 3 fold higher 
in DU 145 cells than PC3 prim ary tum ours that were form ed by orthotopic 
im plantation of the human cancer cells into SCID m ice [215,288]. They 
dem onstrated selective over expression o f PKCa in A lP C  cells.
Krongard and Bai [289] have shown that high levels o f constitutive PKC 
activity in A lP C  cells. In LNCaP cells phorbol ester TPA resulted in > 200 
fold activation of the Fos promoter, and the cells exhibit negligible Fos 
expression in the absence of TPA treatment. These results provide a 
strong evidence that PKC is dorm ant in LNCaP cells and it could be 
activated by TPA. High constitutive PKC activity in A lP C  cells m ay render 
these cells independent o f growth factors and other m itogenic stimuli, 
there by offering the cells a selective growth advantage [215,289]. 
Chelerythrine is a highly selective PKC inhib itor [215,290]. Chelerythrine 
treatm ent has been shown to elicit an apoptotic response in four A lPC  cell 
lines that express constitutively active PKC, but LNCaP cells were
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resis tant to treatm ent. These studies suggest the potentia l value o f PKCa 
as a target of A lPC  therapeutic options.
Currently little inform ation is available w hether in-vitro  observation of 
increased PKCa in A lP C s reflects the PKCa expression in patients w ith 
prostate cancer Lahn et al [282] and Cornford et al [281] evaluated 
expression of d ifferent PKC isoform s expression in patients prostate 
biopsies from 23 men w ith early prostate cancer. PKC a and PKC y were 
increased in com parison to benign prostate tissue. M ost striking finding 
was a decrease in PKCp and concom itant increase in PKCe. Because of 
the current lim itation of reliable antibodies to detect 
activated/phosphorylated PKCa in paraffin em bedded tum our tissue, more 
studies using larger num ber o f tum our specim ens are needed to 
investigate the distribution and variab ility o f PKCa expression in prostate 
cancer. Studies differentiating the role o f PKCa in ASPC and A lPC  /n-vivo 
would facilita te the developm ent o f selective or specific  PKCa inhibitors 
[282].
O ur study is the first to investigate pan PKC expression in prostate 
tum ours that progressed to androgen refractory status. Our findings 
suggest that pan PKC is expressed in both horm one sensitive and 
resistant tum our groups. Increased PKC expression at relapse had a 
significant effect on survival. Increase in PKC together w ith high 
phosphorylated c-Jun expression appear to be poor prognostic ators. It
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does appear from these observations that PKC has a significant role in 
progression of androgen sensitive tum ours to androgen independence. 
AP-1 transcription factor activity is modulated by growth factors, cytokines, 
oncogenes and PKC [199,204]. The AP-1 (Jun/Fos) transcription factor 
contains phosphorylation sites at its N-term inus and near the downstream  
DNA binding region. N-term inal phosphorylation by MAPK fam ily m em bers 
is involved in activation of c-Jun [291,292] Formation of Jun/Jun or 
Jun/Fos dim er requires phosphorylation of c-Jun by c-Jun N-term inal 
kinase (JNK), which is activated by either PKC /  MAP kinase cascade 
[259]. Activation of c-Jun via PKC / MAP kinase pathway is reported to be 
involved in the deve lopm ent o f A lPC  [172,204,205]. In our study, we found 
an inverse correlation between PKC and c-Jun expression in A lPC  
tum ours (Correlation coefficient=-0.387 and p=0.012). Neither 
phosphorylated c-Jun nor c-Fos expression correlated w ith PKC in 
androgen independent tum ours. But both high phosphorylated c-Jun and 
increased PKC expression in patients with A lPC  had a shorter survival 
from  tim e to relapse. These results suggest tha t PKC has a role in the 
developm ent o f A lP C  independent o f c-Jun and AP-1 formation. W hen 
levels o f phosphorylated c-Jun were combined w ith changes in PKC 
expression, the m edian survival fell from 5.5 years to 1.6 years. This 
evidence supports the conclusion that PKC plays an independent role in 
the developm ent o f AlPC.
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The PKC fam ily consis ts o f at least 12 isoforms that have been reported to 
have different and opposing roles in cell growth and differentia tion.[293]. 
As little inform ation is available on the precise isoform s that mediate c-Jun 
activation, we used a pan PKC antibody to assess the role of PKC in the 
developm ent o f A lPC .
Tum our promoters, growth factors, oncogenes and cytokines stim ulate 
COX-2 transcription via PKC and Ras mediated MAPK signalling. [294]. 
High COX-2 expression (histoscore >150) was observed In half o f the 
androgen independent tum ours evaluated. In another third (17/51) o f A lPC  
tum ours COX-2 expression was increased. COX-2 protein and PKC 
protein expression in both ASPCs and A lPC s corre lated with statistical 
significance (p=0.014, cc=0.387 and p=0.002, cc=0.451). This was a 
significant finding. However COX-2 expression in A lPC  had no 
significance to tim e to relapse (table 9). These observations suggest that 
both PKC and COX-2 have a significant role in progression to A lPC.
W e investigated the role o f AP-1 and PKC in prostate cancer patients who 
progressed to androgen independent prostate cancer. Our study was 
unique because we had opportunity to analyse paired prostate tumours. 
W e dem onstrated that AP-1 and PKC expression in both A lPC S and 
ASPCs. Both AP-1 and PKC appear to have significant roles in the 
developm ent o f A lPC . High phosphorylated c-Jun and increased PKC 
expression at relapse are poor prognosticators. Role o f PKCa isoform in
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human horm one sensitive and independent prostate cancer clinical 
material is an im portant area fo r further investigation.
4.2.5 Design of the study & Its Strengths and Weaknesses
A s the study is retrospective, certa inly the design o f the study could be 
improved. A  prospective study would help to recruit adequate num ber of 
patients from different centres. It would be m ore interesting if prostate 
b iopsies are taken at three different time intervals from  each patient 
studied. First biopsy taken at diagnosis, second biopsy taken when PSA 
level has reached nadir and fina lly the third biopsy taken at the tim e of 
relapse. This would help to study protein expression levels at diagnosis 
and then com pare the levels o f expression at response to hormonal 
treatm ent and also after the developm ent of horm one relapse. This gives 
us a better understanding o f protein changes taking place with 
progression of androgen sensitive prostate cancer to androgen 
independent prostate cancer. As the patients norm ally do not need 
biopsies once diagnosis is confirm ed, this m eans that patients are 
subjected to prostate biopsies which is not free o f com plications such as 
sepsis and bleeding. This would need an informed consent from  the 
patients to be studied. It would take longer tim e to com plete the study as it 
takes years fo r the prostate cancer to develop androgen independence.
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Protein expression was studied by im m unohistochem istry which is 
qualitative strictly speaking. Hence quantitative protein estim ation in 
addition to IHC could be carried out and it would be com plem entary to 
IHC.
The study has both strengths and weaknesses.
The strengths of the present study are
1. Patients were selection o f based on strict inclusion and exclusion 
criteria.
2. Ethical approval was obtained from MREC and LRECs.
3. Paired prostate cancer tissue specimens were available at 
diagnosis and after the developm ent o f hormone relapse in each 
patient studied.
4. Six d ifferent proteins expressions were investigated and inter- 
observer variation was analysed using two statistical methods.
5. W e dem onstrated dysregulation o f AP-1 related proteins w ith the 
deve lopm ent of A lPC . Differences in the levels o f protein 
expression were observed as androgen sensitive prostate tum ours 
progressed to androgen independent state.
In androgen sensitive prostate tumours, we dem onstrated a 
statistically significant corre lation in expression o f c-Jun, c-Fos and 
p-Jun proteins (table 14).
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In androgen independen t prostate tum ours c-Jun expression 
corre lated w ith phosphorylated c-Jun with statistical significance
(p=<0 .0 0 0 1 ).
W e also dem onstrated that, high levels of phosphorylated c-Jun 
and an increase in Protein Kinase C expression at relapse were 
associated w ith a decrease in the duration of survival from  relapse 
(p=0.003).
Protein Kinase C expression correlated w ith COX-2 expression in 
both androgen sensitive as well as in androgen independent 
prostate tum ours (p=0.014 & 0 . 0 0 2  respectively).
A  significant corre lation was observed between AR  and AP-1 (p=0.003, 
cc=0.460 fo r phosphorylated c-Jun) in androgen sensitive tum ours (table 
17). An increase in AP-1 form ation (in excess o f AR) m ay represent 
change from  androgen m ediated to androgen independent tum our growth, 
allowing AP-1 to function as an independent transcription factor.
There are weaknesses to the study. It is a retrospective study. A 
prospective power calculation fo r num ber of patients to be studied was not 
carried out, as tim e to com plete the study was a lim iting factor. It was very 
difficult to identify suitab le patients retrospectively. Prostate cancer 
patients do not routinely undergo second biopsy (e.g. TURP) and even if 
they underwent TURP, the patients should have relapsed at the same 
time. Hence recru itm ent was the biggest problem. Many patients were 
excluded as they did not have second biopsy at the tim e of developm ent
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o f A lP C  or the ir tissue was not available fo r the study. Some had a second 
biopsy but they were still horm one sensitive at that time. So a significant 
num ber of patients were excluded.
Protein expression was studied by im m unohistochem istry which is 
qualitative strictly speaking. Hence quantitative protein estim ation in 
addition to IHC should have been carried out and it would have been 
com plem entary to IHC.
W e were unable to dem onstrate a significant correlation between PKC 
expression and c-Jun expression. This could be secondary to using pan 
PKC antibody rather than PKC a antibody.
4.2.6 Retrospective Power calculation
Based on the standard deviation o f difference in histoscores between pre 
and post A lP C  (c-Jun-64.9, p-Jun-47.4, c-Fos-62.5, PKC-39.7, C 0 X 2  - 
45.9 and AR-61.8) fo r 51 paired sets o f measurem ents, a generic power 
calculation was carried out to estim ate the size o f difference in protein 
expression between pre and post A lPC s that the study could be expected 
to detect.
Based on this calculation, a difference in histoscore between pre and post 
A lP C  of 30 would be detected with a statistical power o f 90%. If the 
d ifference in histoscore is 40, then the statistical power would be 99%.
A lso a generic power calculation was performed to estim ate the size o f the 
d ifference in protein expression between pre and post A lPC s that the
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s tudy could reasonably be expected to detect by assum ing that the 
standard deviation o f the difference in histoscores was 50 units fo r all 
proteins (based on pilot data) and that statistical significance would be 
assessed at the 5% level using S tudent’s paired t-test. This was 
calculated for varying num ber o f paired sam ples (30, 40, 50, 60, 70, 80, 
90 & 100),
For 40 paired samples, a difference in histoscore between pre and post 
A lPC  of 30 would be detected w ith a statistical power o f 95.9%. If the 
difference in histoscore is 40, then the statistical pow er would be 99.9%. 
For 50 paired samples, a difference in histoscore between pre and post 
A lPC  of 30 would be detected with a statistical power of 98.6%. If the 
difference in histoscore is 40, then the statistical power would be 100%.
In the present study, a tota l of 51 paired sam ples of prostate cancer 
patients were studied. Protein expression was defined as increased or 
decreased from pre to post A lPC  if there was difference of 2 X mean inter­
observer variation (c-Jun- 57.7, p-Jun-64.78, c-Fos-58.1, PKC-16.6,, 
COX-2 -33.4 & AR -29.98). Hence the statistical power would be 100% .for 
c-Jun, p-Jun and c-Fos proteins, 98.6%  for COX-2 & AR, and fo r PKC- 
80%.
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4.2.7 Hypothesis o f the Study Proved or Disproved?
The hypo thesis of the study was “AP-1 related transcription factors are 
dysregulated in the em ergence o f androgen insensitiv ity” .
The study has shown tha t both androgen sensitive and androgen 
independent prostate cancers express c-Jun, c-Fos, phosphorylated c- 
Jun, PKC, COX-2 and AR  proteins.
A  significant proportion o f tum ours expressed high levels of AP-1 at 
relapse (c-Jun 6 8 .6 %, 35/51; P-Jun, 47%, 24/51; c-Fos 40% , 20/51). An 
increase or no change in AP-1 (c-Jun, P-Jun & c-Fos) was observed in 
>80%  of A lPCs. A lso An increase or no change in PKC (55%), COX- 
2(70% ) and AR  (90%) protein expression in A lPC  was observed. 
D ifferences in the levels o f protein expression were observed as androgen 
sensitive prostate tum ours progressed to androgen independent state.
In androgen sensitive prostate tumours, we dem onstrated a statistically 
significant correlation in expression o f c-Jun, c-Fos and p-Jun proteins 
(table 14).
In androgen independent prostate tum ours c-Jun expression correlated 
with phosphorylated c-Jun w ith statistical significance (p=<0.0001).
W e also dem onstrated that, high levels o f phosphorylated c-Jun and an 
increase in Protein Kinase C expression at relapse were associated w ith 
a decrease in the duration o f survival from  relapse (p=0.003).
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Pro tein Kinase C expression correlated with COX-2 expression in both 
androgen sensitive as well as in androgen independent prostate tum ours 
(p=0.014 & 0 . 0 0 2  respectively).
A lso AR protein expression correlated w ith phosphorylated c-Jun 
expression in both ASPC and A lPC  (p=0.003 & 0.07 respectively). This 
confirm s that both the proteins are involved in the progression o f ASPC to 
A lP C  as dem onstrated in cell line studies [110, 204].
The study has clearly shown tha t AP-1 related proteins are dysregulated 
w ith the em ergence of androgen independent prostate cancer in a subset 
o f patients thus proving the hypothesis.
Role of PKCa isoform in horm one sensitive and independent prostate 
cancer clinical m aterial is an im portant area fo r further investigation.
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Appendix I. Materials 
1. Chem icals and reagents.
Chem ical Source
Absolute alcohol 
Hydrogen peroxide 
Xylene
Fisher Scientific UK Ltd, 
Loughborough, Leicestershire,UK.
Avid in 
Biotin
Calcium chloride 
D iam inobenzidine tetrachloride 
Silane 
Trypsin
Sigma chem ical Co.Ltd; Poole, Dorset, 
UK.
DPX
Ethylene diam ine tetra-acetic acid 
disodium  salt-EDTA
Sodium chloride
Tris (hydroxymethyl) am inom ethane
BDH, Poole, Dorset, UK.
2. A n tib o d ie s
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Antibody Source
c-Jun m onoclonal antibody Novocastra laboratories Ltd, 
Balliol Bussiness Park W est, 
Newcastle upon Tyne
Phosphorylated c-Jun m onoclonal Santa Cruz Biotechnology, Inc.
antibody 2145 Delaware Ave, Santa Cruz 
CA 95060
c-Fos m onoclonal antibody Biogenex, San Ramon, CA 93583.
Protein Kinase c m onoclonal antibody Abeam Ltd,31 Cambridge Science 
Park, Cambridge.
COX-2 m onoclonal antibody Parc d 'Activités du Pas du Lac 
10 bis avenue ampère 
F-78180 M ontigny le Bretonneux 
FRANCE
AR  m onoclonal antibody Novocastra laboratories Ltd, 
Balliol Bussiness Park West, 
Newcastle upon Tyne.
Dako Antibody diluent
Dako Antibody diluent with background 
reducing com ponents
Horse serum
PSA m onoclonal
Mouse lgG1 negative control
DAKO Ltd,Denm ark House, Ely, 
Cambridge, UK.
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3. Kits
Source
DAB Substrate kit fo r Peroxidase 
Vectastatin Elite ABC kit 
Avidin/B iotin Blocking Kit
Vector laboratories, Inc, 30 Ingold 
Road, Burlingame, CA 94010
DAKO LSAB+ Kit, Peroxidase, 
Universal
DAKO Ltd,Denm ark House, Ely, 
Cambridge, UK.
4. M isce lla n y
Source
Cover slips 
Slides
BDH, Poole, Dorset, UK
DAKO Pen DAKO Ltd,Denm ark House, Ely, 
Cambridge, UK.
Gloves Kimberly -C la rk  
Universal Hospital Supplies 
Enfield, EN3 7QJ 
London
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5. Equipm ent
Equipmen t source
Pipettes (Pipetman) Anachem  Ltd. Anachem  House, 
Charles Street, Luton, Bedfordshire.
W eighing Scale (Mettler P1210)
ph m eter (M ettler Toledo MP 
220)
M ettler Toledo Ltd 
64 Boston Road, Leicester.
M icroscope Leitz in W etzlar, Germany.
M icrotome (Leica RM 2135) Leica Instruments, Heidelberger Street, 
Germany.
M agnetic Stirrer (Variom ag- R) Jencons (Scientific) Ltd
Stanbridge Road
Leighton Buzzard, Bedfordshire.
Appendix IL Commonly used solutions
Name Recipe
0 .1% CaClz 0.08g CaCL in 80 mis of distilled water.
0.3% Hydrogen peroxide 5mIs of 30% H2O 2 IN 500 mis of 
distilled water.
10 tim esTBS 60 g TRIS base, 87.6g o f Sodium 
chloride in 800 mis o f distilled water, 
pH- 7.4, made upto 1 litre.
TBS 100 mis o f 10 tim es TBS in 900 m is o f 
distilled water.
Tris EDTA buffer 0.37g Sodium EDTA, 0.55G Trizm a 
base in 1L of distilled water.(pH 8.0)
Appendix III
c-Jun Histoscores in ASPC And AlPC
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AR NO AR NO ASPC
Histoscores
AlPC
Histoscores
AR 1 AR2 130 115
AR3 AR 4 205 115
A R5 AR 6 129 147.5
AR8 AR 9 275 150
AR 14 AR 15 155 135
AR 16 AR 17 62 65
AR 18 AR 19 140 190
AR 23 AR24 135 110
AR 29 AR 30 152.5 182.5
AR 31 AR 32 125 80
AR 33 AR 34 70 140
AR 35 AR 36 248 175
AR 37 AR 38 135 200
AR41 AR 42 225 72.5
AR 43 AR 44 75 60
AR 45 AR 46 85 205
AR 47 AR48 260 175
AR 49 AR 50 190 120
AR51 AR 52 120 152.5
AR 55 AR 56 168 205
AR 57 AR 58 180 172
AR 59 AR 60 198 200
AR 61 AR 62 185 155
AR 63 AR 64 155 181
AR 65 AR 66 246.5 125
c-Jun Histoscores in ASPC And AlPC
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AR NO ARNO ASPC
Histoscores
AlPC
Histoscores
AR 67 AR 68 180 147.5
AR 69 AR 70 180 210
AR 72 AR 73 180 175
AR 74 AR 75 112.5 150
AR 76 AR 77 175 177.5
AR 78 AR 79 15 160
AR 80 AR81 120 180
AR 82 AR 83 151.5 185
AR 84 AR 85 130 205
AR 86 AR 87 172.5 160
AR 88 AR 89 165 115
AR 90 AR91 150.5 160
AR 92 AR 93 147 110
AR 96 AR 97 45 105
AR 100 AR 101 175 160
AR 102 AR103 180 175
AR 104 AR 105 205 200
AR 107 AR 108 100 135
AR 109 AR110 102.5 149
AR 111 AR 112 198 149
AR 114 AR 115 180 290
AR 116 AR 117 270 160
AR 118 AR 119 195 105
AR 120 AR 121 235 160
AR 122 AR 123 100 160
AR 124 AR 125 245 155
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A PPEN D IX IV
Phosphorylated c-Jun Histoscores in ASPC And AlPC
ARNO AR NO ASPC
Histoscores
AlPC
Histoscores
AR 1 A R 2 77.5 117
A R 3 A R 4 135 110
A R 5 A R 6 100 90
A R 8 A R 9 119 115
AR 14 AR 15 77.5 50
AR 16 AR 17 35 0
AR 18 AR 19 95
AR 23 AR 24 50 115
AR 29 AR 30 95 119
AR 31 AR 32 110 5
AR 33 AR 34 55 35
AR 35 AR 36 135 100
AR 37 AR 38 16 135
A R 41 AR 42 132 0
AR 43 AR 44 40 85
AR 45 AR 46 96 125
AR 47 AR48 125 115
AR 49 AR 50 20 90
AR 51 AR 52 135 125
AR 55 AR 56 145 135
AR 57 AR 58 197.5 176.5
AR 59 AR 60 75 105
AR 61 AR 62 95 120
AR 63 AR 64 145 145
A R 6 5 AR 66 145 95
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Phosphorylated c-Jun Histoscores in ASPC And AlPC
AR NO AR NO ASPC
Histoscores
AlPC
Histoscores
AR 67 AR 68 122 125
A R 6 9 AR 70 180 190
AR 72 AR 73 127.5 125
AR 74 AR 75 80 42
AR 76 AR 77 180 105
AR 78 AR 79 170 130
AR 80 AR 81 102.5 130
AR 82 AR 83 80 65
AR 84 AR 85 130 142.5
AR 86 AR 87 89.5 130
AR 88 AR 89 105 90
AR 90 A R 91 90 50
AR 92 AR 93 90 25
AR 96 AR 97 55 25
AR 100 AR 101 26 35
AR 102 AR 103 65 55
AR 104 AR 105 40 45
A R 1 07 AR 108 70 120
AR 109 AR 110 90 105
AR 111 AR 112 105 25
AR 114 AR 115 120 155
AR 116 A R 117 135 75
AR 118 AR 119 110 0
AR 120 AR 121 165 135
AR 122 AR 123 100 125
AR 124 AR 125 180 130
APPENDIX V
c-Fos Histoscores in ASPC And AlPC
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AR NO AR NO
ASPC
Histoscores
AlPC
Histoscores
AR 1 A R 2 72.5 40
A R 3 A R 4 15 115
A R 5 A R 6 65 100
A R 8 A R 9 77.5 140
AR 14 AR 15 50 120
AR 16 AR 17 74 0
AR 18 AR 19 119 95
AR 23 AR 24 62.5 95
A R 2 9 AR 30 115 52
A R 31 AR 32 85 50
A R 3 3 AR 34 5 125
AR 35 AR 36 40 35
AR 37 AR 38 55 155
A R 41 AR 42 100 0
AR 43 AR 44 0 0
AR 45 AR 46 25 37
AR 47 AR48 70 10
AR 49 AR 50 45 41
A R 51 AR 52 0 92
AR 55 AR 56 75 75
AR 57 AR 58 200
AR 59 AR 60 155 97
A R 61 AR 62 160 76
AR 63 AR 64 107.5 85
AR 65 AR 66 125 115
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c-Fos Histoscores in ASPC And AlPC
AR NO AR NO
ASPC
Histoscores
AlPC
Histoscores
AR 67 AR 68 140 110
AR 69 AR 70 155 145
AR 72 AR 73 92.5 90.5
AR 74 A R 7 5 95 45
AR 76 AR 77 155 105
AR 78 AR 79 90 135
AR 80 AR 81 125 140
AR 82 AR 83 152.5 178
AR 84 AR 85 160 147.5
AR 86 AR 87 166 170
AR 88 AR 89 140 15
AR 90 AR 91 155 140
AR 92 AR 93 110
AR 96 AR 97 50 30
AR 100 AR 101 75 177.5
AR 102 AR 103 125 115
AR 104 AR 105 152.5 137.5
A R 107 AR 108 70 65
AR 109 AR 110 147.5 195
AR 111 AR 112 210 172.5
AR 114 AR 115 135 190
AR 116 AR 117 157.5 155
AR 118 AR 119 130 0
AR 120 AR 121 180 20
AR 122 AR 123 130 120
AR 124 AR 125 200 77.5
A PPEN D IX VI
PKC Histoscores in ASPC And AlPC
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AR NO AR NO
ASPC
Histoscores
AlPC
Histoscores
AR1 AR2 190 215
AR3 AR4 300 220
AR5 AR7 230 190
AR8 AR9 230 195
AR14 AR15 172.5 165
AR16 AR17 180 160
AR18 AR20 195 170
AR23 AR26 170 165
AR29 AR30 135 135
AR31 AR32 160 180
AR33 AR34 260 205
AR35 AR36 195 185
AR37 AR38 145 75
AR41 AR42 165 145
AR43 AR44 155 240
AR45 AR46 185 165
AR47 AR48 230 150
AR49 AR50 135 190
AR51 AR52 155 180
AR55 AR56 150 140
AR57 AR58 140 220
AR59 AR60 125 135
AR61 AR62 155 130
AR63 AR64 135 155
AR65 AR66 125 150
PKC Histoscores in ASPC And AlPC
241
AR NO AR NO
ASPC
Histoscores
AlPC
Histoscores
AR67 AR68 175 200
AR69 AR71 180 170
AR72 AR73 135 160
AR74 AR75 160 145
AR76 AR77 190 135
AR78 AR79 200 200
AR80 AR81 130 112.5
AR82 AR83 115 115
AR84 AR85 105 135
AR86 AR87 130 160
AR88 AR89 150 115
AR90 AR91 157.5 140
AR92 AR93 150 150
AR96 AR97 185 160
AR100 AR101 200 162.5
AR102 AR103 185 160
AR104 AR106 125 200
AR107 AR108 175 155
AR109 AR110 175 172.5
AR 111 AR113 170 185
AR114 AR115 185 240
AR116 AR117 220 170
AR118 AR119 230 150
AR120 AR121 220 170
AR122 AR123 240 175
AR124 AR125 230 195
APPENDIX VII
COX-2 Histoscores in ASPC And AlPC
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AR NO AR NO
ASPC
Histoscores
AlPC
Histoscores
AR 1 A R 2 235 150
AR 3 A R 4 235 197.5
A R 5 A R 6 220 237.5
A R 8 A R 9 185 210
AR 14 A R 1 5 172.5 150
AR 16 AR 17 210 190
AR 18 AR 19 140 185
AR 23 AR 24 125 165
AR 29 AR 30 115 155
A R 31 AR 32 110 160
AR 33 AR 34 155 210
AR 35 AR 36 125 160
AR 37 AR 38 175 70
A R 41 AR 42 170 125
AR 43 AR 44 135 125
AR 45 AR 46 115 150
AR 47 AR48 235 145
AR 49 AR 50 105 152.5
AR 51 AR 52 135 160
AR 55 AR 56 185 140
AR 57 AR 58 120 165
AR 59 AR 60 162.5 125
A R 61 AR 62 175 160
AR 63 AR 64 140 130
AR 65 AR 66 95 147.5
CO X-2 Histoscores in ASPC And AlPC
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AR NO AR NO
ASPC
H is tosco res
AlPC
H is tosco re s
AR 67 AR 68 135 175
AR 69 AR 70 145 195
AR 72 AR 73 152.5 155
AR 74 AR 75 135 130
AR 76 AR 77 185 150
AR 78 AR 79 195 160
AR 80 AR 81 175 170
AR 82 AR 83 95 160
AR 84 AR 85 115 145
AR 86 AR 87 152.5 155
AR 88 AR 89 132.5 165
AR 90 AR 91 120 112.5
AR 92 AR 93 180 190
AR 96 AR 97 140 70
AR 100 AR 101 140 75
AR 102 AR 103 140 130
AR 104 AR 105 80 160
AR 107 AR 108 155 80
AR 109 AR 110 190 135
AR 111 AR 112 92.5 155
AR 114 AR 115 170 205
AR 116 AR 117 180 185
A R 118 AR 119 115 40
AR 120 AR 121 106 120
AR 122 AR 123 160 175
AR 124 AR 125 150 170
A PPEN D IX VIII
AR Histoscores in ASPC And AlPC
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AR NO AR NO
ASPC
Histoscores
AlPC
Histoscores
AR1 AR2 150 155
AR3 AR4 145 197.5
AR5 AR7 155 107.5
AR8 AR9 177.5 200
AR14 AR15 64.5 117.5
AR16 AR17 45 130
AR18 AR20 140 220
AR23 AR26 2.5 5
AR29 AR30 110 195
AR31 AR32 147.5 167.5
AR33 AR34 110 157.5
AR35 AR36 170 140
AR37 AR38 2.5 5
AR4I AR42 75 92.5
AR43 AR44 66 53
AR45 AR46 55 114.5
AR47 AR48 54 60
AR49 AR50 25 69
AR51 AR52 105 118
AR55 AR56 74.5 55
AR57 AR58 94.5 192.5
AR59 AR60 27.5 167.5
AR61 AR62 125 217.5
AR63 AR64 60 42.5
AR65 AR66 1 10
A R  Histoscores in A S PC  And A lPC
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AR NO AR NO
ASPC
Histoscores
AlPC
Histoscores
AR67 AR68 95 155
AR69 AR71 167.5
AR72 AR73 102.5 187.5
AR74 AR75 102.5 91
AR76 AR77 45 87.5
AR78 AR 79 0 0
ARBO AR81 70 32.5
AR82 AR 83 87.5 167.5
AR84 AR85 45 170
AR86 AR87 55 92.5
AR88 AR89 120 130
AR90 AR91 75 215
AR92 AR93 112.5
AR96 AR97 75 155
AR100 AR101 57.5 132.5
AR102 AR103 110
AR104 AR106 7.5 30
AR107 AR108 110 165
AR109 AR110 122.5 185
A R  111 AR113 92.6 32.5
AR114 AR115 115 175
AR116 AR117 180 125
AR118 AR119 120 135
AR120 AR121 125 210
AR122 AR 123 160 190
AR124 AR125 115 125
